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THE RESPONS I VENESS OF  MURI N E  TUMORS TO MAL E I C  V I NY L  ETH ER  
Paa l  Chri s t i an Kl ykken , P h . D . 
Med i ca l  Col l ege of  V i rgi n i a  - V i rg i n i a  Commonweal th Un i vers i ty ,  1 979 
Maj or Professor : Al bert E .  Munson , Ph . D .  
Stud i e s  were u nderta ken to c haracteri ze  the i mmune status  of m i ce 
bear i n g  the Lewi s l un g  carc i noma ( LL C )  and to max im i z e  the c ure rate of 
LLC and Mad i son 1 09 carc i noma ( M1 09 )  beari ng  m i ce by empl oy i ng the 
i mmunomodu l ator mal e i c  v i nyl ether ( MV E )  i n  comb i n a t i on wi th  s urgery 
or rad i otherapy .  
The pattern of  i mmunodefi c i ency i n  mi ce bear i ng the L L C  appeared 
to be in contrast  to mos t  s tud i es . LLC  m i ce wi th a mi n imal  tumor bur-
den were found to have a d im i n i s hed ab i l i ty to phagocyt i ze s heep 
erythorcytes ( SRBC )  or e l i c i t  an  a nt i body res ponse  to the s ame ant i gen . 
5 1  
Vascu l ar  c l earance and phagocyt i c  u p ta ke of  Cr- l abel ed SRBC i nto 
ret i cu l oendothel i a l ( RE )  organ s  exh i b i ted a tri phas i c  respon se . L i ver 
phagocytos i s  and vascu l ar c l earance were marked l y  s u ppres s ed 24 and  
48  hours  after tumor i nocu l a t i on . The i n i t i a l decrea se in  RE funct i on 
was fol l owed by a phase of  i ncreased act i v i ty wh i c h progre s s i vel y de-
creased to control l evel s wi th  i ncrea s i ng tumor burden . I gM ant i body 
form i n g  cel l s  to SRBC were reduced to 1 8% of contro l  va l ues  7 days 
after i nocu l at i on and by day 27  no  ant i body form i ng cel l s  cou l d  be 
detected i n  the LLC beari ng mi ce . I n  contra st , de l ayed type hypersen ­
s i t i v i ty to SRBC rema i ned i ntac t unt i l  day 1 7  and no  s i gn i f i cant 
changes i n  i nfl ammatory act i v i ty were noted . Surg i ca l  exc i s i on of 
the pri mary tumor burden on day 1 4  had no effect on s urv iva l  t ime 
but parti a l l y  restored the s uppres sed i mmune functi on s .  
xx 
Accord i ng l y ,  i mmunotherapeuti c reg i mens  were des i gned to treat 
ear l y  i n  the d i sease state or  after cytoreduct ive  therapy i n  an 
effort to have i mmunocompetent a n i ma l s wi th a m i n i ma l  tumor burden . 
Yet , system i c  MVE treatmen t  by i tse l f ,  or  i n  comb i nat i on wi th  s u rg i ­
ca l  exc i s i on or  l oca l  rad i otherapy of the pr ima ry tumor was i neffec­
t i ve i n  pro l ong i ng l i fe s pan . I n travenous  MVE treatment a l so fa i l ed 
to exh i bi t  ant i tumor act i v i ty aga i n s t  the LLC when the metastat i c  
tumor burden was marked l y  reduced by mu l t i pl e  cyc l ophospham i de i njec ­
t i on s .  I n  contrast to systemi c MVE treatment ,  a n  acute i n tra 1 es i ona 1  
i nject ion  of  MVE proved to  be effi cac i ou s  by  i ncrea s i ng l i fe s pan by 
36% . Moreover ,  the comb i na t i on of i ntra 1 e s i ona 1  MVE wi th  l oca l  rad i ­
a t i on o f  the pr ima ry LLC tumor s i gn i fi ca nt ly  prol onged s u rv i va l  t ime 
over the rad i at i on control s .  
The M 1 09 was s hown to be re l at i ve l y  respons i ve to MVE treatment . 
Mu l t i pl e i nj ect i on s  of MVE i n  doses  ran g i n g  from 1 0  to 50 mg/ kg 
s i gn i fi cant ly  prol onged the l i fe span of  the host  and  i n h i b i ted 
the g rowth of  the pr imary tumor . The effi cacy of  MVE therapy appeared 
to be dependent on the d i str i but i on of the po l ymer . Week l y  i ntra -
1 e s i ona 1  i nj ect i on s of  MVE were mos t  effect i ve i n  pro l on g i ng l i fe 
span ear l y  i n  the d i sease  s tate , presumab ly  by i n h i b i t i ng the meta s ­
tat i c  proces s .  A s  the tumor meta s ta s i zed to the l ung  o n l y  MVE i ntro­
duced d i rect ly  i nto the metastat i c tumor bed by i ntrap l eura l  or 
i n ha l a t i on admi n i stra t i on proved to be effi cac i ou s  i n  pro l ong i ng 
l i fe s pan . These data emphas i ze the importance of drug  d i str i b ut i on 
i n  the treatment of  neopl a s i a  wi th  n on s pec i fi c  immunotherapy . 
I NTRODUCT I ON 
The bas i c  a s s umpt i on i n  cancer treatment  i s  that the ach i eve­
ment of  cures or normal l i fe expectancy req u i res  the destruct i on 
or removal  of  a l l ma l i gnant  cel l s .  Four  thera peut i c  modal i t i es 
have the poten t i a l  of accompl i s h i ng t h i s end : s urgery , rad i o ­
therapy ,  chemotherapy and i mmunothera py . Surgery a n d  rad i otherapy 
are the most frequent l y u sed and mos t  effecti ve a pproaches  curren t l y  
ava i l a bl e ,  b u t  ne i ther of  these moda l i t i e s  c a n  be con s i dered curat i ve 
when t he n eopl asm has  metasta s i zed beyond  the pr imary tumor s i te .  
Chemotherapy has proven to be effect ive  i n  se l ected forms of cancer , 
yet i t s a b i l i ty to erad i cate res i dua l  tumor ce l l s  i s  presen t l y  l i mi ted 
by the tox i c i t i e s  a s soci ated wi th  the treatment schedu l e s . 
I mmunotherapy i s  a new and  exc i t i ng fourth treatment moda l i ty 
be i n g  devel oped to a i d  the host  i n  control l ing  cancer . I ts c h i ef va l ue 
l i es i n  the s pec i f i c i ty of  the immune respon se wh i c h  may enabl e i mmuno­
therapy to destroy tumor ce l l s  not  amenab l e to k i l l i ng by conven t i ona l  
treatment  modes . The u nderl y i n g  concept of tumor i mmunol ogy i s  that 
there are characteri s t i c  ant i gens in  or on tumor cel l s  that d i s t i ngu i s h  
them from norma l host ce l l s ,  and  that these ant i gens are capabl e of 
el i c i t i n g  immune respon ses . I t  i s  the hope that immunotherapeut i c  
man i pu l a t i on o f  the host's immune response wi l l  a l l ow for destruct i on 
of tumor cel l s  through  spec i f i c  i mmunol og i c  mechan i sms med i ated by 
thymu s  deri ved l ymphocytes , cytotox i c  ant i bod i e s , n u l l cel l s ,  or armed 
macrophages , or through non - s pec i f i c  mechan i sms med i a ted by act i vated 
macrophages .  
2 
Immun i ty aga i n s t  cancer , however ,  i s  re l at i ve rather than abso-
l ute ( Mathe et �. , 1 969; Zbar et �. , 1 97 2 ) . Host  defenses are 
capa bl e of destroy i n g  sma l l n umbers of  tumor cel l s  ( 1 06 - 1 07 ) ,  but  1 08 
tumor cel l s  a l most  a l ways resu l t  i n  tumor progres s i on .  Because  a neo ­
pl a sm on l y  1 cm i n  d i ameter conta i n s  approx i mate l y  1 09 tumor cel l s, 
most  tumors have a l ready overcome or avo i ded immune defenses  by the 
t ime they are c l i n i ca l l y  detectab l e ( Carter , 1 97 6 ) . Therefore , the 
pract i cal  future of i mmunotherapy a ppears to be part of  a comb i ned 
moda l i ty approac h ,  as i t  i s  u n l i ke l y that i mmunotherapy a l one  wi l l  
bol ster host defenses  s uffi c i en t l y  to reverse tumor growth i n  i nd i -
v i dua l s wi th advanced d i sease . 
The i mmune statu s , or  i mmune competence of the tumor bear i ng  host  
can a l so con st i tute a cr i t i ca l  l im i tati on to  the  s uccess  of  i mmuno-
therapy .  Immunosuppre s s i on o f  m i ce wi th a n t i  thymocyte serum ( Hanna  
et �. , 1 97 3 )  cort i sone acetate ( Chung et �. , 1 97 3 ) , or by thymectomy 
and sub l ethal  i rrad i a t i on ( Bartl ett � �. ,  1 972) del ayed the devel op­
ment  of tubercu l i n hypersen s i t i v i ty and a brogated the ab i l i ty of 
Bac i l l u s Ca l mette-Guer i n  ( BCG )  to suppress  fi brosarcoma growth . Scott 
( 1 97 5 a )  has  produced s i mi l ar f i n d i ngs  wi th Corynebacteri um parvum i n  
that C .  parvum was somewhat  l e s s  effecti ve i n  thymectomi zed , i rrad i ated , 
bone marrow reconst i tuted m i ce than i n  i n tact rec i p i ents . Thymectomy 
has a l so been reported to reduce the ab i l i ty of pyran -copo l ymer to 
protect m i ce aga i n st  the Lewi s l ung  carci noma or B 1 6 mel anoma ( Morahan 
et �. , 1 974 ) . 
Fol l ow i n g  th i s  l i ne of reason i n g ,  the overa l l obj ect i ves of th i s  
research were to ( 1 )  c haracter i ze the i mmune s tatus  of m i ce bear i ng 
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the Lewi s l ung  carc i n oma and  ( 2 )  deve l o p  a rat i ona l  approach ,  con­
s i s t i n g  of  s urgery or rad i otherapy comb i ned w i th immunothera py to 
max i mi ze the cure rate of m i ce bear i ng  the Lewi s l u ng  carc i noma or 
Mad i son 1 09 carc i noma . 
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I .  REV I EW  O F  THE L ITERATURE 
A .  Tumor Sys tems 
1 .  Lewi s l ung  carc i noma 
The tumor model s empl oyed i n  these i nves t i gat i o n s  were the 
Lewi s l u ng carc i noma ( LLC )  and the Mad i son 1 09 carc i noma (M 1 09 ) . 
The LLC wa s d i scovered by Dr . Margaret R .  Lewi s i n  1 95 1  a s  a s pon­
taneo u s ly  occurr i ng carc i noma of the  l u ng of  a C57BL/6  mou se . Tumor 
take rate i s  1 00% and the med i an day of  death i s  2 5  days after s u b ­
c utaneou s ( s . c . )  impl antat i on i n  t he  F1 hybr i d  ( Mayo , 1 972a ; S i mpson­
Herren � �. ,  1 974 ) . The growth of the s . c . i mpl anted LLC f i ts a 
Gompertz i an functi on wi th an i ncrease i n  doub l i n g t ime from 1 . 7 days 
for a 0 . 1 g tumor to 7 . 7  days when the tumor reaches  5 . 0  g ( Mayo , 
1 972a ) . The l ength  of  the cel l cyc l e  ( Tc = 1 6  hrs ) and  the S phase  
( T s  = 9 hrs ) are  not s i gn i fi can t ly  a l tered when  mean  tumor we i g h t  
i ncreases from 0 . 3  t o  2 . 7  g ( Mayo , 1 97 2a ) , yet t h e  major i ty of  pri ­
mary s . c .  tumors u l cerate by day 1 4  and by day 2 1  e s sent i a l l y  a l l of 
the tumors have necroti c cores s urrounded by a prol i ferat i ng s he l l 
( S i mpson -Herren et �. , 1 974 ) . I n  add i t ion , the thymi d i ne i ndex ( T I ) 
decreases  from 35% on day 6 to 1 8% on day 1 6 . These data i nd i cate 
that a decrease i n  the prol i fera t i ve fract i on as the tumor grows 
l arger accounts  for the observed i ncrea se i n  doub l i ng t ime from 0 . 4  
days wi th a 350 mg tumor on day 6 to 2 3  days wi th a 6400 mg tumor on 
day 24 ( Mayo , 1 97 2a ) . After impl ant  the LLC q u i c k l y  nletasta s i zes, 
primari l y  to the l ungs , wi th over 50% of the m i c e  s uccumb i n g  to p u l ­
monary i n s uff i c i ency when t h e  pr imary tumors  are removed o n  day 2 
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posttumor i mpl an t .  Surg i ca l  removal of the pri mary tumor more than 
6 days post impl ant  has no  effect on the l i fespan of the tumor-bea r i ng 
host ( Mayo , 1 972a ) . 
The growth k i net i c s  of the meta s ta t i c  LLC i s  a l so c haracter i zed 
by a progres s i ve i ncrease i n  tumor doubl i ng t i me wi th i ncrea s i ng tumor 
mas s  and age . I n  compar i son wi th the s u bcutaneou s l y  i mpl anted pr ima ry 
tumor the metas tat i c tumors have a s horter doub l i ng t i me ( 0 . 5  days vs . 
4 . 7  days on day 1 5  post i mpl ant )  and  the T I  i s  con s i s tentl y h i g her . 
I n  add i t i on , the ce l l cyc l e  and S phase  are of  s horter  dura t i on i n  
the meta stat i c  tumor measured a t  day 2 5  than i n  the pr imary tumor on 
day 5 or l ater ( S i mpson-Herren et �. , 1 974 ) . Each  of these factors  
i s  con s i stent wi th greater drug  sen s i ti v i ty in  the nletastat i c foc i . 
The LLC i s  refrac tory to mos t  c hemothera�eut i c  agents wi th e s tab­
l i s hed acti v i ty aga i n s t  h uman cancer , yet i s  q u i te sen s i ti ve to 
cyc l ophospham i de and the n i trosoureas ( Mayo et  � . ,  1 9 72b; Gol d i n  et  � . , 
1 97 1 ) .  No opt i ma l  s i n g l e dose  schedu l e for these compounds  ha s  been 
deve l oped s i nce effect i ve treatment  var i es wi th  the exten t of neopl a s i a  
( Humphreys e t  �. , 1 970 ) . 
Stud i e s  wi th  cyc l ophosphami de ( CTX ) by Karrer et �. ( 1 967 ) i nd i ­
cate that the LLC i s  not  curab l e by treatment wi th CTX a l one . However , 
surg i ca l  removal of the pr imary tumor i n  comb i na t i on wi th  CTX treatment 
res u l ts i n  l ong term tumor free surv i vors . S i mi l ar re su l ts have been 
obta i ned u s i ng i rrad i a t i on treatment of the pr imary impl ant  ( J ohn son , 
1 969 ) . These resu l ts correl ate wi th the tumor ce l l k i net i c  s tud i es of 
S i mpson-Herren et  � . ,  ( 1 974 )  and are con s i sten t wi th the conc l u s i on 
reac hed by OeWys ( 1 97 2 )  that the prol i ferat i ve s tate of a tumor cel l 
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popu l a t i on i s  a maj or determi nant  of  sens i t i v i ty of CTX .  Add i t i ona l  
s upport for th i s  concept i s  deri ved from the  ob servat i on that  metas tat i c 
foc i are con s i derab ly  more sen s i t i ve to gamma i rrad i at i on than the pri ­
mary tumor ( S h i pl ey et  a l . ,  1 97 5 ) . An a l tern a t i ve expl anati on for the 
d i vergent  effect of  CTX on the pr imary and meta s tat i c LLC has been 
publ i s hed by Houghton et �. ( 1 97 6 ) . The resu l ts obta i ned from th i s  
d i str i b ut i on s tudy impl y that the greater s en s i ti v i ty of  pu l monary a s  
compared t o  s . c .  Lewi s l ung  tumors i s  d u e  to the attai nment  o f  greater 
CTX concen trat i o n s  i n  the l u ng tumors . I n  compar i son wi th CTX , methyl ­
CCNU i s  s uperi or i n  the treatment  of  LLC . Al though equa l l y  effect i ve 
i n " cur i  n g "  wi de 1 y des  semi  na  ted Lewi s l ung tumor ce 1 1  s ,  methyl -CCNU 
s hows greater effect i veness  aga i n s t  sol i d  tumor mas ses  ( Mayo et  �. , 
1 97 2 b ) . Marked act i v i ty ha s  been documen ted by a n umber of rel i a b l e 
end po i nts  s uch  a s  i ncreases  i n  l i fe-s pan , tumor regres s i on s , some 
cures  and b i oa s s ay of tumor cel l s  for v i a b i l i ty after methyl -CCNU treat­
men t .  
The res pon s i veness  o f  the LLC t o  i mmunotherapy h a s  been s hown to 
be dependent on the dos e ,  do s i ng reg i men and route of admi n i s trat i on 
of the i mmunomodu l ator ,  and more i mportantl y on the tumor burden of 
the m i ce a t  the t ime of  therapy ( Ba s t  et  �. , 1 97 6 ) . Mathe et a l . 
( 1 97 3 ,  1 97 5 )  have reported that one mg of BCG admi n i s tered i n tra ­
veno u s l y  d i sp l ayed ant i tumor act i v i ty aga i n s t  the LLC whereas  the 
same dose i nj ected s u bc utaneou s l y  resu l ted i n  en hancement of tumor 
growth . I n  the fi rst case  the man i festat i ons  of septi cem i a  were 
muc h  more i nten se than i n  the second , a s  the a nt i tumor act i v i ty of 
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BCG seems to be correl a ted wi th the degree of  septi cemi a produced 
( Kha l i l  et � . , 1 97 5 ;  Mathe , 1 97 6 ) . Sys temi c i . p .  or i . v .  admi n i s ­
trat ion  o f  C .  parvum has been i n effect i ve i n  retard i ng primary tumor 
growth and pro l on g i n g  l i fe s pan ( Ca s tro and Sad l e r ,  1 975 ; Morahan and 
Kapl an , 1 976a ) a l though da i l y  i n tra l es i ona l  admi n i s trat ion  of C .  parvum 
i n i t i a ted 24 hrs a fter tumor i nocu l a t i on ha s  proven to be effec t i ve 
aga i n st the LLC ( Morahan and Kapl an , 1 97 6 b ) . Numerous  reports have 
a l so documen ted the ant i neop l a s t i c  act i v i ty of pyran in the LLC tumor 
model ( Morahan et � . , 1 974 ; Snodgra s s  et � . , 1 97 5 ; Morahan and Kapl an , 
1 976a ) . Yet , a s  wi th  BCG and C .  parvum , a moderate i ncrease  i n  l i fe 
span was a fforded on l y  when d a i l y  pyran treatmen t wa s i n i t i a ted earl y 
i n  the d i sease sta te when the tumor burden was mi n i ma l . 
The l imi ted s ucces s  of  immunotherapy aga i n s t  the LLC can  parti a l l y  
be a ttri buted to the i nab i l i ty of  the host  to devel op  an  immune response 
to tumor-assoc i ated anti gens, s i nce Mora han and  Kapl an ( 1 97 7 )  and Otu 
et  a l . ( 1 97 7 )  have been unab l e to detect any concomi tan t  immun i ty or 
tran spl antat i on res i stance to the LLC . When tumors of d i fferent immuno­
gen i c i ties have been compared for s u scepti b i l i ty the more s trong l y  
immunogen i c  tumors have , i n  genera l , been more respons i ve to BCG 
immunotherapy ( Parr , 1 972 ; Bal dwi n and P i mm ,  1 973 ) . A s i mi l a r  corre­
l at i on has been obta i ned wi th C .  parvum ( Sm i th and Scott , 1 97 2 ) , 
C .  granu l o sum ( Mi l a s et � . , 1 974a ) and  L .  monocytogenes ( Ba s t  et � . , 
1 976 ) . 
2 .  Mad i son 1 09 l ung carc i n oma 
The M1 09 was d i scovered i n  1 964 by Dr . Russe l  M .  Mad i son as a 
spontaneou s l y  occurr i n g  l ung  tumor i n  a Bal b/c mou se . As on l y  a 
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few l aborator i es have u t i l i zed th i s  tumor model , the M1 09 has  been 
poorl y character i zed wi th  regard to i ts tumor i gen i c i ty ,  growth 
characteri s t i c s , tumor ce l l k i neti c s  and  i mmunogen i c i ty .  L i ke the 
LLC the M 1 09 tumor i s  a h i g h l y  stab l e transp l antabl e tumor wh i ch 
k i l l s  a l l rec i p i ent  m i ce wi thi n a fa i rl y  narrow t ime range after i noc­
u l a t i on wi th  no evi dence of s pontaneous  regre s s i on .  The tumor metas­
ta s i zes  primar i l y  to  the l ungs  wh i c h resu l ts i n  the death  of  the  host  
in  abou t 35  days  after i mpl ant  ( Ma rks  et  �. , 1 97 7 ) .  However , the  
M1 09 d i s pl ays  a d i fferen t  s pectrum of  act i v i ty than the LLC  to  c hemo­
therapy and  i mmunotherapy . Agents  wi th confi rmed act i v i ty aga i n s t  
the M1 09 such  a s  act i nomyc i n  0, adri amyc i n , daunoru b i c i n , and pro­
carbaz i ne have not d i sp l ayed act i v i ty aga i n s t  the LLC . S i m i l arl y ,  
cyto s i ne arab i no s i de , BCNU , methy1 -CCNU and mel phal an  are act i ve 
aga i n s t  the LLC but i nact i ve i n  the M 1 09 tumor model  ( Wood , 1 97 7 ) . 
However , pyran  copo l ymer has  been reported to be act ive  aga i n st both 
of  these exper imenta l l ung carc i nomas ( Snodgras s  et  �. , 1 97 5 ; 
Schu l tz et �. , 1 97 7 ) . 
B .  A l terat i on s  i n  Immune Status  of  Tumor Beari ng An ima l s 
Modu l at i on of i mmune respon ses  ha s  been repeated l y  observed i n  
cancer pat i en ts and tumor- bear i n g  a n i ma l s .  Severa l s tud i es have i nd i ­
cated en hanced i mmuno l og i c  re spon s i veness  to fore i gn ant i gens  o r  m i to­
gens ( Zo l l a ,  1 97 2 ;  Konda et �. , 1 973 ) . Absence of a detectabl e effect 
on immun i ty by tumors has a 1 s o  been reported (Fauve et �. , 1 974} . HOW­
ever , the maj or i ty of i nvest i gat ions  have noted a progres stve i mmuno-
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l og i c  i mpa i rment i n  an imal s bear i ng pr imary tumors ( Kamo and I s h i da ,  
1 97 1 ; Kamo et  �. , 1 976 ) , those i nfected wi th  oncogen i c  v i ruses 
( Se i ge l  and  Morton , 1 966; Ceg 1 0ws k i  and  Fri edman , 1 968 ) , or those 
treated wi th carGi nogens ( Geri c ke et �. , 1 97 1 ) .  
1 .  Al tera t i on s  i n  ret i cu l oendothel i a l act i v i ty 
The rol e of  macro phages and  the ent i re ret i cu l oendothel i a l  system 
( RES ) i n  neopl a s t i c  d i sease ha s  been exten s i ve l y stud i ed .  I nves t i ga ­
t i on s  u s i ng d i fferent  l aboratory an i ma l s and  tumor l i ne s  have  y i el ded 
confl i ct i n g  data , however .  The neopl a s t i c  proces s  has been s hown i n  
some i n s tances to have a s t i mu l atory effect o n  the RES ( Baum and F i s her , 
1 972 ; Ol d et  �. , 1 960 ) whereas i n  other s tud i es a s i gn i f i cant  RES de­
pres s i on has been observed i n  tumor- bear i ng a n i ma l s ( Stern et  �. , 
1 967 ; Franch i  et �. , 1 97 2 ;  D i luz i o  et  �. , 1 972 ) . 
A s i de from the i n herent d i fferences in tumors and  exper imental  
cond i t i on s , one pos s i bl e  source of  d i s crepancy may be that hepa t i c 
uptake of  fore i gn part i c l e s , wh i c h  accounts  for the major i ty of RES 
act i vity , has been s hown to be var i a b l y  affected i n  tumor-bear i n g  
an i ma l s ( S tern e t �. , 1 967 ) . Moreove r ,  i n creased hepa t i c phagocytos i s  
may be of l im i ted benefi t i n  the ma i ntenance o f  i mmune res pon s i veness  
s i nce the l i ver functi on s ma i n l y  in  c l earance and  degradat i on of 
ant i gen s ( Fre i et �. , 1 965 ; Franz 1 , 1 972 ) . 
I n  contra st  to Kupffer cel l a ct i v i ty ,  spl en i c  and pul monary 
phagocytos i s  a ppear to be regu l arl y and  marked l y  reduced i n  tumor­
bear i ng a n ima l s ( Kampschmi dt  and Pu l l i am , 1 972 ; Stern et �. , 1 967 ) . 
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The wor k  of Stern et �. ( 1 96 7 )  wi th  four  s pontaneous mur i ne tumors 
s uggested that a correl a t i on ex i s ts between sp l en i c  upta ke and tumor 
s i ze .  Other stud i es by Franch i  et �. ( 1 97 2 )  wi th  a mur i ne sarcomma 
tran spl anted i n  d i fferent s i tes i nd i cated that RES act i v i ty i s  not 
i nfl uenced by tumor s i ze s i nce the s . c .  tumor may reach  25% of the 
body we i g ht wi thout a n  impai rment  of  co l l o i da l  carbon c l earance . 
These i nvest i gators conc l uded that the s u ppre s s i on of  the RES funct ion  
i s  re l ated to  the  d egree of cancer  ce l l d i s semi nat ion  i n  the  b l ood . 
2 .  Al terat i o n s  i n  humoral immun i ty 
Al tered B-cel l respon s i veness  to s heep erythrocytes ( SRBC )  i n  
l ymphoma s , a s c i tes and so l i d  mu ri ne  tumors  ha s  been measured a t  the 
l evel of the i nd i v i du a l  ant i body cel l i n  l ympho i d  t i s s ues ( Ger i c ke 
et � . , 1 97 1 ; Kamo and I s h i d a , 1 97 1 ; Ceg l owsk i  and  Fri edman , 1 968 ; 
Kamo et �. , 1 97 6 )  and a t  the l evel  of  serum ant i bodies ( Se i gel  and 
Morton , 1 966 ; Cegl ows k i  and Fri edman , 1 968 ) . General l y ,  the res u l ts  
have  i nd i cated that the degree of  depre s s i on of the pr imary ant i body 
respon se i s  d i rect l y  re l ated to the extent of neopl a s i a  at the t ime 
of i mmun i za t i on . I n  contrast ,  stud i es on the secondary or  the 
amnest i c  response have y i el ded d i vergent resu l ts .  Se i gel  and Morton 
( 1 96 6 )  reported that the secondary respon se  to S RBC i s  not depres sed 
i n  m i ce i nfl i cted wi th Rau s c her  v i ru s , whereas the wor k  of Ceg l ows k i  
a n d  Fri edman ( 1 968 ) i n d i cated that both 7 s  a n d  1 9s ant i body form i ng 
cel l s  are s uppres sed i n  secondary- st imu l ated m i ce bea r i ng the same 
l eu kemi a .  I n  mastocytoma-beari ng  DBA/2 m i ce Kamo and Fri edman ( 1 97 7 )  
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noted a sel ect ive  depre s s i on of I gM ant i body form i ng cel l s  wi th no 
s i gn i f i cant c hanges i n  I gG l evel s .  
Mea suremen t of compl ement act i v i ty i n  tumor bear i ng a n ima l s has  
a l so y i el ded d i vergent resu l ts .  Stud i es wi th seven transpl antabl e 
mur i ne tumors i nd i cated that host  compl ement  act i v i ty i s  depres sed 
i n  a l l cases  after tumor tran s fe r ,  but the rate and extent of depre s -
s i on wa s vari abl e ( Hartve i t ,  1 965 ; Dra ke et � . , 1 973 ) . The res u l t s  
of t hese  exper iments suggested that  d i fferent compl ement components 
may be affected in  each case  a s  there wa s no correl a t i on between i mmune 
adherence and hemo l yt i c compl ement act i v i t i e s . Furthermore , there 
appeared to be no corre l a t i on between the mean s u rv i va l  t ime of tumor 
bea r i ng a n ima l s and depre s s i on of compl ement  act i v i ty .  I n  contra s t , 
Thunol d ,  et � .  ( 1 973 ) reported normal Cl q  and C3 l evels i n  m i ce bear i ng  
Ehrl i c h carci noma wh i l e  Weimer  et � .  ( 1 964 )  noted el eva ted serum com­
p l ement l evel s i n  tumor-bear i ng ra ts and  rabb i ts . Whether these d i f -
ferences are due to en hancement or  s u ppre s s i on of ant i body f i x a t i on 
has not yet been c l ar i f i ed .  
3 .  Al terat i on s  i n  cel l med i ated i mmun i ty 
Depres sed cel l med i a ted i mmun i ty has  been reported for a vari ety 
of mu ri ne tumor systems . The presence of a growi ng tumor has  been 
documented to cause  s i gn i fi cant  curta i l ment of graft-versu s-host  reac -
t i on s  � v i vo ( S i d ky and Auerbach , 1 976 ; Med z i hrad s ky et � . , 1 972 ) 
as we l l  a s  s uppres sed bl a s togen i c  responses  to phytohemagg l u t i n i n  ( PHA)  
and other m i togen s � v i tro ( Levy et � . , 1 974 ; Padaraths i ngh  et � . ,  
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1 977;  K i l burn et  �. , 1 974; G i l l ette and Boone , 1 97 5 ) . Other i nvest i -
gat ions  have revea l ed a correl a t i on between tumor growth and l os s  of 
T-he l per cel l act i v i ty ( Ta katsu  et �. , 1 974 ) . The work of G i l l ette 
and Boone ( 1 97 3 )  u t i l i z i ng f i ve d i fferent mur i ne tumor l i nes suggested 
that the T-cel l depre s s i on i s  a genera l i zed phenomenon i ndependent of 
tumorogen i c i ty ,  i mmunogen i c i ty or  t i s s ue of  or i g i n  of  the tumor .  
4 .  Proposed mecha n i sms for tumor i nduced i mmuno l og i c  
def i c i enc i e s  
Under ly i n g  the d i mi n i s hed i mmuno l og i c  competence of tumor beari ng 
an ima l s are hematol og i cal  c hanges and a l terat i on s  in l ympho i d  cel l pop-
u l a t i on s .  I n  C57BL/6  m i ce bear i n g  the LLC a marked hemo l yt i c  anem i a  
h a s  been observed i n  conjunct i on wi th the appearance of  thrombocyto­
pen i a  ( Pogg i et �. , 1 97 6 ) . I n  s u bsequent s tud i es wi th  the s ame tumor 
l i ne , bone marrow smears have revea l ed a moderate normob l a st i c  hyper-
pl a s i a  ( Pogg i  et �. , 1 977 ) . The work of  other i nvest i gators  have s u g ­
ges ted t hat  a T cel l defi c i ency i n  t he  reg i ona l  l ymph nodes accompan i es 
progres s i ve tumor g rowth ( Lori ng and Sch l e s i nger , 1 970; Rowl and et �. , 
1 974 ) . 
Spl enomega l y ,  wh i c h  often accompan i es tumor growth , has  been 
attri buted to the ex i stence of a con s i stant a n t i gen i c  s t imu l u s  ( Kamo 
and Fri edman , 1 97 7 ) , an i ncrease  i n  erythropo i e t i c  act i v i ty ( G i l l ette 
and Boone ,  1 97 5 ) , the presence of metas ta s i zed tumor cel l s  ( Kamo 
et �" 1 97 6 )  or  an i ncrease  i n  the n umber of trapped l ymphocytes 
( Fightl i n  et �. , 1 975 ) . Yet desp i te th i s  sp l en i c  enl argement , a 
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h i stol o g i c  l os s  of thymu s  dependent areas of the spl een has  been 
noted by several i nvest i gators ( G i l l ette and Boone , 1 974 ; Takatsu 
et �"' 1 972 ; G i l l ette and Boone , 1 975 ) . Data publ i s hed by G i l l ette 
and Boone ( 1 975 ) i nd i cated that the l ymphocyte content  of  sp l een cel l 
prepara t i on s  from tumor-bear i ng  an imal s drops from 80 to l es s  than 
25% wi th  a concomi tant i ncrease i n  myel o i d  e l ements . 
I n  contra s t ,  the work of  Tra i n i n  and  co-workers wi th the LLC s ug ­
gests  t hat  the  sp l een i s  compri sed of  l ymph o i d  s ubpopu l at i ons  wi th 
oppo s i ng reacti v i t i es . Fract i onat i on of sen s i t i zed l ympho i d  cel l s  by 
vel oc i ty sed i mentat i on y i el ded a s ubpopu l at i on of  l ymphocytes i n  a 
b l a st s tage capab l e of  enhanc i ng tumor growth and of  nonspec i fi ca l l y  
suppress i ng the ant i gen i c  respon se e l i c i ted by a fract i on o f  sma l l er 
l ymphocytes ( Sma l l and Tra i n i n , 1 976 ) . The occurrence of the sp l en i c  
s u bpopu l at i on s  i n  normal  mi ce i nd i cated that the di fference between 
normal sp l een s and the sp l een s of  tumor-bear i ng  a n i ma l s wa s quant i ta­
t i ve ( Treaves et �. , 1 976 ) .  As tumor growth proceeds ,  there was an 
i ncrease in s uppressor ce l l n umber and act i v i ty .  The i n h i b i tory 
act i v i ty of the l arger b l a s t  ce l l s  predomi nated a t  the t ime of v i s i b l e  
l ung  metastas i s  ( Treaves e t  �., 1 974 ) . Adopt i ve transfer experiments 
ut i l i z i ng l ympho i d  cel l s  from the sp l een , thymus and bone marrow i nd i ­
cated that thymu s  deri ved s pl een lymphocytes are the cel l s  wh i c h  
med i ate the i mpa i rment o f  i mmune reac t i v i ty a n d  en hancement of  tumor 
growth ( Um i e l  and Tra i n i n , 1 974 ; Carnaud et  �"' 1 974 ) . 
However ,  i t  has  not yet been demonstrated whether the same T­
l ymphocyte can exh i b i t  both s uppy"e s s i ve and act ive  propert i es under 
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chan g i ng cond i t i on s  or  whether d i st i nct  s pl en i c  s ubpopu l at i on s  ex i st .  
I t  i s  a l so unc l ear a s  to whether the same s u bpopul at i o n  o f  suppre s sor 
cel l s  can suppress  an  a nt i gen i c  respon se  and a l so be i nvol ved i n  tumor 
growt h enhancement ,  a l though both types of s u ppres s i on have been e l im i ­
nated by i dent i c a l  procedures ( Rotter and  Tra i n i n , 1 97 5 ) . 
Further i nves t i gat i o n s  have revea l ed that a so l ub l e fac tor found 
in  the med i a  of c u l tured s pl een cel l s  from LLC bear i ng  a n i ma l s has  
s i m i l ar s u ppre s s i ve act i v i ty ( Treaves et  a l . ,  1 97 6 ) . Removal  of 
T - lymphocytes prevented the a ppearance of  th i s  factor in the c u l ture 
med i a  whereas  removal  of  B - l ymphocytes  and  macrophages was wi thout 
effect . Th i s  s u ppressor act i v i ty ,  however ,  i s  bel i eved to be nons pec i ­
f i c because  non-rel ated i mmune act i v i t i e s  s u c h  a s  PHA res po n s i vene s s  
i n  tumor bear i ng  an ima l s were a l so s u ppressed by s uch  factors ( Ad l er 
et  �. ,  1 97 1 ) .  I n  add i t i on , th i s s uppre s sor fac tor d i d  not  req u i re 
stra i n  compati b i l i ty between the factor-produ c i n g  ce l l s  and  the rec i ­
p i ents . The s uppressor  factor produced i n  LLC  bear i n g  a n ima l s cou l d  
a l so en hance the syngene i c growth o f  tumors i n  C3H m i ce . Pa ra l l el 
i n vest i gat ions  i n  other tumor l i nes by the s ame i nvest i gators imp l y  
that t h e  a ppearance of  suppre s sor factors i s  a genera l i zed phenomenon 
i n  tumor bear i n g  m i ce ( Treaves et � . ,  1 97 6 ) . 
Stud i es a i med a t  e l uc i da t i n g  the mode of act i on of th i s  s uppre s ­
sor  s ubstance s uggested t h at  th i s  so l ub l e factor s uppres ses  t he  i mmune 
competence of  the hos t , wh i c h  l eads  i nd i rectl y to en hancement of tumor 
growth . Prev i ou s  s tud i es by Carnaud � �. ( 1 974 )  wh i c h have documented 
an  i ncreased n umber of  l ung  metastases  i n  i mmuno l og i ca l l y  i mpai red LLC 
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animals support this concept. The cell types and immune reactivities 
affected by this suppressor factor are yet to be determined. 
A number of other possible mechanisms for the decreased immunolo­
gic capabilities of tumor-bearing animals also appear in the literature. 
All the proposed mechanisms require continued presence of the tumor 
for immune suppression. This dependency is evidenced by the reversi­
bility of immunosuppression after surgical removal of the tumor burden 
(Bray and Keast, 1975; Gillette and Boone, 1975). Additional support 
for this concept is derived from transfer experiments which demonstrated 
that spleen cells from immunologically impaired tumor bearing animals 
could still express immune competence when transferred to irradiated 
syngeneic recipients (r-1ocarelli et � . , 1973; James f1�., 1974b; 
Hrsak and Marotti, 1975). 
Several reports have proposed that the imnunosuppression results 
from the recruitment of reactive T and B cells from the spleen in 
response to the tumor (Gillette and Boone, 1975). Alternatively, in 
studies which have shown no change in lymphoid populations the possi­
bility exists that the reactive lymphoid cells may have been replaced 
in the spleen by more immature, less reactive cells (Padarathsingh 
et �., 1977). The work of Frost and Lance (1973) suggested that the 
presence of a tumor suppresses lymphocyte trapping, i.e. the migration 
of lymphocytes to the spleen to promote the antigen, macrophage and 
lymphocyte interaction necessary for the generation of an immune 
response. 
Attuned to the observation of Webb (1970) that serum "recognition 
factors" are important for macrophage function, Saba and Antikatzides 
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( 1 975 ) have reported a correl a t i on between decreased l evel s of opson i c  
serum prote i n  and i mpa i red phagocyto s i s  i n  tumor-beari ng  a n ima l s .  I n  
add i t i on ,  North et �. ( 1 97 6 )  have recent l y  d i s covered a d i a l i zab l e 
phagocytos i s  depress i ng factor i n  tunlor bear i n g  m i ce . These f i n d i ng s , 
ta ken together wi th the observat i on s  of  depressed phagocyto s i s i n  tumor­
bear i ng an imal s suggests  that decreased l evel s of a recogn i t i on factor 
and i n creased l evel s of  a phagocytos i s  depres s i ng factor may affec t  
macrophage funct i on , wh i c h ,  i n  turn , may s u ppress  t h e  norma l i mmune 
respon s i vene s s  of  a tumor beari ng  a n i ma l . Furthermore , a s  the add i t i on 
of peri toneal  exudate cel l s  effec t i ve l y  restores norma l i mmunocompe­
tence to s pl een cel l s  from tumor bear i ng a n i ma l s ,  a nt i gen i c  compet i t i on 
for s pec i fi c  s i tes  on macrophages ha s  a l so been con s i dered the pos s i bl e  
mechan i sm of  i mmunol og i c  suppre s s i on ( Pros s  and E i d i nger , 1 974 ; Fel dman 
and Schrader , 1 974 ) . 
E l eva ted l evel s of  a normal serum component , a l pha2-g 1 0bu l i n, 
dur i ng  progre s s i ve tumor growth ha s  a l so been reported to affect general 
i mmune competence . Al though  the actua l  mechan i sm of  s u ppres s i on by 
th i s  serum factor i s  s t i l l  unc l ear ,  i nvest i gat i on s  by Menzo i an et � .  
( 1 974 )  have s uggested that t h e  target cel l s  for a l pha2 -g 1 0bu l i n  are 
T cel l s .  
Sol u b l e factors rel eased by tumor cel l s  a l so appear to be abl e 
to i n h i b i t  or regu l ate l ymphoprol i ferat i ve respon ses . Prostagl and i n s , 
RNA , i mmune compl exes , a l ong  wi th pept i des  and  prote i n s  of var ious  
mo l ec u l ar we i g hts  have  a l l been impl i cated i n  s uppres s i ng the  host  
res i s tance i n  tumor- bear i n g  m i ce .  A rev i ew of  th i s  s ubject has  been 
recent ly  publ i s hed by Kamo and Fri edman ( 1 97 7 ) . 
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Las t l y ,  the wel l documen ted effects  of  n u tr i t i onal def i c i en c i es 
and m i cro b i al contam i nat i on mu s t  al so be con s i dered as contr i b u t i n g  
fac tors to  t he  s uppressed i mmune s tatus of tumor-bear i ng an i mal s .  
The work  of Jose and Good ( 1 973 ) has reveal ed t hat m i ce mai ntai ned 
on d i ets def i c i en t  i n  e s sent i al ami no ac i d s exh i b i t  marked l y  suppressed 
humoral and cel l u l ar responses . S i m i l ar l y ,  c h ron i c  i n fec t i on wi th 
l act i c dehydrogenase v i ru s  and other nononcogen i c  v i ruses  has al so been 
s hown to i nduce i mmunosuppre s s i on i n  tumor-bear i ng an i mal s ( I o r i o et �. , 
1 974 ; Ri l ey ,  1 974 ) . 
I n  s ummary , the ab i l i ty to man i fest  normal i mmune res pon s i veness  
i s  u s ual l y  comprom i sed in  tumor-bear i ng  hosts . A number of pos s i b l e  
mec han i sms have been c i ted for the tumor- i nduced i n numosuppres s i on 
wh i c h i mpl i cate d i fferent aspects  of  the host  defen se system . The 
rel evance of t h i s work  i s  that the se l ect i on of  a part i c u l ar i mmuno­
potent i ator to be u sed i n  t umor - i mmunotherapy may , in  part , depend on 
whether the t umor- bear i ng host  i s  s uppres sed or  not and , i f  so , what 
the nature of the i mmunodef i c i ency is , i . e .  does i t  res i de at the T 
ce l l ,  B ce l l ,  o r  macrophage l eve l ? 
C .  Immunomodul ators a s  Ant i tumor Agents 
At present our  ab i l i ty to con trol tumor g rowth wi th non s pec i fi c  
i mmunotherapy i s  modest  but progress  has been made toward defi n i ng 
cond i t i on s  for opt imal i mmunotherapy . Tumor s i ze has con s t i tuted a 
cr i t i cal l im i tat i on of therapy wi th most  i mmunomodul ators Mathe et �. , 
1 969; Zbar et �. , 1 972 ) . I n  general , l arger tumors are l e s s  s u scept i -
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bl e to immunothera py .  D i rect contact between the tumor cel l s  and 
the i mmunomodu l a tor favors s ucce s s fu l  immunotherapy ( L i k hi te, 1974; 
et  �. , 1 976 )  yet  even  when contact  between immunomodu l ators and tumor 
cel l s  i s  a s sured , some tumors have res i s ted treatmen t  ( Sparks et  �. , 
1 974 ) . The a b i l i ty of the host  to deve l op an immune response  to tumor 
assoc i ated ant i gens  a l so a ppears  to contri bute to s uccessfu l  immuno­
therapy .  T h e  more s trong 1 y i mmunogen i c tumors have , i n  genera 1 ,  been 
more s u sceptab l e to treatmen t ( Parr , 1 972; Ba l dwi n and P imm ,  1 9 73 ) . 
The i mmune s tatus  of t he tumor-bear i ng host  i s  another con tr i but i ng 
factor whi ch  i n fl uences the effi cacy of i mmunotherapy . The tumor 
growth reta rd i ng properti es  of many i mmunomodu l ators are l es s  effec ­
t i ve i n  i mmunosuppre s s ed a n i ma l s ( Hanna  et  �. , 1 9 73; Scott , 1 9 7 5 ) . 
Furthermore , the adm i n i stra t i on of i mmunomodu l ators to a n ima l s wi th  
l ow l eve l s  of immune res pon s i veness  has been reported to  enhance  tumor 
growth ( Prehn , 1 97 1 ; Sj ogren et  �. , 1972 ) .  These f i ndi ngs  i nd i cate 
the pos s i bl e  dangers i nvol ved wi th  i mmunotherapy and empha s i ze the 
neces s i ty for del i neat i ng the mode of act i on and parameters of  appl i ­
cat ion before rat i onal immunotherapeut i c reg i mens  can  be des i gned . 
Of a l l the  i mmunomodulators s hown to i n h i b i t  growth of syngene i c  
tumors two immunomodu l ators were se l ected for s tudy i n  these i nves ­
t i gat ion s: the syn thet i c  polyan i on pyran and the b i ol og i ca l  vacc i n e  
C .  parvum . 
1 . Pyran copo 1 ymer 
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Pyran copo lymer ( 4 ,  5 - d i carboxy tetrahydro- 6 -methyl ene pyran-
2 - s ucc i n i c  ac i d ,  d i a nhydr i de po l yme r ) , i s  one of the most  w i de ly  
stud i ed po l yan i on po l ymers . The copo l ymer wa s f i rst  synthe s i zed 
by Butl er ( 1 960 )  by po l ymeri zat ion  of d i v i nyl ether ( D I VE ) and mal e i c  
anhydr i de ( MA )  i n  a 1 : 2 copo l ymer ra t i o  and i s  therefore often refer­
red to  in  the l i terature a s  D I VEMA . Yet , s i n ce the tetrahydropyran 
r i ng i s  an i n tegra l part of the po l ymer c h a i n ,  the po l ymer became 
wi de ly  known as pyran copo lymer and i s  i ndexed i n  the med i ca l  l i tera­
ture a s  suc h .  
Pyran copo lymer i s  a typ i ca l  anhyd r i de wh i c h under phys i o l og i c  
cond i t i on s  becomes hydrol yzed to the correspond i n g  carboxyl i c  ac i d .  
The hydrol ysate o f  pyran has been found to be fa i rl y  stab l e and not 
read i l y  b i odegrada bl e ,  wh i c h  may account for i ts pro l onged act i v i ty 
( Otten bri te and Rege l son , 1 977 ) . Structure act i v i ty s tu d i e s  have 
i n d i cated that the b i o l og i cal  act i v i ty of  pyran i s  dependen t on a h i g h  
den s i ty of free carboxyl ate groups s i tuated a l ong t h e  backbone o f  
the po l ymer .  Pyran po l ymers wi th ca rboxyl ate funct i on s  bound by am i ­
dati on of noncarboxyl ated po l yethyl enes  are i nact i ve at  compara bl e 
doses  ( Bres l ow ,  1 9 76 ) . 
Synthet i c  po l ya n i on s  are known to produce a wi de s pec trum of 
effects on i mmune react i v i ty .  Pyran copo l ymer has  been s hown to 
i n duce the produc t i on of i n terferon ( Meri gan and Regel son , 1 967 ; 
Mer i gan and F i n ke l s te i n ,  1 968 ) , mod i fy RES func t i on ( Mun son et � . , 
1 9 70 ) , and to have i mmunoadj uvant ( Brown et  �., 1 9 70 ; Bai rd and 
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Kapl an , 1 97 5 )  and ant i v i ra l  acti v i ty ( H i rsch  et  �. , 1 9 72 ; Mora han 
et  �. , 1 97 5 ; Morahan and Kapl an, 1 9 76a ) . The ant i v i ra l  acti vi ty 
of pyran has been s tudi ed i n  a number of systems . Pyran trea tment 
protects m i ce from morta l i ty fol l owi ng a l ethal  i nfect i on wi th both 
RNA or DNA cytopa t h i c  v i ruses  ( Came e t  �. , 1 969 ; B i l l i a u  et �. , 1 97 0 ;  
Morahan et  �. , 1 97 2 ) .  Treatment of  m i ce wi th pyran a l so i n h i b i ts 
tumor format i on and del ays morta l i ty after i nfec t i on wi th RNA or DNA 
tumor v i ruses  ( H i rs h  et � . ,  1 97 3 ; Regel son , 1 96/ ) .  The greatest  
protec t i on i s  observed wi th prophyi ac t i c  trea tment  of pyran . Thera ­
peu t i c  treatment often does not a l ter the course  of d i sease  parti cu l ar­
l y  wi th rap i d l y  fata l  i nfect i on s . 
These resu l ts s uggest  that pyran may act  very ear ly  dur i ng the 
v i ral i nfecti on , the drugs  may need to be act i va ted by the a n ima l ,  
and/or the drugs  may act  through  modu l at i on o f  host  responses . Con­
s i derab l e effort has been  d i rected toward defi n i ng the mechan i sm of 
ant i v i ra l  a c t i on . I n ves t i ga t i on s  have fa i l ed to demons trate a corre l a ­
t i on between i n terferon i nduct i on and ant i v i ra l  a ct i v i ty ( Regel  son 
et �. , 1 970 )  and mount i ng  exper imental  ev i dence suggests  that acti ­
vated mac rophages are i nvol ved i n  the ant i v i ra l  a c t i on of pyran 
( B i l l i a u et  �., 1 97 1 ; Morahan et  �. , 1 97 2 ; Morahan � �. ,  1 9 77 ) . 
Pyran copo lymer has  a l so been s hown to have i mmunoadj uvant acti ­
vi ty i n  several a n i ma l  mode l  systems . Severa l i n vest i gators have 
demon strated the abi l i ty of pyran to enhance the pr ima ry ant i body 
re spon se  to the T-dependent ant i gen s heep erythrocytes ( SRBC ) 
.!..!:l v i vo ( Braun  et  �. , 1 970 ; t�ora han � �. ,  1 97 2 ; Ba i rd a nd Ka pl an, 
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1 975 ) . I n  contra s t , pyran wa s unab l e to enhance ant i body forma t i on 
to SRBC i n  thymectomi zed ,  i rrad i a ted , bone marrow recon s t i t u ted mi ce , 
or  to a thym i c  i ndependent ant i gen E .  col i l i popo l ysaccha r i de ( L PS ) 
i n  norma l m i ce  ( Ba i rd and Ka pl an , 1 97 5 ) . H i t h  rega rd to T -ce l l 
reacti v i ty a s  mea sured by ce l l  med ia ted cytotox i c i ty ,  pyran treatment 
pr i or to a l l ogene i c  tumor ce l l c ha l l enge caused a decrea s e  in s p l een 
cel l cyto l yti c act i v i ty i n  addi t i on to del ay i n g  the t i me of the peak 
response  ( Ba i rd and Kapl an , 1 975 ) . A s i n g l e i ntravenous  i nject ion  
of pyran ha s a l so been s hown to  s i gn i f i cant ly  depre s s  the � v i tro 
b l a s togen i c  response  of sp l een cel l s  to PHA a s  mea s ured by counts  per 
mi nute of  tri t i ated thymi d i ne  i nto DNA at  var i o u s  t i me s  2 - 1 4 days 
after � v i vo admi n i stra t i on ( Ba i rd and Kap l an , 1 975 ) . 
These  resu l ts are con s i stent wi th a dua l act i on of  pyran on T­
l ymphocytes and macrophages i n  the modu l at i on of the i mmune res pon se . 
The enhancement of the  ant i body respons e  to SRBC and the  i nab i l i ty to 
obta i n  comparab l e enhancement of the ant i body response to a T­
i ndependent ant i gen ( LP S )  or  a T -dependent  ant i gen ( SRBC ) in  T ­
depl eted mi ce i s  compat i bl e wi th  a di rect act i on on thymu s -deri ved 
l ymphocytes . The i n h i b i tory effect of pyran on ce l l -med i a ted cyto ­
tox i c i ty cou l d  be due to a di rect acti on on T ce 1 1 s ,  or an i ndi rect 
effect med i ated by macrophages . The i n h i b i tory e ffects of pyran on 
PHA b l a s togene s i s may be mac rophage medi ated , a s  removal  of g l a s s  
adherent ce l l s  from the sp l eens  o f  pyran treated m i c e  res tored the 
PHA respon se  ( Ba i rd and Kapl an , 1 977 ) . 
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The  ant i neopl a st i c act i v i ty of  pyran has  been wel l documented i n  
var i ous  tumor l i ne s  i nc l u d i ng  the Rauscher ( C h i r i go s , 1 970 ) , L 1 2 1 0 
( Mohr  et  �. , 1 976a ) , LSTRA (Mohr et �. , 1 97 5 )  and MBL-2  ( Mohr 
et  �. , 1 97 6 b )  l eu kem i a s  a s  we l l  as  the Mad i son 1 09 carc i noma ( Ma rks  
et  �. , 1 97 7 ) , B- 1 6 mel anoma ( H i rc h  et  �. , 1 97 3 ) , a methyl c ho l anth­
rene i nduced f i brosarcoma ( Morahan and  Kapl an , 1 976a ) and  the Lewi s 
l ung  carc i noma ( Morahan et �. , 1 974 ; Snodgras s  et  �. , 1 97 5 ) . 
Stud i es by Marks  et  �. ( 1 97 7 )  wi th  the M1 09 tumor i nd i cate that 
da i l y systemi c i . p .  trea tment wi th pyra n ( 50 mg/ kg ) i n i t i ated 24 hours 
after tumor i nocu l at i on caused a s l i g ht  reduct i on in  tumor vol ume 
and  produced an average i ncreased l i fe span ( I LS )  of 53% ( range 33% -
72% i n  1 2  experi ments ) .  Da i ly i . p .  treatment wi th  pyran ( 50 mg/ kg )  
on days 1 -8 after tumor i nocul at i on has  a l so been s hown to i n h i bi t  the 
growth of the LLC  and i ncrease  the mean surv i va l  t i me ( MST ) from 3 1 . 9  
days to 50 . 4  days ( Snodgra s s  e t  �. , 1 97 5 ) . I n tra l e s i ona l  treatment 
wi t h  pyran  ( 50 mg/ kg ) on days 3 ,  5 and  7 proved to be more effi cac i ous  
aga i n s t  the LLC . Two mi ce of 1 5  rema i ned tumor free for 60  days after 
tumor i nocu l a t i on and growth was marked l y  retarded i n  the others 
( Morahan and Kap l a n , 1 9 77 ) . 
Experi ment s  des i gned to determi ne  the a b i l i ty of pyran to syner­
g i ze w i th  convent i onal  modes  of t herapy have  y i e l ded d i vergent resul t s . 
Surg i ca l  exc i s i on of the pr imary LLC tumor on day 1 4  comb i ned wi th  i . p . 
pyran treatment twi ce a week  thereafter resu l ted i n  a s i gn i f i cant  
number of l ong -term survi vors ( ) 1 00 days ) wh i c h  s howed no s i gn s  of  
pul monary meta sta s i s .  S i mi l ar experi ments  ut i l i z i ng CTX  as  a cyto-
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reduct i ve agent fa i l ed to pro l ong the MST over  that  observed with  CTX 
a l one ( Dr .  Page S .  Morahan ,  Dept . of Mi crob i o l ogy , MCV ; unpubl i s hed 
observa t i on s ) .  
The rel at i ve success  of pyran aga i n s t  the M1 09 and LLC  ha s  to be 
qua l i fi ed ,  however . The treatment reg i mens  ut i l i zed i n  these  experi ­
ments  do not offer a rea l i s t i c  approach to the management of cancer 
wi th  i mmunomodu l ators , as the tumor burden of the  mi ce at  the start 
of systemi c or  i nt ra l e s i ona l  treatment  wa s bel ow the po i n t of detecta ­
bi l i ty ( Snodgras s  et  � . , 1 975 ) . Moreover , the  meta sta t i c abi l i ty of 
the LLC  tumor l i ne u ti l i zed in  the comb i ned moda l i ty s tud i es has  to 
be quest i oned a s  only 80% of the pr ima ry tumors had meta s ta s i zed by 
day 14 , a s  ev i denced by a 20% surv i va l  rate i n  the  s urgery control s .  
Paradox i ca l l y ,  certa i n  v i ra l l y  i nduced tumors are s t i mu l a ted 
by pyran ( Ga zdar  et � . , 1 972 ; S chu l l er et � . , 1 975 ) . T h i s s t i mu l a ­
t i on may b e  rel ated t o  the  a b i l i ty o f  pyran t o  i nduce hepa tospl enomega l y  
o r  s p l enomeg a l y  i n  norma l mi ce . Pyran has  a l so been s hown to cause  
accel erated deve l opment  of benzo ( a ) -pyrene i nduced s k i n  tumors  i n  
mi ce ( Kr i pke and Bors a s , 1 974 ) and t h i s ra i se s  the  i mportant  po i nt 
t ha t  i mmunomodul ators can often i n h i b i t  or enhance t umor g rowth depend­
i ng on a vari ety of factors i nc l u d i ng the  route  of drug a dmi n i strati on 
( S chu l l er et �. , 1 97 5 )  and i mmune s tatu s  of the t umor-bear i ng host  
( Prehn , 1 97 1 ; Sj ogren et �. , 1 972 ) . 
The ant i tumor act i v i ty of pyran  i s  apparen t l y  not due to d i rect 
c ytotox i c i ty .  Stud i es o f  � v i tro cytotox i c i ty have s hown that 
greater than 1 mg/ml of pyran i s  requ i red to destroy 50% of  e i ther 
tumor cel l s  o r  normal ce l l s ,  in contrast  to n i trogen mustard wh i c h 
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at  concentrat i ons  of 9 . 5  ug/ml destroyed 50% of the cells ( Morahan 
et �. , 1 974 ) . Severa l l i nes  of ev i dence s uggest  that the mechan i sm 
of anti tumor act i v i ty i s  med i ated by macrophages .  When severa l prepa -
rati ons  of pyran and polyacryl i c  a c i d  were tested for ant i tumor act i v i -
ty aga i n s t  the LLC , only those preparati ons  whi ch  acti vated macrophages 
had ant i tumor act i v i ty ( Morahan and Kaplan , 1 976a ) . Moreover , peri -
toneal macrophages  harvested from mi ce  treated wi th  pyran ( 50 mg/ k g )  
i ntraperi toneally were cytotox i c  for L L C  tumor cell s � v i tro , wherea s 
norma l macrophages were wi thout effect ( Kap l an � �. ,  1 974 ; Rege l son 
et �. , 1 974 ) . Pyran act i vated per i toneal macrophages mi xed wi th  LLC 
tumor cell s � v i tro and transp l anted i nto syngene i c  rec i p i ents  has 
also been s hown to i n h i bi t  tumor growth  � v i vo ( Ka p l a n  and  Mora han , 
1 976 ) . Morpholo g i c ally , Snodgra s s  et  � ( 1 97 5 )  have noted an  i n creased 
i nf iltrat i on of h i s t i ocytes i nto the pr ima ry tumor bed i n  pyran ( i  . p . ) 
treated mi ce . Although these  data i nd i cate that pyran act i vated macro -
pha ge s  have ant i neopla s t i c act i v i ty ,  proof i s  st i l l  needed that these  
cell s a re pyran ' s  major  effector ce l l � v i vo .  
Both the b i o l og i c  act i v i ty and tox i c i ty of pyran ha s  been s hown 
to be c l o sely related to i ts molecu l ar we i ght  ( Regel son � �. ,  1 975 ) , 
a l though th i s  relat i on s h i p does not appea r to be  a l i nea r one . Mo st  
of the experi mental resea rch with  pyran has  been  done  wi t h  the po l y ­
d i sperse , broad molecular we i g ht range polymer Hercules X A  1 24 - 1 7 7  
wh i c h has  an average mol ecular we i g ht  of 30 , 000 dalton s .  Th i s  com-
pound has been reported to cause  s en s i t i z at i on to endotox i n ,  i n h i b i t i on 
of mi crosomal enzyme s  and hepatos plenomegaly i n  an ima l  model s 
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(Ottenbri te et  �. , 1 978 ) .  C l i n i ca l l y ,  pyran was found to i nduce 
thrombocytopen i a , fever , hypoten s i on , s e i z ures , and compl ete l o s s  
o f  v i s i on ( Regel son et  �, 1 977 ) . Other tox i c  s i de effects  i nc l uded 
fac i a l  edema , onset of  ang i na wi th  myocard i a l  i nfa rct i on , confu s i on 
and somno l ence . 
I n  an effort to i mprove the therapeut i c  i ndex of  pyran , Dr . Dav i d  
Bre s l ow ( Hercu l e s  I nc . , W i l mi ng ton , Del . ) has  prepared pyran a t  l ow 
temperatures i n  acetone u s i ng a free-rad i cal  i n i t i a tor and tetra hy­
drofuran as a c ha i n -transfer agent ( Bre s l ow ,  1 976 ) . T h i s method has  
yi e l ded control l ed mol ecu l ar  we i ght  po l ymers wi t h  narrow pol yd i sper­
s i ty wh i ch ,  a t  the request  of Hercu l es I nc . , have been renamed ma l e i c  
v i nyl  ether ( MVE ) . Recent stud i es by Mora han et �. , ( 1 978 ) have 
s hown that the l ower mo l ecu l ar  we i g ht  MVE fracti ons  po s se s s  l ower 




as wel l as decreased a b i l i ­
ti e s  to sen s i t i ze to endotox i n ,  i n h i bi t  mi crosomal enzymes or i nduce 
hepatosp l enomega l y .  The ant i tumor act i v i ty o f  two o f  these  fra c t i on s , 
MVE · 2  ( M . W .  1 5 , 500 ) and MVE · 3  ( M . W .  2 1 , 300 ) were i nvesti gated i n  the 
course of our work . 
2 .  Corynebacteri um parvum 
A number of anaer"ob i c coryneforms have been s hown to pos se s s  
anti tumor act i v i ty ( Ha l pern et  �. , 1 966 ; Woodruff a nd  Boa k , 1 966 ) , 
yet unti l recentl y ,  the taxonom i c  c l a s s i f i cati on of these  orga n i sms 
has been confu s i ng .  I n  1 972  Johnson and Cumm i n s  attempted to c l a r i fy 
the taxonomy of the anaerob i c coryneforms u s i ng sero l ogy , cel l wa l l  
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compo s i t i on and DNA homo l ogy . Thei r concl u s i on s  were that  they s hou l d  
be ca l l ed Prop ion i bacter i a , s i nce t hey produce prop i o n i c  a c i d  by fer­
menta t i on , and s hou l d  be d i v i ded i n to three groups ; P .  acnes , 
P .  gra n u l o s um and P .  a v i d um .  Stud i es by O ' Ne i l l  e t  �. ( 1 97 3 )  found 
ant i tumor act i v i ty among representa t i v e  organi sms from a l l three g roups , 
wi t h  no s i n g l e  spec i e s s howi ng  outr i ght  super i ori ty .  Accord i ng to th i s  
sc heme , the  Burroughs  We l l come Corynebacter i um parvum , u t i l i zed i n  the 
presen t stud i e s i s  c l a s s i fi ed as P .  acnes . However , the  ori g i n a l  ter­
m ino l ogy of  C .  parvum ha s  been reta i ned by mos t  i nvest i gators and  wi l l  
be referred to a s  s uch  i n  these  s tud i e s . 
C .  parvum , i n  the form of hea t -k i l l ed o r  forma l i n - k i l l ed vacc i nes , 
produces a wi de s pectrum of effects on i mmune react i v i ty .  Pretreat ­
ment  of mi ce w i t h  C .  parvum has protected them a ga i n st s ubsequent  i n ­
fec t i on wi th  a vari ety of pathogen s . The effects of C .  parvum aga i n s t  
Staphyl ococcus  a u reus , Bordete l l a  pertus s i s ,  Sa l mone l l a  enter i t i d i s  
and L i s ter i a  monocytogenes  have  been  ev i dent both from pro l onged sur­
v i va l  or permanent  protect i on aga i n st i nfect i on and from decrea sed 
bacte r i a l  counts  in  the l i ver and sp l een ( Ad l am et  �. , 1 97 2 ; R u i ten­
berg and van Noorl e Jansen , 1 975 ) . C .  parvum has  a l so been s hown 
to protect aga i n s t  protozoa l i nfecti ons . An i ncrea sed r e s i stance to 
ma l ar i a  wa s cau sed by C .  parvum i nj ected i n traveno u s l y  6 - 1 9 days be­
fore i n travenous  i nj ect i on of P l a smod i um berghe i  s porozo i te s  ( Nu s senz­
we i g ,  1 967 ) . A s i mi l ar protect i on aga i n s t  P .  v i ncke i , P .  chabaud i , 
and Toxopl asma gond i i has  been reported ( C l ark  e t  a l . ,  1 97 7 ; 
Swartzberg e t  �. , 1 975 ) . The a n t i v i ra l  act i v i ty of C .  parvum has 
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been demonstra ted wi th  encephal omyocard i t i s  v i ru s . I ntraperi toneal 
and i ntravenou s i nocu l a t i ons  of  encephal omyocard i t i s  v i ru s  cau sed 
the deat h  of 95% of norma l Swi s s  m i ce , but l es s  than 50% of those 
treated i ntraper i tonea l l y  wi th C .  parvum ( 0 . 5  mg ) two to seven days 
earl i er ( Cerutt i , 1 975 ) . 
A macrophage-med i a ted res i stance to i nfect i on ha s  been i mp l i cated 
by severa l  i nvesti gators . Protecti on aga i nst  S .  enteri t i d i s d i d  not 
corre l ate w i th any augmenta ti on of s pec i f i c  anti - sa l monel l a  i mmuni ty 
( Col l i n s  and Scott , 1 974 ) , and  protection  aga i n s t  L .  monocytogenes 
st i l l  occurred  i n  the athymi c nude mouse  ( Ru i tenberg and van Noor l e 
Jansen , 1 975 ) . Moreover , Swartz berg et �. ( 1 97 5 )  ha ve reported that 
per i tonea l macrophages from C .  parvum pretreated mi ce i nfected w i t h  
T .  gond i i  were capa b l e of k i l l i ng Toxop l a sma � v i tro . S i mi l arl y ,  
peri tonea l exudates of C .  parvum pretreated mi ce i nfected wi th  
encepha l omyocard i t i s v i ru s  conta i ned a factor wh i c h i n h i bi ted mu l t i ­
pl i ca t i on of the v i ru s  � v i tro ( Cerutt i , 1 975 ) . The  i n h i b i tor was 
res i stant to heat i ng at  56 °C  for 30 mi nutes , but d i d  not requ i re the 
i ntegr i ty of cel l -prote i n  synthes i s ,  a c hara cteri st i c of the b i o l og i ­
ca l  acti vi ty of i nterferon . Moreover , C .  parvum , i n  contras t  to pyran , 
was i ncapab l e  of i nduc i ng i nterferon i n  an � v i tro model ( Cerutt i , 
1 975 ) . 
C .  parvum has  a l so been s hown to mod i fy i mmuno l og i c  respon ses  
to  unre l ated ant i gens . System i c  pretreatment of m i ce  wi th  C .  parvum 
has been s hown to ampl i fy the anti body response to the thymus­
dependent ant i gens  SRBC  ( Bi ozz i  et �. , 1 968 ) and keyho l e  l i mpet 
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hemocyan i n  ( W i ener and Bandi eri , 1 975 ) and to the thymus - i ndependent 
anti gens d i n i trophenol hapten coup l ed to a l evan ca rri er ( de l  
Guerc i o ,  1 97 2 ) a nd  pneumococca l  po lysacchari de S I l l  ( James et  �. , 
1 974a ) .  Howard et � . , ( 1 97 3 )  have reported that the predomonant ly  
T-ce l l dependent I gG response to  SRBC i n  mi ce wa s amp l i fi ed by 
C .  parvum in T-ce l l depr i ved mi ce , wh i c h s uggests  that C .  parvum may 
be opera t i n g  as a T-ce l l bypas s  mechan i sm , pos s i bl y  through d i rect 
s t imu l a t i on of  B ce l l s .  Moreover , lol a ( 1 97 5 )  has  demon strated that 
C .  parvum was mi togen i c  for B l ymphocytes  � v i tro . 
Conversel y ,  C .  parvum treatment has been a s soc i ated wi th  depres ­
s i on of  ce l l -med i a ted i mmune respon ses  to  unrel ated ant i gens . Syste­
m i c  pretreatment wi th  C .  parvum has been s hown to ma rked l y  depress  the 
DTH response to p i cryl c h l o r i de ( A s herson and Al l wood , 1 97 1 ) and SRBC 
( Scott , 1 974a ) , pro l ong the s u rv i va l  of s k i n  a l l ografts ( Ca stro , 1 974 ) 
and protect Fl rec i p i ent  mi ce aga i n s t  the l ethal  effects  of g ra ft 
vers u s  host res u l t i ng from an i nj ec t i on of pa renta l s p l een cel l s  
( B i ozz i  et  � . , 1 965 ) . � v i tro stud i e s  of sp l een cel l s  from C .  parvum 
trea ted m i ce have s hown a depres sed res pon s i venes s  i n  a mi xed l ympho ­
cyte react i on or  to the T -ce l l mi togen PHA ( Scott , 1 97 2 ) . 
The acti va ted macrophage has  been a l l uded to by severa l i nvest i ­
gators a s  the cel l type i n strumenta l i n  C .  parvum med i a ted a l terat i ons  
i n  i mmune respon s i vene s s . W i ener ( 1 97 5 )  s ugges ted that  the  s t i mu l a ­
tory effects of  C .  parvum on ant i body product i on are most  proba b l y  
med i a ted by act i vated macrophages ,  a s  macrophages from C .  parvum 
treated mi ce were more effect i ve than norma l macrophages at  promot i ng 
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a n  i n  v i tro prima ry response  t o  SRBC . Wa tson a n d  S l j i v i c  ( 1 976 ) con-
f i rmed these data and further demonstrated that ant i body respon ses  to  
macrophage i ndependent ant i gens  were not affected by C .  parvum . More ­
over ,  Wi ener and Band i eri  ( 1 97 5 )  have s hown that C .  parvum acti vated 
macrophages reta i n  l arge amounts  of ant i gens  on the i r  s urface and 
suggest that the i r  i nten s i f i ed presenta t i on of anti gen to l ymphocytes 
may be a causa l  factor i n  the adj u vant  act i v i ty of  C .  parvum . Scott 
( 1 974b ) attempted to anal yze the mechan i sm underl y i ng the depre s sed 
cel l -med i a ted reacti v i ty and has  s hown that the DTH depre s s i on d i d  
not occur  i n  s p l enectom i zed mi ce and removal  o f  macrophages  from 
C .  parvum s t i mu l ated sp l een ce l l s  compl ete l y  restored PHA react i v i ty .  
The effi cacy o f  C .  parvum i n  an imal  tumor mode l s has been h i g h l y  
vari a b l e .  As  wi th  pyra n ,  th i s  var i a b i l i ty may b e  re l a ted t o  t h e  i mmuno­
gen i c i ty of the tumor under s tudy ( Sm i t h  and Scott , 1 97 2 ) , the  s i ze of 
the tumor ma s s  a t  the s ta rt of t herapy ( F i s her et  �. , 1 970 ; Scott , 
1 975a ) , the i mmune competence of the tumor bea r i n g  host  ( Scott , 1 97 5b )  
a nd  the route of C .  parvum admi n i stra t i on ( Scott , 1 974c ) . 
Severa l l aborator i es have exami ned the ant i tumor act i v i ty of 
C .  parvum aga i n s t  the LLC . Ora l admi n i strat i on of  C .  parvum has been 
s hown to be i neffect i ve aga i nst  the LLC . Confl i ct i ng resu l ts have 
been reported for i . p .  and i . v .  C .  parvum trea tment aga i n s t  the LLC . 
Sad l er  and Castro ( 1 976 ) have reported that C .  parvum ( 0 . 4  mg ) admi n -
i stered i . v .  o r  i . p .  7 days after tumor i nocu l at i on resu l ted i n  s i gn i -
f i cant  reduct i on s  i n  the g rowth o f  the pr ima ry tumor and the n umber 
of meta stati c nodu l e s observed on day 2 1 , yet no l i fe s pan data were 
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presented . I n  contrast , Mora han and Kap l an ( 1 976a ) have reported 
that systemi c i . p .  or  i . v .  admi n i strat ion  of C .  pa rvum wa s i neffect ive 
i n  reta rd i n g  the g rowth of the LLC or extendi ng the MST of the tumor­
bea r i ng  mi ce . Di rect i ntra l es i ona l  trea tment wi th  C .  parvum ( 70 mg/ k g )  
o n  day 3 post tumor i nocu l at i on ha s  produced compl ete regres s i on s  i n  
1 7% of mi ce bea r i ng t h e  LLC , yet t h e  rema i n i ng 83% d i sp l ayed an acce l e ­
rated tumor growth rate ( Morahan and Kap l an , 1 977 ) . These data i nd i cate 
some of the dangers i nvol ved wi th  C .  parvum t herapy and s uggest that 
there may be a ba l ance between the benef i c i a l  ant i tumor effects  of 
C .  parvum and i ts i mmunosuppre s s i ve effects . 
I n  comb i nat i on wi th  s urgery , Sad l er  and Castro ( 1 976 ) have repor­
ted that s i ng l e i . v .  or i . p . , but  not s . c .  i nj ec t i ons  of C .  parvum 
( 0 . 4  mg ) wi t h i n  4 days before s urgery reduced the i nc i dence of 
meta s tat i c nodu l es in  the LLC tumor mode l . Yet , the s i gn i fi cance of 
these resu l ts must be q uest i oned a s  aga i n  no l i fe s pan  data were pre ­
sented . 
S i mi l ar to pyran , the ant i tumor act i v i ty of C .  parvum i s  apparent­
ly  not due to d i rect cytotox i c i ty .  C .  parvum added to mou s e  s arcoma 
cel l s  � vi tro d i d  not i n h i bi t  t he i r  DNA synthes i s  or a l ter the i r  
abi l i ty t o  form co l on i es � v i tro (M i l a s and Scott , 1 978 ) . The resu l ts 
of numerous  i nvesti gat i ons , however ,  are compat i b l e  wi th  a macrophage 
med i a ted ant i tumor response . Scott ( 1 974b )  has  demonstraed that 
peri tonea l macrophages from mi ce trea ted wi th C .  parvum i n h i b i ted 
the � vi tro growth and DNA synthes i s  of syngene i c  ma s tocytoma ce l l s ,  
and a d i rect cytotox i c  effect of C .  parvum act i va ted macrophages on 
LLC cel l s  has been descri bed by Morahan and Kap l an ( 1 976a ) . Non-
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adherent peri tonea l cel l s  from C .  parvum s t imu l ated mi ce d i d  not 
i n h i bi t  tumor ce l l growth � vi tro and procedures for remov i ng l ympho­
cytes from peri tonea l ce l l s  such a s  exten s i ve was h i n g , tryps i n i zati on 
or i rrad i a t i on d i d  not i mpa i r  the ant i tumor act i v i ty of the peri tonea l 
cel l s  ( S cott , 1 974b ) . S i mi l arl y ,  the cytotox i c  act i v i ty of  C .  parvum 
treated sp l een cel l s  wa s found to be unaffected by treatment wi th  
anti -theta -serum and compl emen t ,  wherea s macrophage removal  u s i ng 
rayon adherence o l umns or i ron magneti c techn i ques  a l mo st  ent i re l y  
abol i s hed t h e  response  ( Ki rchner e t  �. , 1 975 ) . 
The i nvol vement of  act i va ted macrophages � v i vo i s  i mp l i ed by the 
f i n d i ngs  of McBr i de et �. ( 1 975 ) . They demons trated that gol d s a l ts , 
wh i c h i n h i b i t  macrophage l ysosoma l enzyme act i v i ty ,  suppre s sed the 
� v i vo protecti ve act ion  of C .  parvum aga i nst  muri ne f i brosarcoma 
cel l s .  Moreover , Mora han and Kap l a n  ( 1 97 7 )  have s hown that the add i -, 
t i on of  peri tonea l macrophages from C .  parvum s t i mu l ted mi ce to LLC 
cel l s  � v i tro and  trans p l a nted i nto syngen e i c  rec i p i ents  resu l ted 
i n  s uppre s s i on of tumor growth � v i vo .  Morpho l og i ca l l y ,  M i l a s et a l . 
( 1 974b ) have noted that mou se  tumors regre s s i ng a fter C .  parvum treat ­
ment were heav i l y  i nf i l trated wi th  macrophages .  Aga i n , a s  wi th  pyran , 
these data i nd i cate that C .  parvum a c t i va ted macrophages have ant i neo ­
p l a st i c act i v i ty ,  yet d i rect ev i dence i s  st i l l  needed that macrophages 
are C .  parvum ' s  major  effector ce l l � v i vo .  
D .  Rad i at i on and The Immune Response 
The effi cacy of rad i otherapy in  cancer treatment has  been 
rea sonab l y  wel l def i ned s i nce i ts f i r s t  therapeut i c  app l i ca t i on 
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aga i n s t  a ba sa l  ce l l epi thel i oma i n  1 899 ( Kap l an , H .  S . , 1 97 7 ) . Yet , 
rad i otherapy l i ke s urgery and c hemotherapy ha s  been s hown to be i mmu­
nosuppress i ve wh i ch cou l d  consti tute a cr i t i ca l  l i mi tat i on to the 
combi ned use of  radi othera py wi th  i mmunomodu 1 a tors i n  the treatment 
of cancer . 
The s uppre s s i ve effects  of rad i a t i on on the h umora l  ant i body 
respon se  have been recog n i zed for many yea rs ( Hektoen , 1 9 1 5 ) . D i xon 
et �. ( 1 95 2 )  demonstrated the dose dependent nature of t h i s s uppre s ­
s i on by i rradi at i ng rabb i ts  two days pr ior  t o  the i nj ecti on o f  bov i ne 
gamma -g l obu l i n .  A s l i g ht  i n h i b i t i on of serum anti body l evel s was 
observed wi th  7 5  rads ( r ) , whereas  200r was a l mo st  tota l l y  i mmunosup­
pre s s i ve .  Cel l u l ar i mmune react i ons  have a l so been s hown to be 
i n h i b i ted as evi denced by pro l ongat i on of a l l ogene i c  g raft s urv i va l  
( Tyan a n d  Co l e ,  1 963 ) , a n d  s uppre s s i on o f  DTH ( Uhr a n d  Scha rff , 1 960 )  
a nd  graft versus  h o st  react i ons  ( Sprent et  �. , 1 974 ) . Yet , perhaps 
the best i l l u strati on s  of the s uppre s s i ve effects of i on i z i ng rad i a ­
t i on have been demonstrated i n  properl y contro l l ed s t ud i e s s howi ng 
a decreased res i stance to i nfect i on wi th spec i f i c  pathogens . An 
i ncrea sed s u scepti bi l i ty to v i ra l  i nfect i on has been frequen t l y  ob­
served in  i rrad i a ted mi ce wi th many types of v i ra l  d i sea ses  i nc l u d i n g  
i nfl uenza ( Smorod i ntsev , 1 957 ) , encepha l omyel i t i s  ( Ta l mage , 1 95 5 )  and 
hepati t i s ( Smi th , 1 963 ) . Stud i e s  wi th  fungal ( Tro i ts ky ,  1 962 ) , 
ri c ketts i a l ( Stoner et  �. , 1 96 5 )  and bacter i a l  pathogen s ( Sc hechme i ster 
et �. , 1 952 ) have documented s i mi l ar f i nd i ng s . Col l ecti vel y ,  these 
stud i es amp l y demonstrate the i mmunosuppres s i ve nature of i on i z i ng 
radi at i on . 
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However , c l o ser exami nat i on of the l i terature revea l s that rad i a ­
t i o n  h a s  d i vergent  effects o n  the i mmune response . Depend i ng o n  a 
number of var i a b l e s , i n c l udi ng the cel l types i nvo l ved i n  the i mmune 
response  and the t ime of rad i a t i on rel a t i ve to ant i gen i nj ecti on , 
i mmune respons i veness  can  be suppressed , unchanged or a ugmented . 
1 .  Rad i a t i on and macrophage act i v i ty 
I t  i s  genera l l y  con s i dered that macrophages are q u i te res i stant 
to rad i a t i on . Di rect h i s to l og i c  stud i es have not s hown ev i dence of 
damage ( Brecher et  �. , 1 948 )  and macrophages i n  i rrad i a ted l ympho i d  
t i s sues  have been noted to b e  very act ive  i n  p hagocyti z i ng t h e  debr i s 
of dead ce l l s  ( Smi th  et �, 1 967 ) . The m i g ra tory act i v i ty of macro­
pha ge s  ha s a l so been  s hown to be q u i te rad i ores i s ta n t  ( Muramats u  et �. , 
1 966 ) a l though Gradeburg et �. ( 1 97 5 )  have reported that the capac i ty 
of phagocytes to repl i cate i s  a s  rad i osen s i t i ve a s  any other ce l l 
popu l a t i on . The i n  v i vo abi l i ty of macrophages to phagocyti ze  and  
c l ea r  RE  part i c l e s from the bl oods tream ( Ge i ger and Ga l l i l y ,  1 974 )  
and the � v i tro capac i ty of mou s e  peri tonea l cel l s  to  eng u l f SRBC 
( P erk i n s  et  �., 1 966 ) has  a l so been shown to be unaffected by doses 
of i rrad i at i on up  to l O , OOOr . 
Ana l ys i s of  vari ou s  b i ochem i ca l  pa rameters however , s uggests  that 
rad i a t i on may enhance macrophage act i v i ty .  Ge i ger and Ga l l i l y ( 1 974 )  
have reported t h at  DNA synthe s i s a nd  c ho l i ne upta ke i n  i rrad i a ted macro­
phages were s l i gh t l y  h i g her and RNA synthe s i s was 6 t i mes  h i gher than 
in  non i rradi a ted control s .  Macrophages i rrad i a ted � v i vo a l so exh i -
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bi ted an enhanced capa c i ty to rel ea se  l ymphocyte acti vati ng factors 
(Ge i ger et �. , 1 973 ) , a mea s ure of macrophage acti vat i on ( Gery et  � . , 
1 972 ) .  Further evi dence of i ncrea sed act i va t i on i s  deri ved from 
stud i e s  wh i c h have demon s trated that l evel s of l ysosoma l enzymes such  
a s  ac i d  phosphatase , catheps i n  and  beta -g l ucuron i da s e  were e l evated i n  
macro phages der i ved from heav i l y  i rradi ated a n i ma l s ( Schmi dke and 
Di xon , 1 973 ) . 
2 .  Rad i at i on and h umora l i mmun i ty 
As  prev i ou s l y  menti oned , rad i a t i on ha s a pronounced detr i menta l 
effect on ant i body forma t i on when i t  i s  g i ven before ant i gen . However , 
numerous i nvesti gators u s i ng var i o u s  ant i gens  i n  ra bb i ts  ( Ke u n i n g  
et �. , 1 963 ) , g u i nea p i g s  ( V 1 a hov i c  and Stankov i c ,  1 96 1 ) and m i ce 
( Hoffste i n  and D i xon , 1 974 ) have confi rmed the i n i t i a l f i nd i ng s  of 
Ta l i a fe rro and Ta l i aferro ( 1 954 )  that  rad i a t i on g i ven after ant i gen i c  
c ha l l enge can res u l t i n  enhancement o f  ant i body product i on . The degree 
of enhancement appears  to be dependent on the anti gen , the t ime i nter-
va l between ant i gen cha l l enge and rad i at i on , and the dose of rad i a t i on . 
Stud i e s  by Schmi dke and Di xon ( 1 97 3 )  have i nd i cated that the 
i ncrea sed respons i venes s  i n  p l aque formi ng ab i l i ty i nduced by rad i at i on 
was not on l y  dependent on the pr imi ng  dose of ant i gen but a l so the t ime 
i nterva l between S RBC cha l l enge and i rrad i at i on . Who l e  body i rrad i a -
t i o n  wi th  440r a t  t i mes other than 4 days after SRBC i nj ect i on ( i  . e .  
3 ,  5 or 6 days ) d i d  not resu l t  i n  enhancement , but  i n  fact suppressed 
the PFC response  i n  v i tro . S im i l ar fi nd i ngs  have been s hown after 
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l oca l  i rrad i at i on wi th  920r of mur i ne l ymph nodes dra i n i ng the s i te 
of ant i gen i nj ecti on . I rrad i a t i on 3 or 4 days after anti gen c ha l ­
l enge resu l ted i n  augmented l evel s of serum ant i body , whereas  i rradi ­
at i on on days 1 or 2 re s u l ted i n  immunosuppress i on ( E l tri ng ham and 
We i s sman , 1 97 7 ) . Al though the proper compar i sons  cou l d not be made 
in the a bove stud i es , the work  of F i tc h  et �. ( 1 956 ) s uggests  that 
in s i tua t i ons  where i rrad i a t i on after ant i gen i c  cha l l enge resu l ts  i n  
immunosuppre s s i on , the degree o f  i mmunosuppress i on may not b e  a s  g reat 
a s  when i rrad i a t i on precedes ant i gen . The dose of rad i at i on a l so 
appea rs  to be a cr i t i ca l  l im i tat i on a s  1 7 5r and 1 25r  who l e body 
expos ure enhanced pr ima ry anti hemocyan i n  ant i body respon ses  i n  SWR/J 
and C3H m ice  respec t i ve l y ,  whereas 300r and 1 50r were i mmunosuppre s ­
s i ve ( Hoffs te i n  and Di xon , 1 974 ) . 
3 .  Rad i a t i on and cel l med i a ted i mmun i ty 
Genera l l y ,  the effects  of rad i a t i on on ce l l -medi ated i mmune 
responses  have pa ra l l e l ed those observed for h umora l immun i ty .  Rad i a ­
t ion  h a s  been reported to suppre s s  DTH reacti ons  when rad i a t i on has  
been g i ven befo re anti gen sen s i t i zat i on (Tr i pathy and Mackanes s ,  1 969 ) , 
wherea s enhancement  of del ayed hypersen s i t i v i ty has  been s hown when 
rats where immun i zed w i t h  bov i ne serum a l bumi n 1 0  days before rece i v i ng 
BOOr of whol e body i rrad i a t i on ( V i s akorpi , 1 972 ) . Model s for measur i ng 
the effects of  rad i a t i on on cel l u l a r  immun i ty ut i l i z i ng Besno i t i a  
jel l i son i  have  s hown that 600r  admi n i stered up to 22 days before 
i nfect i on i n h i b i ted the pr ima ry i mmune respon se  as mea sured by the 
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i nfected a n ima l ' s  s u rv i va l  t ime whereas 1 , BOOr of fracti onated 
who l e  body expos ure were req u i red to i n h i bi t  an estab l i s hed cel l u l ar 
i mmun i ty to th i s  pathogen ( Fren kel  and W i l son , 1 972 ) . 
4 .  P roposed mechan i sms for rad i a t i on i nduced i mmuno l og i c  
enhancement 
These res u l ts s uggest  that cel l -med i a ted i mmun i ty ,  l i ke h umora l 
immun i ty ,  ca n be s uppres sed , unchanged , or  a ugmented by i rrad i a t i on . 
Yet , the � vi vo expre s s i on of i mmune responses  i s  dependent upon the 
i nteract i on of var i o u s  s u bpopu l at i ons  of T and B ce l l s  a s  wel l as the 
parti c i pati on of other non l ympho i d  cel l s .  Di rect s t ud i e s  attempti ng 
to a s se s s  the rel at i ve rad i o sens i t i v i ty of l ymphocyte s u bpopu l at i ons  
and  a scr i be poten t i a l  mechan i sms for  the  a bove f i n d i ng s  have  revea l ed 
that the sens i ti v i ty of l ymphocytes i s  not on l y  a funct i on of  the dose 
of i rrad i a t i on , but i s  a l so dependent on the l ymphocyte s u bpopu l at i on ( s ) 
under i nvest i gat i on , the i r  meta bo l i c  ra te , and the i r  state of d i ffer-
enti at i on . 
A var i ety of approaches have been ut i l i zed to demonstrate tha t 
B cel l s  are more rad i osen s i t i ve than T ce l l s .  Anderson et  � ( 1 974)  
have reported that i rrad i a ted B cel l s  surv i ved con s i dera b l y  l es s  we l l 
than i rrad i a ted T ce l l s  when pl aced i n  t i s s ue c u l ture and fol l owed for 
v i ab l e counts . S i mi l arl y ,  after who l e body i rrad i a t i on ,  a much g rea t -
er reduct i on i n  n umbers of s p l e n i c  B cel l s  than T ce l l s  wa s ob served 
when cel l s u s pen s i ons  were exami ned by i mmunofl uorescence ( Nossa l  and 
P i ke ,  1 97 3 ) . 
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S ubpopu l a t i ons  of T and B ce l l s  have a l so been s hown to d i ffer 
in rad i osen s i t i v i ty .  The d i fferen t i a l  res pons i veness of T ce l l s  to 
PHA and concanav� l i n  A ( Con A) has been empl oyed to defi ne two s u b ­
popu l a t i ons  of T cel l s ,  ori g i na l l y  termed Tl a nd  T2 ( Greaves  et  !L. , 
1 974 ) . T
2 ce l l s  a re preferenti a l l y  respon s i ve to Con A and Tl ce l l s  
equa l l y  response to PHA and Con A .  The work  of Stobo and Pau l  ( 1 97 3 )  
uti l i z i ng tr i t i ated thymi d i ne upta ke a s  a mea sure of T ce l l re spon -
s i venes s  i nd i cated that Tl ce l l s  were more sen s i t i ve to i mmuno suppres ­
s i on by i rrad i a t i on than the T2 popu l at i on . .  O f  perhaps more rel evance 
to th i s  thes i s  proj ect are the fi nd i ngs  of Tada et !L. ( 1 9 7 1 ) wi th  
s uppressor  T cel l s .  The i r  work  i nd i cated that suppre s sor  T ce l l s  
were pa rt i cu l a r ly  sen s i t i ve to l ow doses of i rrad i at i on ( 2 5 -200r ) 
i n  rel at i on to other T cel l s u bpopu l a t i ons , a nd that l ow doses  of 
i rrad i a t i on resu l ted in  augmented l eve l s of i mmune respon s i venes s  
to  T -dependent ant i gen s . B cel l heterogene i ty wi th  regards  to  rad l o ­
sens i t i v i ty h a s  a l so been i mpl i cated by severa l i nvest i gators u s i ng 
cu l tured B l ympho i d  cel l l i nes ( Orewi n ko et !L. ,  1 972 ; Han et !L. ,  
1 974 ) . 
The apparent d i fferences i n  the rad i osen s i t i v i ty of rest i na l ym­
phocyte s u bpopu l at i ons  have not been a scr i bed to b i ochemi ca l d i s s i mi ­
l ari t i es . I kada ( 1 96 9 )  and A l tman and Gerber ( 1 970 )  have stud i ed the 
b i ochemi ca l  consequences of i rrad i a ted l ymphocytes i n  deta i l  and both 
g roups  concl uded that the a l terat i ons  descri bed i n  the i r  respecti ve 
manuscr i pts appea red to be a secondary phenomena occurr i nq s ub sequent l y  
to some undefi ned pr ima ry event . More recent i nvesti ga t i ons  by 
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Anderson and Warner ( 1 976 ) have s uggested that the l ymphocyte hetero­
genei ty wi th  regards to i rrad i at i on was rel a ted to s u bt l e d i fferences 
in the l ymphocyte pl a sma membranes . 
The metabo l i c  rate of l ymphocytes has  a l so been s hown to i n ­
fl uence rad i osen s i t i v i ty i n  that the proce s s  o f  l ymphocyte s t i mu l a t i on 
ha s been characteri zed  by a descreased rad i o sen s i t i v i ty of the 
respond i ng popul a t i on . Vaughan -Smi th  and L i ng ( 1 974 ) , u s i ng tri t i ated 
thymi d i ne to a s se s s  the response of porc i ne l ymphocytes  to Con A ,  
found a roug h l y  exponen t i a l  decrea se  i n  the respon s i venes s  of T 
cel l s  a s  the t ime was i ncrea sed between i rrad i a t i on and s t i mu l a t i on . 
After a 48- hour  separa t i on , the res ponse  was a bout 1 %  of  the non­
i rrad i a ted control c u l ture . However , when Con A was g i ven before 
i rra d i at i on , there was a marked decrease  i n  l ymphocyte rad i osen s i t i ­
v i ty a s  refl ected by a 1 50r s ho u l der on the dose s urv i va l  c urve . 
Simi l ar f i nd i ng s have been reported for mur i ne l ymphocytes u s i ng 
ant i gens  or another T cel l mi togen , PHA ( Conrad , 1 969 ; S prent et  �. , 
1 974 ) . 
I t  ha s been postu l ated by severa l i nvesti gators that s t i mu l ated 
l ymphocytes are more rad i ores i stant beca use  of i ncrea sed repa i r  mecha ­
n i sms . Prempree and Merz ( 1 969 ) documented an i ncrea sed a b i l i ty of 
PHA s t imu l ated mur i ne l ymphocytes to repa i r  c hromosome brea ks  as com­
pared to nons t i mu l ated control s .  S i m i l ar data ha s  been reported for 
h uman l ympho i d  cel l l i ne s  ( Drewi n ko and H umphrey , 1 97 1 ) Stefanescu  
et �. ( 1 972 ) confi rmed that above f i nd i ng s  and noted that the tra n -
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s i t i on from the res t i n g  to the prol i ferat i ng state wa s accompa n i ed 
by the deve l opment of brea k-repa i r  competence . Further evi dence for 
thi s theory has been deri ved from the stud i e s of L i nda h l  and Ede l man 
( 1 968 ) wh i c h noted that PHA s t imu l ated per i p hera l b l ood l ymphocytes 
conta i ned ma rked l y  e l evated DNA po l ymerase  and l i ga se act i v i ty ,  two 
of the enzymes i mp l i cated i n  repa i r  of DNA brea ks  ( Regan � �. ,  1 97 1 ) .  
The i mpl i cat i on s  from the above stud i es are that rad i a t i on not 
on l y  reduces the tumor burden , but  under spec i fi c  c i rcums ta nces , may 
enhance i mmune respon s i venes s . A l though a l l  the reports c i ted i n  th i s 
thes i s  dea l wi th nontumor anti gen s , the pos s i bi l i ty exi s t s  that rad i a ­
t i on can augment immune respon s i veness  toward tumor ant i gens a s  wel l .  
The h i g h rad i o sen s i t i v i ty of B cel l s  and suppressor  T ce l l s ,  i mp l i ­
cdted a s  detr imenta l a s pects of ant i tumor i mmune res ponses , coup l ed 
wi th the rad i ore s i s ta nce of macrophages and prol i fera t i ve T ce l l s  
s uggests  that ant i tumor i mmu n i ty cou l d  poss i b l y  be se l ect i ve l y  pre ­
served or augmented after expos ure to rad i a t i on . I rra d i a t i on ha s a l so 
been s hown to produce changes  i n  the ant i gen i c  structure of  t i s sues  
(Al ekeoff , 1 970 )  wh i c h cou l d  poss i bl y  en hance ant i tumor i mmun i ty by 
an a l terna t i ve mode , i . e .  i ncrea s i n g  tumor cel l ant i gen i c i ty .  
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I I .  MATER IALS AND METHODS 
A .  Exper imenta l An i ma l s 
C57BL/6 and BDF1 ( C57BL/6 x DBA/ 2 )  m i ce were u sed for exper i men­
tati on in  the LLC stud i es wherea s Ba 1 b/c and CDF1 ( Ba 1 b/c x DBA/2 ) 
mi ce were u t i l i zed  i n  stud i e s  i nvol v i ng the M1 09 tumor system . 
These mi ce were obtai ned through  the courtesy of the Nati ona l Cancer 
I n st i tute from S i monsen Labora tori e s  ( G i l roy , Ca l i f . ) .  
Upon arr i va l , the m i ce  were randomi zed and accl i ma ted for a t  
l ea s t  o n e  week  pri or t o  experi menta l u s e . The mi ce were ma i nta i ned 
on Pur i na Laboratory Chow and tap water � l i b i tum i n  temperature 
contro l l ed q uarters wi th a 1 2  hr l i g ht  - 1 2  hr dark cyc l e .  
Rout i ne l y  s i x  to e i ght  week  o l d ma l e  or fema l e  m i ce , we i gh i ng 
from 1 8  to 25  gm , were u sed for exper i mentat i on .  I n  s t ud i es des i gned 
to mea sure the DTH response to SRBC , 1 0  week  o l d mi ce were u sed to 
opt im i ze the DTH respon se . W i th i n  a s i ng l e  experi ment however , a l l 
mi ce were matched for age and  sex . 
Mouse  sera were per i od i ca l l y  tested for the presence of l ac t i c  
dehydrogenase v i ru s  by M i crobi o l og i ca l  A s soc i a tes  ( Bethesda , r1d . )  
and found to be negat i ve . 
B .  Enumera t i on of Cel l s  
Concentrat ion s  of  s p l een ce l l s ,  red b l ood cel l s ,  whi te b l ood 
cel l s  and tryps i n i zed tumor cel l s  were determi ned on a Cou l ter Counter 
model  ZBI  ( Cou l ter E l ectron i c s ;  H i a l ea h ,  F l a . ) .  Pri or to use wi th  a 
41  
spec i f i c  cel l type , the Cou l ter Counter was ca l i brated by modu l ati ng 
the amperage , a perature and  thre s ho l d setti ngs  accord i ng to the 
spec i f i ca t i o n s  set forth i n  the � n struct i on man ua l . To i n s ure 
con s i stency i n  count i ng , a known concentrat i on of  5 mi cron  Latex 
parti c l es ( Dow Chem i ca l  Co . ;  I n d i anapol i s ,  I nd . )  was counted each t i me 
a s  an  i nternal s tandard . When i ncon s i sten c i e s  i n  count i ng  arose due 
to brief peri ods  of  e l ectr i ca l  i n terference , cel l samp l e s  were 
ma i nta i ned at 4°C unt i l the i nterference s u b s i ded . 
C .  Determ i n a t i on of Ce l l  V i a bi l i ty 
Cel l v i a bi l i ty was determi ned by the trypan bl ue  exc l u s i on te st  
( Merchant et �. , 1 964 ) . To approx i matel y l xl 05 ce l l s  i n  a vol ume 
of 0 . 5  ml was added 0 . 1  ml of 0 . 5% trypan bl ue ( Gi bco ; Grand  I s l a nd , 
NY )  i n  a 1 2x75  mm tes t  tube . The resu l t i n g  sol ut i on was mi xed and  
a l l owed to  s tand  a t  room temperature for 5 mi n utes  before count i ng 
on a hemocytometer ( Ameri can Opt i ca l  Co . ;  Buffa l o ,  N Y ) . The  percent­
age of v i a b l e  cel l s  exc l ud i ng  the dye was determi ned by coun t i n g  
approx i matel y 1 00 cel l s  wi th  t h e  a i d  o f  a N i kon b i noc u l ar l i g ht 
mi croscope ( N i ppon Kogaku K . K . , J apan ) .  
D .  Ma i ntenance of Tumor L i nes  
1 .  Lewi s l ung  carc i noma 
The LLC was ma i nta i ned by i nocu l at i on of l x l 06 LLC cel l s  i n to 
the gl uteus  max i mus  of C57BL/6 m i ce . At b i weekl y i nterva l s the 
tumor bear i ng  hosts were sacri f i ced by cerv i ca l  d i s l ocat i on and  LLC 
cel l s u s pen s i on s  prepared by tryps i n i z i n g s teri l e  non -necrot i c  
tumor sect i o n s  ( vo l ume o f  sec t i ons  a pprox imate l y  1 c c ) for 4 5  mi n .  
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at  room temperature i n  0 . 25% s teri l e  tryps i n  ( Di fco . , Detro i t ,  Mi c h . )  
i n  EMEM ( G i bco ; Grand I s l and , NY ) conta i n i ng Earl e ' s  ba l a nced s a l t 
sol u t i on and 1 00 u/ml pen i c i l l i n and 1 00 ug/ml streptomyc i n .  
Steri l e  fetal ca l f serum ( G i bco ; Grand I s l and , N Y )  at  a concentra t i on 
of 6 ml / 1 00 ml of  med i um was added after the 45 mi n ute tryps i n i zati on 
peri od to s top enzymat i c act i v i ty .  The tumor ce l l s  were was hed and 
centri fuged at  200xg for 1 0  mi n u tes  in  an  I n ternat i onal  CRU-5000 
centri fuge ( Damon , I EC D i v i s i on ; Needham , Ma s s . ) ,  res u s pended i n  
EMEM and  counted on a Cou l ter Counter model  Z B I  ( Cou l ter E l ectron i cs ; 
H i a l eah , F l a . ) .  Tumor cel l v i a b i l i ty ,  a s  determi ned by trypan 
bl ue excl u s i o n , was norma l l y  better than 98% . 
Bacteri a l  contami nati on was mon i tored by i ncuba t i ng 5xl 05 ce l l s  
wi th 2 ml of 50% Bra i n  Heart I nfu s i on ( BH I ) broth ( Di fco ; Detro i t ,  
Mi c h . )  for 72  hrs at  37°C , 5% CO2 , 95% a i r .  Bacteri a l  contami nat i on 
was detected by a v i s ua l  i ncrea se  i n  the turbi d i ty of the BHI broth . 
V i ra l  contam i nati on wa s mon i tored by peri od i ca l l y  send i ng serum samp l e s 
from the tumor bear i ng  hosts  to Mi crobi o l og i ca l  A s soc i ates ( Bethesda , 
Md . ) .  
2 .  Mad i son 1 09 l un g  carci noma 
The M1 09 was ma i nta i ned i n  Ba l b/c mi ce by i ntramu s cu l ar i nocu ­
l at i on of  5x l 05 tryps i n i zed tumor cel l s  at  b i week l y  i nterva l s .  The 
tumor cel l s u s pen s i on s  were prepared i n  a s l i g ht l y d i fferent fa s h i on 
from the procedures u sed wi th  the LLC i n  that non -necroti c M1 09 
tumor sec t i ons  underwent a ser i es of f i ve 1 0  mi n ute tryps i n i za t i on 
( 0 . 25% )  peri ods . After each 1 0  mi nute peri od , t he tumor cel l s u s pen -
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s i ons  were decanted  and exposed to 6% ster i l e  fetal ca l f serum 
( G i bco . ,  Grand I s l and , NY ) i n  EMEM . Cel l n umber and  v i a b i l i ty were 
determi ned for each  fracti on a s  prev i ou s l y  descri bed . Fract i on s  
whi ch y i e l ded tumor cel l s  of greater t han  85% v i a b i l i ty were then 
pool ed  and u sed for experimentati o n . Th i s  procedure was ut i l i zed 
in order to max im i ze  the y i el d and  v i a bi l i ty of the tumor ce l l prepa ­
rat i on , a s  the M1 09 appeared to be more sen s i t i ve to the l ethal  act ions  
of tryps i n  than  the  LLC . Bacteri a l  contami nat i o n  was  mon i tored by 
i ncubat i ng 5x l 05 M1 09 ce l l s  wi th  2 ml of BH I broth for 72 hrs  a t  
3 .  P81 5 mastocytoma 
The  P81 5 mastocytoma , u ti l i zed i n  the M1 09 concomi ta n t  i mmu n i ty 
stud i es , wa s ma i nta i ned i n  DBA/2 mi ce by ser i a l  i . p .  pa s sage of 
4 1 0  ce l l s  every 1 0  days . The a s c i t i c  tumor cel l s  were harvested  
a septi ca l l y  in  RPMI  1 640 med i um ,  was hed 2x  by centri fugat i on  a t  
200xg , and  enumerated on  a Cou l ter Counter . V i ab i l i ty and  bacter i a l  
contam i nat i on were mon i tored a s  before . 
E .  F l ow M i crofl uorometri c Ana l ys i s  of Cel l s  
Res i ding i n  the Primary Tumor Bed 
To determi ne  the types and rel a t i ve number of cel l s  res i d i ng i n  
the LLC pri mary tumor bed tryps i n i zed s u spen s i on s  of " tumor cel l s " 
were ana l yzed i n  a Cou l ter E l ectron i c s  TPS- l  fl ow mi crofl uoremeter 
( H i a l ea h ,  F l a . ) .  The procedure for prepari ng the tumor cel l s u s pen ­
s i on for fl ow mi crofl uorometr i c  ana l ys i s  wa s accord i ng to the method 
of Cri s sman and Ste i n kamp ( 1 973 ) . Tumor ce l l fragments obta i ned 
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from 1 4  day o l d  i . m .  LLC  tumors  were tryps i n i zed , wa s hed i n  ca l c i -
um free PBS and fi xed on i ce i n  70% ethanol  for 3 0  mi n .  The cel l 
s u spen s i on was centri fuged at  2000xg for 5 mi nutes  at  4°C  fol l owed by 
d i ge s t i on i n  RNa se ( 1 0  ug/ml ; S i gma , l ot no . R5875 ) at  37°C  for 30 
mi nutes . After i ncubat ion  the RNase  was hydrol yzed i n  d i s t i l l ed water 
for 30 mi nutes at  37°C . The ce l l s  were s u bsequent l y  was hed twi ce wi th 
ca l c i um free PBS and s ta i ned wi th  a 6 . 9xl O-5  M so l u t i on of  prop i d i um 
i od i de ( P I )  monohydrate i n  1 . 1 %  sod i um c i trate ( Ca l b i ochem , l ot no . 
53705 9 )  for 30 m i n utes at  room temperature . The ce l l s  were then 
wa s hed twi ce wi th  ca l c i um free PBS at  2000xg for 5 m i n u tes  and 
resu spended to a f i n a l  concentra t i on of l xl 06 ce l l s/ml . 
A s i ng l e ce l l s u spen s i on of  the sta i ned s amp l e was exposed i n  
the fl ow chamber of the fl ow mi crofl uoremeter to a focu sed  argon 
i on l a ser  beam ( 488 nm ) . A redd i s h -orange fl uorescence resu l t i ng 
from the l a ser exc i ta t i on of the P I - sta i ned ce l l s  wa s col l ected and 
quanti tated through a comb i nat i on of appropri a te mi rrors , f i l ters 
and photomu l t i pl i ers . The res u l t i ng e l ectr i c a l  pu l ses  based on the 
exc i ta t i on of the DNA - P I  fl uorescence i n  each cel l were co l l ected 
and s tored i n  a pu l s e - he i ght  d i s tri but i on ana l yzer . H i stograms gene­
rated from ana lys i s  of 1 0 , 000 ce l l s  were d i sp l ayed on the o s c i l l o scope 
and s imu l taneo u s l y  pri nted . 
For comparat i ve purposes , LLC ce l l s  grown i n  t i s s ue  cu l ture 
( obta i ned courtesy of J . A .  Munson , Dept . of Mi crobi o l ogy ,  MCV ) were 
s ta i ned wi th  PI and a na lyzed as a bove . 
The rel at i ve DNA content of the s ta i ned cel l s  was determi ned 
by i nterpretat ion  of  the DNA d i str i but ion  h i stograms . The absc i s sa  
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of t he h i stograms was d i v i ded i nto 1 2 7 channel s of i n crea s i ng l i near 
va l ue of DNA content wh i l e  the ord i nate represented re l at i ve cel l 
number . 
The fl ow mi c rofl uoremeter was a l so ut i l i zed to separate cel l 
popu l at i ons  accord i ng to cel l s i ze .  Non - s ta i ned " tumor "  cel l s  were 
su spended i n  ca l c i um free PBS and i ntroduced i nto the fl ow chamber 
as prev i ou s l y  descri bed . As  the cel l s  transversed a 75  urn d i ameter 
ori f i ce , an  e l ectron i c  s i gna l  was produced wh i c h  was proporti onal  to 
cel l vol ume . The pattern d i sp l ayed on the osc i l l o scope wa s u sed to 
sel ect appropri a te channel s for separat i on and col l ecti on of cel l 
popu l at i on s  of d i fferent  vol umes . The cel l s  were s ubsequen t l y  
centri fuged at  2000xg f o r  1 0  m i n ,  wa s hed a n d  res u spended i n  1 0% feta l 
ca l f serum . Smears were f i xed w i t h  methano l , sta i ned vl i t h G i emsa 
Sta i n  ( F i sc her Sc i ent i f i c Co . ;  Fa i r  Lawn , N . J . )  and observed under 
a N i kon b i nocu l a r  l i g ht  m i croscope ( N i ppon Kogaku  K . K . , Japan ) .  
F .  C hromosome Analys i s  o f  Lewi s Lung Ce l l s  
LLC c hromosoma l a n a lys i s was performed accord i ng to a mod i f i ca ­
t i on o f  the method o f  Hungerford ( 1 96 5 ) . Approxi mate l y  1 07 tryps i n i zed 
LLC cel l s  were s u spended i n  a 1 %  col cem i d  ( Gi bco ; Grand I s l and , NY ) :  
sa l i ne sol u t i on and a l l owed to s i t  at room temperature for 3 hours . 
The cel l s  were centri fuged at  200xg , res u s pended i n  a 0 . 075 M KCl 
hypoton i c  sol u t i on and i ncubated at  37 °C  for 1 hour . Fol l owi ng i n c u ­
bat i on smears  were f i xed w i t h  Carnoy ' s  f i xat i ve ( a cet i c  a c i d :  
methanol 1 : 3 )  and sta i ned \� i t h G i emsa . The n umber of c hromosomes 
per cel l wa s enumerated at  1 00 x ma gn i f i cati on empl oy i n g  a Ze i s s  
b i nocu l ar  l i g ht m i c roscope . 
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G .  Empl oyment  of Footpad Tumors 
in  Exper imenta l Stud i e s  
For � v i vo tes t i n g  L L C  footpad tumors  were e stab l i s hed i n  
C57BL/6 o r  BDFl mi ce by i nocu l a t i n g  l x l 0
6 tryps i n i zed  tumor cel l s  
i nto the l eft h i n d  footpad i n  a vol ume of 0 . 02 ml  ut i l i z i ng a mi c ro-
syr i n ge p i pette ( Hami l ton Co . ;  Reno , Nev . ) .  T he  M1 09 and  P8 1 5  footpad 
tumors  were establ i s hed under s i mi l ar cond i ti on s  by i nocu l a t i on of 
5x l 05 M1 09 ce l l s  i nto Ba l b/c and CDFl mi ce and 5x l 0
5 P81 5 cel l s  i n to 
CDF
l mi ce . The footpad tumor model s fac i l i tated meas urement of 
pr ima ry tumor s i ze and provi ded fl ex i b i l i ty a s  the pr ima ry tumor s  
cou l d  b e  l oca l l y  i rrad i ated or exci sed by s u rg i ca l  amputa t i on wi thout 
probl ems of l ocal  tumor recu rrence . 
1 .  Meas urement of pr ima ry tumor s i ze 
Pr imary tumo r  s i ze was eval uated by mea s u r i n g  the tumor mas s  
a l ong two d i men s i on s  i n  mm wi th  an  eng i neer ' s  m i crometer ( Comb i mi ke , 
Mi tutoyo Mfg . Co . ;  J apan ) .  The  tumor vol ume (mm
3
) wa s ca l cu l ated by 
the method of Att i a  and  Wei s s  ( 1 966 ) i n  wh i c h the  tumor vol ume 
(V ) = 0 . 4  ab2 , where a = l onger a x i s and b = sma l l er a x i s .  
2 .  S u rg i ca l  exc i s i on of pr ima ry tumors  
For s tud i es on  the meta stat i c  LLC and  M1 09 , the tumor bear i ng  
m i ce  and a ppropri ate non t umor contro l s were anesthet i zed i . p .  wi th  
60  mg/ kg pentoba rb i ta l  ( Di abuta l . D i amond Laboratori e s ; Oes Mo i nes , 
I owa ) . The tumor bea r i n g  or  control l eg s  were then exc i sed a bove 
the knee j o i nt under a sept i c  cond i t i on s  wi th  a pa i r  of 1 40 mm 
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sc i ssors and  cauteri zed u s i ng a T hermo Cautery Un i t  ( Statham I nc . ; 
Oxnard , Ca l i f . ) .  The i nc i s i on s  were c l o sed wi th s ta i n l e s s  s teel 
suture c l i ps ( C l ay Adams ; Pars i ppany , N . J . )  wh i c h were removed seven 
days after s urgery . 
W i th  the LLC  s urgery was norma l l y  performed on  days 1 3 - 1 5 ,  a t i me 
at  wh i c h 1 00% of the a n i ma l s had l ethal  pu l monary metas ta s i s .  Wi th  
the  M1 09 , stud i e s  were done  in  order to determi ne  the meta sta t i c  rate 
of the tumor . 
The morta l i ty rate a s soc i ated wi th  t h i s s urg i ca l  procedure was 
norma l l y  l e s s  than 2% . 
3 .  Local i r rad i at i o n  of pr imary tumors 
Local i rrad i a t i on of  the primary LLC and M1 09 tumors was performed 
u s i ng a cobal t-60 ( 60Co ) tel ethera py un i t  ( P i c ker X-ray Corp . ; C l eval and , 
Oh i o ) . Pr ior  to i rrad i a t i on the m i ce were anestheti zed i . p .  wi th 60 
mg/ kg pentobarbi ta l  and the tumor beari ng l egs secured to a s pec i f i ­
cal l y  des i gned l uc i te pl ate wi th  m i cropore s urg i ca l  ta pe ( 3M Co . ;  
Sa i nt Pau l , M i nn . ) .  An 8 cm t h i c k  cerro bend doughnut  was then p l a ced 
on top of the l u c i te pl ate to reduce the who l e body exposure to l e s s  
t han  1 %  of the tumor dose  ( personal  commun i cat i on , Dr . John  Wi l son ; 
Rad i at i on B i o l ogy D i v i s i on , MCV ) . 
To determ i ne the actual  expos u re rate of the te letherapy un i t ,  
four one mi n ute exposure read i ngs  on a Farmer Secondary Standard 
Dosemeter ( Cap i ntec Nucl ear and Ba l dwi n I n strument Co . ;  London , 
Eng l and ) were taken a t  the start of each experi ment . The dose rate , 
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and thus  the tota l tumor dose , was ca l cu l ated by the method of Johns  
and Cunn i ngham ( 1 97 1 ) in  wh i c h the dose rate ( rads/m i n )  = average 
dosemeter rea d i n g  x 3 . 8 1  x 0 . 96 , where 3 . 8 1  i s  a c hamber factor 
ca l i brated year ly  for th i s  part i cu l ar u n i t  by the Nat i onal  Bureau 
of Standard s and  0 . 96 i s  the convers i on factor from Roentgen s to rad s .  
The dose ra te ranged between 1 85 - 1 60  rads/mi n d ur i n g  the course of  
exper iments . 
To i n s ure that the mi ce were rece i v i ng a u n i form exposure of 
l oca l  i rrad i a t i on the 1 uc i te pl ate conta i n i n g  the test a n i ma l s and 
the cerrobend doughnut were s l owl y rotated throughout the expos ure 
peri od . A 1 /4 i n ch 1 u c i te " bu i l d  u p "  pl ate , l ocated i n  the center of 
the cerro bend doughnut , was a l so  empl oyed to create a more homogeneou s  
dose d i str i but i on throughout the tumor mas s . 
The morta l i ty rate a s soc i a ted wi th  th i s procedure was 0% a t  a l l 
t ime s . 
4 .  Assessment  of  concom i tant  i mmun i ty 
For a s sessment  of  concomi tant  tumor i mmun i ty i n  the M1 09 , Ba 1 b/c 
or COF 1 m i ce were i nocu l ated in the l eft h i nd footpad wi th  5x1 0
5 
M1 09 
ce l l s .  E l even days l ater these  tumor bear i ng  and norma l m i ce were 
cha l l enged i n  the ri ght  footpad wi th varyi ng  amounts  of M1 09 tumor 
cel l s  rang i ng from 1 x 1 04 to 1 x1 06 M1 09 cel l s ,  or  1 x1 05 P81 5 tumor ce l l s .  
Concomi tant  i mmun i ty was meas u red by the a b i l i ty of mi ce i mmun i zed 
I'li th a primary t�l 09 tumor to s uppress  the g rowth of a secondary M1 09 
cha l l enge . The s pec i fi c i ty of the concomi tant  i mmune response  wa s 
eva l uated by exami n i ng the ab i l i ty of COF1 m i ce bear i n g  a primary 
M1 09 tumor to suppres s  the growth of a P8 1 5  ma stocytoma footpad tumor . 
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H .  Quant i f i ca t i on of P u l monary 
Meta s ta s i s  i n  Tumor Bea r i ng Mi ce 
The extent of p u l monary meta s ta s i s  in  LLC bear i ng  a n i ma l s was 
eval uated by enumerat i ng  the number of s urface tumor nod u l e s  accord i ng 
to the method of  Wex l er ( 1 966 ) . The tumor bea r i n g  mi ce were sacr if i ced 
by c h l oroform and the trachea and chest  cav i ty exposed by a m i d l i ne 
chest  i nc i s i on . The trac hea was tran sected we l l  a bove the car ina  
i nto wh i ch a #1 8 b l unt  need l e and  syr i nge , conta i n i ng 2 ml of  contra st  
med i um ,  was  f i tted t i g ht l y  wi th s urg i ca l  s uture . A s  the contra s t  
med i um was i njected , t h e  l ungs  became d i s tended a n d  sta i ned deep b l ack . 
The l ungs  were then d i s sected from the thorac i c cage , r i n sed i n  tap 
water to remove exce l l i n k ,  and p l aced in Fekete ' s  so l u t i on ( Fe kete , 
1 938 ) to b l each the tumor whi te and to preserve the l ung . The extent 
of meta s ta s i s  was q uant i tated by count i ng the n umber of s u rface tumor 
nodu l e s  under 2 1 / 2 x magn i f i ca t i on . Th i s  procedure was adequate 
when the number of tumor nodu l e s was l e s s  than 25 , but  became unsat i s -
factory wi th  l ungs  heavi l y  l aden wi th  tumor . 
The contra st  med i um was prepared by mi x i ng  85  ml of  d i s ti l l ed 
water wi th  1 5  ml of  I nd i a i n k  (Gunther Wagner ; NYC , N . Y . ) .  To fac i l i -
tate u n i form d i s pers i on of  the i n k  parti c l es 0 . 5 ml of ammon i a  water 
was added to t h i s so l u t i on . 
I .  Prepara t i on of Drugs , Antiqens and RE Parti c l es 
1 .  Ma l e i c  v i nyl ether copo l ymers (MVE ) 
MVE · 2  ( MW 1 5 , 500)  and  MVE · 3  (MW 2 1 ,300)  wh i c h  have the s tructure 
s hown be l ow ,  were k i nd l y  s u pp l i ed by Dr . Dav i d  Bres l ow of Hercu l es 
Resea rch Center ; Wi l mi n gton , Del aware . The drugs were d i s so l ved i n  
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F i§ure 1 
Ma l ei c  v i nyl ether (4 , 5-di carboxytetrahydro-6-methyl ene 
pryan -2-succ i n i c  ac i d ,  di anhydri de pol ymer ) was prepared at 
l ow temperatures i n  acetone us i n g  a free rad ica l  i n i t i ator 
and tetrahydrofuran as a cha i n -transfer agent , wh i c h y i el ded 









phys i o l og i c  s a l i n e  ( 0 . 9%NaC l ) at room temperature and adj u s ted to 
pH7 . 4  by the add i t i on of I N  NaoH . MVE i nj ected i . p .  or i . v .  wa s admi n ­
i stered i n  a vol ume o f  0 . 1  ml / 1 0g body we i ght  wherea s i ntratumor ( i  . t . )  
and i ntrap l eura l i nj ect i ons  of  MVE were del i vered i n  0 . 01 m l / 1 0g body 
we i ght ut i l i z i ng a mi crosyr i nge p i pette ( Hami l ton Co . ;  Reno , Nevada ) .  
The MVE compounds were prepared on a week l y  ba s i s  a nd  s tored at  4 ° C .  
2 .  Corynebacter i um parvum 
C .  parvum ( Lot no . CA 380 ) was k i nd l y  prov i ded by Dr . R i c hard L .  
Tutt l e  of Burroughs  Wel l come Co . ( Research Tr i ang l e Park , N . C . ) a s  a 
forma l i n - k i l l ed s u spen s i on conta i n i ng 7 . 0 mg dry we i g ht of organ i sms 
per ml . The prepara t i on s  were s tored at 4°C unt i l use . For i . v .  
adm i n i strat i on the C .  parvum s u spen s i on s  were d i l uted w i t h  p hys i ol og i c  
sa l i ne and i njected i n  a vo l ume o f  0 . 1  m l / 1 0g body we i ght . For i ntra ­
tumor i nject i o n s  the C .  parvum s u spen s i on s  were concentrated by 
centri fug i n g  the prepara t i on s  at 800xg and  resu s pend i n g  the pel l ets 
in l e s ser vol umes of phys i o l og i c  s a l i n e . Twenty m i c ro l i ters of these 
concentrated prepara t i on s  were then del i vered to the test a n i ma l s 
u s i ng a m i c rosyri nge p i pette . 
3 .  Cyc l ophospham ide  
Cyc l opho sphami de ( NSC-2627 l ) wa s s u pp l i ed by  the  Nat iona l  Cancer 
I n st i tute . The compound was d i s so l ved i n  steri l e  s a l i n e  wi th i n  30 
mi n utes of use and a dmi n i s tered i . v .  i n  a vol ume of 0 . 1  ml / 1 0g 
body we i ght . 
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4 .  Carrageenan 
Carrageenan ( Lot no . RE7228 ) , u sed to i nduce an i nfl amma tory 
res pon se i n  LLC  a n ima l s was obta i ned from Ma r i ne Col l o i d s I nc . 
( Spr i n gfi e l d ,  NJ ) and prepared a s  a 1 %  so l u t i on i n  ster i l e  sa l i ne . 
5 .  Sheep erythrocytes 
Sheep red b l ood ce l l s ,  used to a s ses s  the i mmune status  of LLC 
a n i ma l s ,  were obta i ned from the MCV central  a n ima l  faci l i t i e s . The 
s heep bl ood wa s drawn steri l y  by veni puncture from the s ame s heep 
( # 1 2 7 )  once per week . F i fty rnl of fre s h ly  drawn bl ood were i mmed i ate l y  
mi xed wi th 60  ml s teri l e  A l severs so l uti on . T h e  s heep b l ood wa s pre­
pared for experi menta l u se  by centri fugati on at 900xg for 10 m i n utes 
at 4 ° C .  The buffy coat of l ymp hocytes a t  the i nterface of the SRBC 
and the A l severs so l u t i on wa s removed by asp i ra t i on and the cel l s  
was hed an add i t i ona l  two t i mes  wi th A l severs so l u t i on by centri fugati on 
at 900xg for 1 0  m i n utes at 4 ° C . The ce l l concentrat i on was determi ned 
on a Cou l ter  Counter and the su spens i on adj u s ted to a fi na l  concentra ­
t i on of 5x l 09 SRBC/ml . Appropri ate d i l u t i on s  of SRBC for exper imenta l 
use  were done wi th A l severs so l u t i on . 
P repara t i on of s teri l e  A l severs so l u t i on wa s performed i n  the 
fol l ow i n g  manner . To each  1 l i ter  so l u t i on 20 . 509 dextrose ( S i gma 
Chem i ca l  Co . ;  St . Loui s ,  Mo . ) ,  8 . 00g sod i um c i trate dehydrate 
( Ma l l i n ckrodt ; St . Lou i s ,  Mo . ) ,  0 . 5 5g c i trate a c i d  monohydrate ( S i gma ) 
and 4 . 20g sodi um ch l ori de ( J . T .  Baker Chemi cal  Co . ;  Ph i l l i p sburg , NJ ) 
were d i s sol ved i n  d i st i l l ed water . The A l severs sol u t i on wa s 
steri l i zed i n  a Cast l e a utoc l ave ( Wi l mot Ca st l e Co . ;  Rochester , N Y )  
by autoc l a v i n g  for 1 5  mi n utes . 
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5 1  6 .  Chromi um l a bel ed s heep erythrocytes 
5 1 Chrom i um l a be l ed SRBC , u sed to eva l uate the functi ona l  acti v i ty 
of the RES , were prepared by the methods  of Greaves � �. ( 1 969 ) . 
The l abel i ng procedure con s i sted of i ncubat i ng 1 0  ml of 5xl 09 SRBC/ml 
wi th one m i l l i Cur i e of sod i um 5 l chromate ( s pec i f i c  act i v i ty ,  289-368 
mi l l i Cur i e/mg ; New Eng l and N uc l ea r ;  Boston , Ma s s . )  at  37 °C  for 30 
mi nutes i n  a Dubnoff s ha ker bath ( Prec i s i on S c i ent i fi c Co . ;  C h i cago , 
I l l . ) .  The  c hromated erythrocytes were then repeated l y  wa s hed w i t h  
equal  vol umes o f  Al severs so l u t i on a n d  centri fuged at  900xg u nt i l a 
0 . 1  m l  a l i quot of the s u pernatant  wa s no more than 500 cpms a bove 
background , as mea sured in a Beckman model 300 gamma counter ( Beckman 
I n s trument s ; Fu l l erton , Ca l i f . ) .  The ce l l s u spen s i on was then d i l uted 
wi th  nonrad i oacti ve S RBC and A l sever ' s  so l u t i on to yi el d a 1 0% so l uti on 
( hema tocri t va l ue )  wi th  a pprox imatel y 200 , 000 cpm per 0 . 1  ml . The 
chromated SRBC were s tored at  4°C for up  to one wee k . Pri or to i . v .  
adm i n i strat i on  i nto BDFl m i ce the l a bel ed SRBC were wa shed and 
centri fuged at  900xg and  res u spended i n  ster i l e  phospha te buffered sa l i ne .  
7 .  L i ster i a  monocytogenes 
L i ster i a  monocytogenes ( s tra i n  1 9303 ) u sed in  host res i stance 
stud i es wi th  the LLC , was c u l tured i n  the fo l l owi ng  ma nner . To 3 ml of 
frozen L i ster i a  stock obta i ned courtesy of Dr . H .  J .  We l s h i mer ( Dept . 
of M i c rob i o l ogy , MCV ) was added 250 ml of steri l e  B H I  broth . The 
cu l ture was i ncubated i n  a Dubnoff s ha ker bath  at  37°C for approx i mately 
6 hours or unt i l the s pectrophotometri c absorbance va l ue wa s between 
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0 . 40 and 0 . 45 at  6 1 0  nm ( Var i a n  Tectron model 635 spectrophotometer ; 
Sunnyva l e ,  Ca l i f . ) .  Prev i ou s  stud i es from our  l aboratory have i nd i ­
cated that an  ab sorbance va l ue of 0 . 40 y i e l d s  a concentrat i on of 
2 . 5  - 3 . 0xl 08 bacteri a/ml ( Ms . G i n ny Sanders , persona l commun i cat i on ) . 
The i ncuba t i on mi xture was then a l i q uoted i nto 2 ml s teri l e  v i a l s a nd 
stored at  -70°C  ( Kel v i nator deep freeze seri e s  1 00 ;  Man i towoc , W i s . )  
unt i l u se . 
To determ i ne  the actua l  t i ter of L i steri a ,  pl ate counts  were per-
formed on the  days of exper imenta t i on by ser i a l  1 : 1 0  d i l u t i o n s  of  the 
L i s ter i a  i n  steri l e  d i s t i l l ed water . D i l ut i ons  from 1 0 -6 t o  1 0-8 were 
p l a ted out on tryptone g l ucose yea st  agar pl a tes ( D i fco ; Detro i t ,  
M i c h . )  and i ncubated for 48 hours a t  3 7 ° C  ( Forma Sc i ent i f i c CO2 
i ncuba tor model  3028 ; Mari etta , Oh i o ) . The n umber of col ony form i n g  
un i ts ( C FU ) were t hen enumerated w i t h  t h e  a i d  of a darkf i e l d  Quebec 
col ony counter ( Amer i can  Opt i c a l  Co . ;  Buffa l o ,  N Y )  and the t i ter 
cal c u l a ted by mul t i p ly i ng  the average n umber of col on i e s  per pl a te 
by 1 06 to 1 08 respecti vel y .  
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8 .  I -L i ster i a  monocytogenes 
1 1 2 5 L '  t '  t d RE t '  1 t 1 t - 1 S  er1 a monocy ogenes , u se a s  a par 1 C  e 0 eva ua e 
the phagocyt i c  act i v i ty of the f i xed macrophage system , was rad i o l a be l ed 
as fo l l ows . To a cu l ture of 2 . 5  - 3 . 0xl 08 L i steri a/ml were added 750 
LlCi  of 1 2 5 1 i ododeoxyuri d i ne  ( s pec i f i c  acti v i ty > 5C i /mg , New Engl and 
Nuc l ea r ;  Boston , Ma s s . )  and  1 2  ml of 5xl O-4 M fl ourodeoxyuri d i ne 
( S i gma Chemi cal  Co . ;  St . Lou i s ,  Mo . ) .  The fl ourodeoxyuri d i ne was 
added to i n h i bi t  t hym i dyl ate synthetase  ( He i del berger , 1 96 5 )  and  
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thus  a l l ow for a greater i n corporati on  of i ododeoxyur i d i ne i nto 
the DNA of  the L i steri a .  The m i xture was i ncubated for 60  m i n u tes 
at  37°C  fol l owed by the add i ti on of 1 . 2 5  m1  forma l dehyde ( J . T .  
Baker Chemi ca l  Co . ;  Ph i l l i ps burg , N . J . )  to i nact i vate the L i s teri a .  
The c u l ture was i ncubated for an  a dd i t i ona l  30 m i n utes under the 
s ame cond i t i on s  and then centri fuged a t  1 750xg for 30 mi n utes  at 
room temperature . The pel l et was re su s pended i n  1 25 m1 EMEM , 
a 1 i q uoted i nto steri l e  i nj ec t i on v i a l s and stored at  -70° C .  The 
1 25 res u l t i ng I - l abe l ed L i ster i a  y i e l ded approx i matel y 200 ,000 
cpm/0 . 1  m 1 . 
J .  L D50 Determi nat ion s  
To  obta i n  acute tox i c i ty data on the fi ve MVE  fract i on s  a n d  
C .  parvum , groups  of mi ce were i nocu l ated i . v .  at  a con stant rate 
wi th  5 doses  of the respect i ve compounds  i n  0 . 1  m1 / 1 0g body we i ght . 
The m i ce were observed for morta l i ty for 1 4  days and  the LD50 and  
s l ope determ i nat ion s  ca l cu l ated by  the method of L i tchfi e l d  and  
Wi l coxon ( 1 949 ) . 
K .  I n ha l a t i on Procedures 
To i ncrease the effect i ve concentrati on of  MVE -2 i n  the 
meta s tat i c tumor bed , the noses and  mouths  of the test an i ma l s 
were exposed to an atom i zed mi s t  of MVE-2  generated by a 
DeV i l b i s s model 6 5  nebu l i zer ( Somerset , Pa . ) .  A s  s hown i n  F i g ure 
2 the nebu l i zer u n i t  con s i sts  of a transducer that generated 
v i bra t i ona l  energy wh i ch nebu l i zed or atomi zed the MVE so l u t i on 
i nto 5 m i cron parti c l es .  A fi l tered a i r  supp l y  carr i ed the 
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F i gure 2 
I nhal ati on apparatus 
The nebul i zer generated v i brat i onal energy wh i ch atomi zed 
the MVE sol uti on i nto 5 mi cron parti c l es . A f i l tered a i r  s upply 
carr ied the aerosol i zed mi st  from the nebul i zer chamber to an 
expos ure chamber where the noses and mouths of test  mi ce were 
exposed to the mi s t .  
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aeroso l i zed mi s t  from the nebu l i zer c hamber to an  exposure 
chamber where the noses  and mouths  of the restra i ned test a n ima l s 
were exposed to the mi st  ( exposure c hamber and mouse  restra i ners 
des i gned and constructed by Mi sters E .  Ta l l ey and  E .  M .  D imen , Dept . 
of  Pharmaco l ogy ) . The m i s t  was vented through  a carr i er hose 
attached to an  a s p i rator and  d i s c harged i nto a s i n k . 
A s  the nebu l i zer  un i t  has  not yet been ca l i brated , the 
dos i ng reg i mens  con s i s ted of  expo s i n g  each  group of mi ce on  a 
b i wee k l y  bas i s  to 1 0  ml of phys i o l og i c  s a l i ne or MVE -2 ran g i ng 
i n  concentra t i on from 0 . 1  mg/ml to 1 00 mg/ml . The exposure 
t ime was l arge l y  dependent upon the v i scos i ty of the test so l u t i on 
but norma l l y  ranged from 1 0  to 1 5  �i n utes . Stud i es are now be i ng 
conducted by Mr . Kimber \�h i te ( Dept . of Pharmacol ogy ) to 
cal i bra te the i n ha l at i on procedure . 
L .  A s says for Immunol ogi c Respons i veness  
1 .  Hemo l yt i c  pl aque a s say 
The Cunn i ngham mod i f i cat i on ( Cummi ng ham and Szenberg , 1 968 )  
of  the Jerne p l aque a s say ( Jerne and  Nord i n ,  1 96 3 )  wa s u sed to 
measure the primary 1 9M anti body response to SRBC i n  m i ce  bea r i ng 
the orimary or metas tat i c LLC . Three days after tumor i nocu l a t i on 
and every fourth day thereafter groups  of  tumor bea r i ng and 
control  m i ce were i mmun i zed wi th  4xl 08 SRBC by the i ntraperi tonea l 
route . Four days after i mmun i zati on the mi ce were sacr i fi ced by 
cerv i ca l  d i s l ocat ion  and the i r  sp l een s removed , we i g hed and 
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pl aced i n  col d ( 4 ° C )  RPM I - 1 640 ( G i bco ; Grand I s l and , N . Y . ) .  Sp l een 
cel l s u s pen s i on s  were prepared by gen t l y  pres s i ng the sp l en i c  
contents through  a 1 00 mes h  sta i n l e s s  steel screen wi th a ru bber-end 
pl unger from a 1 0  c . c .  syri nge . The ce l l s  were was hed twi ce at  
200xg for 10  mi n utes  at  4 °C , counted on a Cou l ter Counter and ad­
j u sted to  a con stant cel l concentrati on of 2xl 06 cel l s !ml by the 
add i t i on of RPMI - 1 640 med i um .  Cel l v i a b i l i ty was norma l l y  greater 
than 99% . 
The s p l een cel l s u spen s i on s  were added i n  vol umes of  0 . 1 , 0 . 05 
and 0 . 025  ml to three separate we l l s  of  a M i croti ter I I  test  pl ate 
( Fa l con Pl a st i c s ; Oxnard , Cal i f . ) p l aced on i ce .  To each  we l l  0 . 01 ml 
gu i nea p i g  comp l ement ( Fl ow Labs ; Roc kvi l l e ,  Md . ) ,  0 . 0 1 ml  of 6x l 09 
SRBC!ml and  enough  med i um were added to ma ke a tota l vol ume of 0 . 1 5  
ml . The contents of each wel l were mi xed wi th  a Pasteur p i pette 
and appl i ed to a two - s i ded c hamber formed by j o i n i ng two g l a s s  
m i croscope s l i de s  ( S c i ent i f i c Products No . M6 1 30 ;  McGraw Park , I l l . )  
wi th doub l e - s i ded tape ( Scotch Brand No . 41 0 ;  3MCo . ;  St . Pau l , Mi nn . ) . 
The two chambered s l i des were sea l ed wi th  a wa rmed 1 : 1 m i xture of 
petro l eum je l l y  ( Vase l i n e ;  Chesebrough  Pond s , N . Y . )  and  parafi n 
wax ( Fu l fwax ; Fort Worth , Tex . )  and i ncuba ted for 45 m i n utes at  37°C . 
Stud i e s  by Harri s et �. ( 1 96 6 )  have s hown that dur i ng  the 
i ncubat i on peri od pl a sma cel l s  synthe s i z e  and secrete ant i bod i es , 
wh i c h a l ong wi th  comp l ement , l yse su rround i ng  SRBC . The l ysed S RBC 
l eave cl ear pl aques  wi th an  ant i body secreti ng  pl a sma cel l in the 
center of each pl aque . Accord i n g l y ,  I gM pl aque formi ng  cel l s  ( P FC ) 
were enumerated by count i ng pl aques  w i t h  the a i d  of a col ony counter 
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at  2 1 /2 x magn i fi cat i on . Al l data were eval uated a s  PFC/ 1 06 
nuc l eated sp l een cel l s  ( s pec i f i c  act i v i ty )  and tota l PFC/ sp l een . 
2 .  Del ayed type hypersen s i t i v i ty a s s ay 
The DTH respons i venes s  of BDFl mi ce beari ng the LLC was quant i ­
tated by mod i f i ca t i on of a rad i o i sotope footpad a s say ori g i na l l y  
deve l oped by Paranj pe and Boone ( 1 9 74 ) . The rat i ona l e  beh i nd th i s 
tec hn i que i s  that the i ncrease i n  vascu l ar  permeab i l i ty wh i c h 
accompan i es the DTH react i on ( Crowl e and Hu , 1 96 7 )  a l l ows for the 
extravasat ion  of rad i ol abel ed a l bum i n  from the bl ood stream i nto the 
extracel l u l ar space of the footpad . 
Prel im i nary exper iments des i gned to opt i m i ze the DTH a s say wi th  
regards to  the cha l l enge dose , vol ume and t i me after sen s i t i za t i on 
a s  we l l  a s  the d urat i on of exposure of  the test a n i ma l s to the rad i o -
l abel ed a l bumi n are presented i n  the RESULTS sect i o n . The optima l  
protocol  a n d  t h u s  t h e  protocol u sed for experimentat i on con s i sted 
of sen s i t i z i ng the test a n ima l s to SRCC by i nject ion  of l xl 07 cel l s  
i n  0 . 02 ml i nto the front l eft footpad . Unsen s i t i zed control s 
rece i ved phys i o l og i c  sa l i ne .  A c ha l l enge dose of 1 08 SRBC was admi n -
i s tered i nto the s ame footpad o n  day 4 .  Fourteen hours after 
chal l enge the mi ce were i nj ected i . v .  wi th one uCi 1 2 5 I _ l a be l ed 
human serum a l bum i n  ( s pec i fi c  act i v i ty ,  8 . 5  uCi /mg ; Mal l i nc krodt 
Nuc l ea r ;  St . Loui s ,  Mo . )  and four hours thereafter the test foot 
and contra l ateral foot were exci sed and rad i oa s sayed i n  a gamma 
counter ( Bec kman model  300 ) . 
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DTH reacti v i ty was  cal c u l ated a s  a s t imu l ati on i ndex ( 5 1 ) 
a s  fol l ows : 
5 1  s en s i t i zed l eft ft pad 
right ft pad 
x unsens i t i z ed l eft ft pad 
n ght tt pad 
i n  wh i c h the 5 1  i s  equal  to the d i fference i n  the rat i os of the 
rad i oacti vty in the test ( l eft ) foot d i v i ded by the rad i oact i v i ty 
i n  the contra l atera l ( r i g h t )  foot between sen s i t i zed and unsen s i -
ti zed a n ima l s .  
A react i on i n  wh i c h po l ymorphonuc l ear cel l s  ( PMNs ) predomi nate 
among i nfi l trat i ng cel l s  i s  wi de l y  i nterpreted a s  an  Arthru s react i on , 
whereas  a predomi nantl y mononuc l ear cel l i nfi l trate i s  thou g ht to 
s i gna l  a DTH react i on ( Ge l l and H i nde , 1 954 ) . Yet stud i es by Col l i n s  
a n d  Mac kaness  ( 1 968)  a n d  Cooper ( 1 972 ) have i nd i cated that i f  the 
c ha l l eng i ng ant i gen i s  part i cu l ate and reta i ned l ong  enough a t  the 
cha l l enge s i te ,  a mouse  can make humoral  ant i bod i e s  at th i s  s i te 
and devel op a react i on wh i c h i s  del ayed because  of the t i me req u i red 
for these ant i bod i e s to be manufactured and react , rather than because 
the react i on i s  a " true " DTH . 
Therefore , to a scerta i n  whether the above protocol res u l ted i n  
a "tru e "  DTH reacti on footpads  from sen s i t i zed and control a n i ma l s 
were p l aced i n  a 1 0% forma l i n  so l ut i on ( J . T .  Baker Chemi ca l  Co . ;  
Ph i l l i ps burg , N . J . )  and  s ubmi tted to the Dept . of Oral Pathol ogy 
( School  of Dent i stry , MCV ) for rou t i ne h i s topathol og i c  exami nati on . 
The t i s sues  were dehydrated wi th  a l cohol , c l eared wi th  xyl ene and 
embedded i n  paraffi n .  Seven m i crometer t h i c k  sect i on s  were s u b -
sequent ly  sta i ned wi th  hematoxyl i n  a n d  eos i n  a n d  exami ned under a 
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l i g ht mi croscope for the presence of mononucl ear cel l s ,  PMNs and  
pl a sma cel l s .  To further confi rm the a bsence of a humoral component 
i n  our a s s ay system the dra i n i ng brac h i a l  and ax i l l ary l ymph nodes 
from a n i ma l s  sen s i ti zed wi th  SRBC were a septi ca l l y  removed , poo l ed 
and a s sayed for pl aque formi ng a bi l i ty a s  prev i ou s l y  descri bed . 
3 .  Carrageenan i nduced i nfl ammatory a s say 
A carrrageenan i nduced i nf l ammat i on ( Levy , 1 969 ) wa s u sed to 
measure the capab i l i ty of  the LLC beari ng m i ce to mount an  i nfl ammatory 
response . Twenty e i g ht days after tumor i nocu l at i on na i ve BDFl m i ce 
or BDFl m i ce beari ng a primary and/or meta stat i c LLC rece i ved a 0 . 02 
ml i nj ect i on of a 1 %  carrageenan sol ut i on or phys i o l og i c  s a l i ne i n  
the front  l eft footpad i n  concert wi th  an  i . v .  i nject ion  of one u C i  
1 2 5 
I - l a be l ed human serum a l bumi n ( Ma l l i nc krodt Nuc l ea r ;  St . Lou i s ,  Mo . ) .  
Three hours thereafter the test foot and  contral atera l  foot were 
exc i sed and rad i oas sayed i n  a gamma counter ( Beckman model 300 ) . The 
i nfl ammatory response was ca l cu l a ted as a SI  as prev i ou s l y  descri bed . 
4 .  RES a s s ay 
The functi ona l  acti v i ty of the RES i n  LLC a n i ma l s wa s eva l uated 
by meas u r i n g  the vascu l a r  c l earance and organ d i stri but i on of two 
RE . 1 1 2 5 8 part l c e s ; I - l abe l ed L i steri a ( 3x l O  L i ster i a /ml ) and  
5 1 Cr- l a be l ed S RBC ( 1 0% sol u t i on ) . The  protocol  con s i s ted of i nj ect i ng  
t he  RE parti c l e i ntraveno u s l y  i nto the  l ateral ta i l  ve i n  of the  test 
an ima l s in  a vol ume of 0 . 1  ml / 1 0g body we i ght . At sel ected t imes 
from 1 to 1 5  m i nutes after i nj ect i on 0 . 01 ml  b l ood samp l es were ta ken 
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from the t i p of the ta i l , hemo l yzed i n  2 ml of d i st i l l ed water and  
rad i oa s s ayed in  a gamma counter . 
As the c l earance of both of  these RE parti c l es have been s hown 
to fo l l ow fi rst order k i neti c s  ( Ha l pern , 1 959 )  vascu l ar c l earance 
was determ i ned by ca l cu l at i ng the c hange in b l ood concentrat i on of 
the RE  parti c l e wi th  respect to t i me . The data wa s expres sed as a 
phagocyt i c  i ndex ( K )  wh i c h i s  equa l  to the rate of c l earance . To 
a pprox imate the c i rc u l at i ng  b l ood vol ume i n  the test a n ima l s ,  the 
ca l cu l ated number of cpms at  t i me zero wa s d i v i ded by the n umber 
of i nj ected counts/ml . 
Organ u pta ke of the 5 1 Cr-SRBC rema i ned con s tant  from 30 to 90 
mi nutes  after i . v .  i nject ion  ( see RESULTS sect i on ) .  Therefore , 
s i xty m i n u tes  after i n j ec t i on of the RE  parti c l e  the m i ce were 
sacr i f i ced by decap i tat i on and  a l l owed to exsangu i nate . The l i ver , 
sp l een , l ung , thymus , k i dneys and primary tumor were then exc i sed , 
we i g hed and  rad i oa s s ayed . The data was ca l cu l ated a s  percent organ 
upta ke (%  tota l cpms ) and a s  cpms/mg t i s sue . 
Son i cated LLC ce l l s ,  used i n  the RES a s say , were prepared by 
i ncubat i n g  5x l 07 tryps i n i zed LLC cel l s  at room temperature for 30 
m i nutes i n  a Col e -Parmer model  8845 -4 son i cator ( C h i cago , I l l . ) .  
The son i cated tumor cel l fragments were then centri fuged at  900xg 
for 1 5  m i n u tes , was hed 3x i n  EMEM and  res u spended to t he i r  or i g i na l  
vol ume . 
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5 .  Host res i stance to L i steri a monocytogenes 
The effect of the LLC on res i stance to L i steri a monocytogenes , 
an i nfec t i on i n  wh i c h macrophages and i mmune T cel l s  have been s hown 
to be i nvol ved i n  the e l im i nati on of the bacter i a  ( Mac kenes s , 1 9 70 ; 
North , 1 97 3 ) , wa s eval uated i n  the fol l owi ng  manner . Na i ve and 
tumor bear i ng  mi ce were cha l l enged i . v .  wi th  1 03 to 1 08 L i s ter i a  
two days pr ior  to a footpad i nocu l at i on o f  l xl 06 LLC ce l l s ,  one day 
after LLC i nocu l at i on or 1 2  days a fter LLC i nocu l a t i on . Morta l i ty was 
recorded da i l y  for 1 4  days and  the f i fty percent  l ethal  endpo i nt 
( LD50 ) ca l cu l ated by the method of L i tchfi e l d and W i l coxon ( 1 949 ) . 
The effect of the LLC on host res i stance to L i steri a monocytogenes 
wa s then determi ned by measur i ng  changes i n  the LD
50 
of the pathogen 
in tumor bear i n g  and control mi ce . 
M .  Stat i st i cal  Ana lys i s  
The l evel  of confi dence for a l l experi ments was set a t  n i nety-fi ve 
percent .  A stated i ncrease or decrease i s  understood to be stati s t i ca l l y  
s i g n i f i cant based u pon th i s  l evel  of confi dence . The student t test 
was emp l oyed to determi ne i f  a d i fference exi sted between a control  
and experimental group , and a one-way anal ys i s of var i a nce was u sed 
when one control group was compared to more than one experi mental  
group . The method of L i tchfi e l d and Wi l coxon ( 1 949 ) wa s used to 
determ i ne LD50 and s l opes of dose response curves . L i near regress i on s  
were eva l uated by t h e  method of l ea st  s quares . 
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I I I .  RESULTS 
A. Characteri zat ion  of the Lewi s Lung Carc i noma 
1 .  Pr ima ry tumor growth 
The growth character i s t i c s  of the LLC i mpl anted i ntramuscu l ar ly  
have been descri bed i n  deta i l  by Mayo ( 1 972a ) and  S i mpson -Herren  
et � ( 1 974 ) . Yet ,  stud i es by Geran et � ( 1 972 ) s uggests that the 
l oca ti on of tumor i mp l ant  affects the pr imary tumor growth c haracte­
ri st i c s . Thus , i n i t i a l  experi ments were conducted to compare the 
growth c haracter i s t i c s  of  the LLC i mp l anted i n  the g l uteus  max i mus  
and in  the h i nd footpad ( F i g ure 3 ) . Exami nat ion  of the da ta revea l s 
that no d i fference exi sts  between the growth ra tes wi th a corre l at i on 
coeffi c i ent  of  0 . 98 , a l though the a bso l ute va l ues  for the i . m .  tumor 
are s i gn i f i ca n t l y  h i gher on  days 1 5  through  24 . These data a l so  i n d i ­
cate that both tumors fol l ow Gompertz i a n  growth w i t h  a decrea se  i n  
growth rate a s  the tumor burden i ncreases . Gros s  exami nati on o f  the 
i . m .  and  footpad tumors revea l ed that the maj or i ty of tumors u l cerated 
by day 1 4  and by day 21 e s sen t i a l l y  a l l of the tumors had necroti c 
cores s urrounded by a prol i fera t i n g  s hel l . 
Prel im i nary experiments were a l so conducted to determi ne whether 
tumor vol ume mea surements  cou l d be used to accuratel y refl ect tumor 
we i ght . Presented i n  F i g ure 4 are the growth curves for the LLC 
footpad tumor a s  determi ned by tumor we i g ht and tumor vol ume mea sure­
ments . I n  accordance wi th  the f i nd i ngs  of Atti a and We i s s ( 1 966 ) , 
the tumor vol ume measurements  accurately  refl ected the pr imary tumor 
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F i g ure 3 
Growth characteri sti cs of LLC imp l anted i n  the 
g l uteus max imus and h i nd footpad 
BDFl mi ce were i nocul ated in the g l uteus max imus ( .. ) or  h i nd 
footpad ( » )  wi th l x l 06 LLC cel l s .  On days 5 through 24 groups of 
mi ce ( n rangi ng from 8 to 23 ) were sacri fi ced , thei r pri mary tumors 
exci sed and we i ghed . Res u l ts are reported as mean tumor we i ghts 
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burden of the  tes t  a n i ma l s .  A l i near ana l ys i s  revea l ed a pos i ti ve 
corre l a t i on between the two curves wi th  a correl ati on coeffi c i ent of 
0 . 98 . As tumor vol ume mea surements  coul d be made of  l i v i n g  a n i ma l s ,  
the pr ima ry tumor burden of the test a n i ma l s  was norma l l y  determi ned 
by th i s  method . 
2 .  Meta s t i c  spread 
In mos t  thera peut i c  reg imens for cancer the f i rs t  avenue of 
defense  i s  s urg i ca l  removal  of the pr imary tumor ma s s . Yet often 
t imes the tumor has  metasta s i zed beyond the pri mary tumor s i te pr ior  
to  detect i on and s u rg i ca l  i nterventi on . Thu s , other treatment moda ­
l i t i es are emp l oyed to reduce i f  not e l i mi nate the meta sta t i c  foci . 
To m i m i c  th i s  c l i n i ca l  s i tuat i on ba se l i ne exper i ments were conducted 
to determi ne what doses of LLC con s i s tentl y produced l ung  metasta s i s  
after footpad i nj ecti on . A s  s hown i n  Ta b l e 1 doses of LLC cel l s  from 
3x1 05 to 1 x1 06 produced 1 00% meta sta s i s wi th i n 1 4  days of i nocu l a t i on . 
The 50% meta s ta s i s  produc i ng cel l n umber wa s 9 . 5x1 04 ce l l s  
( 4 . 8x1 04 _ 1 . 9x 1 05 , 9 5% confi dence l im i ts ) . A dose of 1 x 1 0
6 LLC ce l l s  
was se l ected for s ubsequent exper imenta l  stud i es . 
To determ i ne when 1 00% of the test a n i ma l s had a meta sta t i c  
tumor burden after i nj ec t i on o f  1 x 1 0
6 
ce l l s ,  t h e  pr ima ry tumor 
was surg i ca l l y  exci sed on days 1 0 ,  1 3  or 1 5 .  As can be seen , 
meta sta s i s  occurred very ear ly  i n  LLC beari ng  mi ce wi th  1 00% deaths  
recorded when the pr ima ry tumors were removed 1 0  days a fter i nocu l a ­
t ion  ( Tab l e 2 ) . Surg i ca l  exc i s i on o f  the pr imary tumors o n  day 1 3  
or thereafter had no effect on the mean surv i va l  t i me .  
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F i g ure 4 
Correl ati on between tumor we i ght and tumor 
vo l ume measurmen ts i n  LLC bea r i ng mi ce 
BDFl mi ce were i nocul ated in the l eft hi nd footpad wi th l x l 0
6 
LLC cel l s .  On day 5 through 24 primary footpad tumors were exc i sed 
and we i ghed ( 4t ) ,  or measured wi th d i a l  ca l i pers to est imate tumor 
vo l ume (0 ) Resu l ts are expressed as  mean tumor wei ghts (mg ) and 
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Tabl e 1 
Degree of meta sta s i s  after i nj ec t i on of va ri ous 
doses of Lewi s l ung cel l s  
BDFl mi ce were i nj ected i n  the h i nd footpad wi th va ri ous doses 
of LLC cel l s .  On day 13 the pri mary tumors were surg i ca l l y  exc i sed 
and the mi ce fo l l owed for morta l i ty .  Mean survi a l  t imes ( MST ) + 
S . E .  deri ved from 1 0  to 20 mi ce per group . 
Dos e of  LLC 
( ce l l n umber ) 
l xl 06 
3xl O� 
1 xl 0
4 3xl O 
1 x l  04 
Morta 1 i tv 
( n umber dead/ tota l ) 
1 2/ 1 2 
20/ 20 
5/ l 0  
1 / 1 2  
1 / 1 1  
MST ( days ) of mi ce 
that d i ed 
26 . 4+ 1 . 0  
32 . 8+1 . 1 




Tab l e 2 
Effect of primary tumor exc i s i on on 
s urv i va l  of LLC beari ng mi ce 
BDFl mi ce were i nocu l ated wi th  l X 1 0
6 LLC cel l s  in  the l eft 
hi nd footpad and tne primary tumors removed on days 1 0 ,  1 3 ,  1 5 .  
Mean s urv i va l  t ime (MST j � S . E .  deri ved from 8 mi ce per group ex­
cept for pri mary tumor control s where the number of mi ce was 1 6 .  
Day of Surgery 
1 0  
1 3  
1 5  
bp < 0 . 05 a s  compared to nons urgery group . 
I1ST 
( days ) 
28 . 9�1 . 7b 38 . 7+3 . 1  
3 1  . 3+2 . 6  
30 . 5+2 . 3  
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To q uant i tate the meta stati c s pread of the LLC to the l u ngs  the 
method of Wexl er ( 1 966 ) was empl oyed ( Tab l e 3 ) . Surface tumor nodu l e s 
became v i s i bl e  i n  two test a n i ma l s ( n= l O )  a s  earl y a s  day 9 .  Twel ve 
days after LLC i nocu l ati on 1 00% of the mi ce had v i s i b l e  s urface 
nodu l es and by day 1 5  the l ungs  were hea v i l y  l aden wi th  tumor . 
Al though  the LLC metas ta s i zed pr imari l y  to the l ungs  s ub -
cutaneous  i mpl anta t i on of l i ver , sp l een and k i dney from LLC bear i ng  
mi ce a l so re s u l ted i n  t he  outgrowth of  prima ry tumors ( Tab l e 4 ) . 
The presence of tumor cel l s  cou l d  not be detected i n  per i p heral 
bl ood smears . 
Under ly i n g  the progre s s i ve tumor growth and meta stat i c  spread 
of the tumor bea r i n g  mi ce were hema tol og i ca l  changes and a l tera -
t i on s  i n  l ymphoreti c u l a r  organ we i ghts  (Tabl e 5 ) . The erythrocyte 
count dropped progres s i ve l y  from control va l ues of 9 . 3�0 . 2xl 06/mm3 
on day 9 to 2 . 6�0 . 3x l 06/mm3 on  day 2 1 , whereas the l eu kocyte count 
i ncrea sed 3 fo l d  dur i ng  the same t ime frame . Peri phera l  b l ood smears 
revea l ed a ret i cu l ocytos i s  wi th a s l i g ht  e l eva t i on i n  PMN ' s  and mono-
cytes in  the tumor beari ng mice 2 1  days after tumor i nocu l a ti on . An 
i n crea se  i n  l ung and  sp l een we i g ht  accompan i ed tumor growth wherea s 
thym i c  i nvol ut i on was noted i n  the termi nal  stages of d i sease . The 
a l terat i on s  i n  l i ver we i g ht ,  expres sed a s  percent of tota l body 
we i ght  refl ect the i nteract i on between an i n crea s i ng tumor ma s s  and  
decrea s i ng tota l body we i ght . Al though the  a l terat i on s  a re stati sti ­
ca l l y s i gn i fi cant , no  b i o l og i ca l  trends  are ev i dent . 
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TaBl e 3 
Quanti f i c at i on of  pu lmonary metasta s i s 
i n  LLC m i ce 
BDFl mi ce were i nocu l ated i n  the l eft h i nd footrad wi th l X1 0
6 
LLC cel l s .  On days 7 through 1 5  �roups of m i ce ( n rang i ng from 7 
to 1 0 )  were sacr i fi ced and the i r  l ungs  i n s uffl ated wi th contrast  
med i um .  The  extent of pu l monary metas tas i s  was  quanti tated by 
count i ng s u rface tumor nodu l es and reported as means + S . E .  
Day a fter LLC 




1 0  
1 1  
1 2  
1 3  
1 4  
1 5  
Number of  s urfa ce 
tumor nodul es 
o 
o 
0 . 2+0 . 1  
0 . 8+0 . 4  
2 . 4+1 . 3 
5 . 8+3 . 1 
1 1  . 7+4 . 1  
1 9 . 1 +6 . 2  
> 25a 
aLungs ,(Iere heavi l y  1 aden wi th tumor nodul  es whi c h  were too n umerous 
to count . 
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Tabl e 4 
Metas tat i c spread of the LLC of the sp l een , . l iver and k i dneys 
BDFl mi ce were i nocu l ated i n  the l eft h i nd footpad wi th l X 1 0
6 
LLC ce l l s .  Twenty fou r  days after tumor i nocu l at i on the sp l een , 
l i ve r ,  k i dneys and l ung were a septi cal l y  removed and i mpl anted s . c .  
i nto na i ve BDFl rec i p i ents . The l i ver and l unqs  were cut i nto 
ha l ves to fac i l i ate impl anta t i on . Meta stat i c spread of the LLC to 
these organs  was determi ned by the outgrowth of pri mary tumors . 
The i n c i dence of tumors and mean s u rv i va l  t imes ( �ST ) + S . E .  deri ved 
from 3 mi ce per grou p . 
Impl anted T umor i nc i dence MST 
organ ( % )  ( days ) 
l ung  1 00 35 . 2+4 . 7  
sp l een 1 00 45 . 3+6 . 1  
1 i ver 1 00 49 . 2+6 . 7  
k i dney 1 00 58 . 6+9 . 0  
Tab l e 5 
E ffect  of the Lewi s l ung  carci noma on organ wei ghts and 
hematol ogy 
6 
BDFl mi ce were i nocu l ated i n  the h i nd footpad wi th l x l O  LLC  cel l s .  At the i nd i cated 
t imes after i nocu l ati on b l ood s ampl es were ta ken from the t i p  of  the tai l and  en umerated on  a 
Cou l ter Counte r .  The l i ve r ,  l un� , s p l een , thymus  and k i rlneys were then exc i sed and  we i g hed . 
Res u l ts expressed a s  mean s  +S . E .  deri ved from 5 mi ce per group except for the non-tumor 
contro l s  ( day 0 ) where N=70 . 
Days Pos t I nocu l at i on 
0 3 9 1 5  21  
Primary tumor wt . 1 4 . 6+3 . 7  21 . 0+8 . 2  3 1 5+36 1 450+200 2 1 40+440 
(mg ) 
L i ver wt . 6 . 26+0 . 07 6 . 36+0 . 2 1 5 . 69+0 . 1 8a 6 . 80+0 . 1 Sa 7 . 32+0 . 28a 5 . 98+0 . 06a 
(% body wt ) 
Lung wt . 1 . 1 4+0 . 02 1 . 1 7+0 . 1 3  1 . 2 2+0 . 05 1 . 27+0 . 1 0  1 . 34+0 . 07a 1 . 59+0 . 1 7a 
(% body wt ) 
0 . 53+0 . 03a 0 . 52+0 . 0 1 a 0 . 6 3+0 . 03a 
a 
2 . 20+0 . 1 8a Sp 1 een wt . 0 . 43+0 . 01 1 . 1 3+0 . 2 1 
( %  body wt ) 
0 . 1 2+0 . 02a Thymus  wt . 0 . 2 7+0 . 0 1 0 . 34+0 . 05 0 . 34+0 . 04 0 . 2 3+0 . 03 0 . 2 7+0 . 03 
( %  body wt ) 
2 . 63+0 . 29a Eryth rgcyt3s 9 . 09+0 . 09 8 . 56+0 . 47 8 . 68+0 . 35 9 . 32+0 . 22 5 . 54+0 . 39a x l O  /mm 
1 7 . 8+ 3 . 4a 37 . 3+4 . 2a Leucoc�tes 1 0 . 9+0 . 5  1 0 . 3+0 . 9  1 2 . 5+0 . 7  1 2 . 1  +0 . 8  x l O /mm3 




3 .  F l ow mi crofl uorometr i c  stud i e s on the cel l s  res i d i ng 
i n  the Lewi s l ung pri mary tumor bed 
The effi cacy of MVE and C .  parvum a s  anti -tumor agents  i s  
bel i eved to be dependent upon act i va t i on of host i mmune cel l s  i n  
c l o se  prox imi ty to tumor cel l s .  Yet , f i n d i ng s  by Snyderma n et  � 
( 1 976 ) s uggest  that the c hemotacti ve res pon s i venes s  of i mmune cel l s  
i s  marked l y  depressed i n  tumor beari ng  a n i ma l s ,  wh i c h may resu l t i n  
a d im i n i s hed capac i ty of host  cel l s  to be mobi l i zed to the tumor bed . 
Thu s , stud i es were conducted to determi ne whether ma crophages and  
other i mmune cel l s  re s i ded in  the LLC pr ima ry tumor bed . 
S hown i n  F i gure 5 i s  a DNA h i s togram prepared from a 1 4  day LLC 
imp l ant . The h i stogram revea l ed that two popu l a t i on s  of cel l s  ex i sted ; 
a noncyc l i ng popu l at i on of ce l l s  centered i n  channel  2 0 ,  and  a cyc l i ng 
popu l at i on of  ce l l s  whose Gl , S and G2M pea ks  ranged from channel  32 
to channel 80 . 
To i nvesti gate the po s s i b i l i ty that the f i rst pea k of cel l s  repre­
sented a ho st  cel l i nf i l trate h i stograms were generated from LLC cel l s  
grown i n  t i s s ue  c u l ture . As can be seen i n  F i gure 6 the pea k centered 
i n  channel  20  was absent , s uggest i ng that the noncyc l i n g  cel l s  were 
of host or i g i n  and that LLC cel l s  were aneupl o i d .  
To confi rm the noti on that LLC cel l s  obta i ned from a n  i . m .  
i mp l ant  d i dn ' t  conta i n  a mi xture o f  d i p l o i d  and  aneup l o i d  ce l l s ,  a 
chromosome a n a lys i s  from a 1 6  day LLC i mp l ant  was performed . The 
ana l ys i s of 22  LLC preparat i ons , an examp l e of wh i c h  can be seen i n  
F i gure 7 ,  y i el ded a chromosome n umber between 6 6  and 7 7 . The norma l 
d i pl o i d  number of chromosomes i n  mi ce i s  40 ( Ma k i no , 1 95 1 ) .  
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F i §ure 5 
DNA di str i but i on h i s togram prepared from a 1 4  day 
Lewi s l ung impl ant 
BDFl mi ce were i nocul ated in the g l uteus maximus wi th l xl 0
6 
LLC cel l s .  Fourteen days after impl ant the primary tumors were ex-
ci sed , tryps i n i zed and stai ned wi th propi d i u� i od i de .  The h i s togram 
was generated by el ectri ca l  pu l ses ba sed on the DNA-propi d i um i od i de 
fl uorescence i n  1 0 , 000 cel l s .  G l , S ,  G2 and M refer to phases of 
the cel l cyc l e .  
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F i g ure 6 
DNA di stri buti on h i s togram orepared from Lewi s l ung 
cel l s  grown in ti s s ue cul ture 
Lewi s l ung cel l s  grown in ti s sue cu l ture were tryps i n i zed and 
sta i ned wi th prop i d i um i od i de . The h i s togram was generated by e l ec -
tri ca l  pu l ses based o n  the DNA-propi d i um i od i de fl uorescence i n  
1 0 , 000 cel l s .  Gl , S ,  G2 and M refer to phases of the cel l cyc l e .  
a:: w CD 
:2 ::J Z 
....J ....J W U 
W > 





C H A N N E L  N U M BER 
R E LAT I V E  DNA CONTE NT 
80 100 
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F i gure 7 
Aneup l o i dy of Lewi s l ung cel l s  
An exampl e  of aneup l o i dy i n  LLC cel l s .  The bas i c  di p l o i d  
number i n  m i c e  i s  4 0  whereas the LLC exh i b i ted a chromosome number 
between 66 and 77 . 
.84 
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Ana l ys i s  of the noncyc l i ng ce l l s  was accompl i s hed by the ab i l i ty 
of  the fl ow mi crofl uoremeter to sort out and col l ect  vari ous  pea k s  
obta i ned from a cel l vol ume h i stogram ( F i gure 8 ) . Cel l s  col l ected 
from c hannel s 39 to 53  conta i ned host i mmune cel l s  and tumor cel l s  i n  
a rat i o  o f  5 : 1  ( Tab l e 6 ) . Smea rs prepared from th i s center pea k y i e l ded 
the fol l owi ng d i fferent i a l : 42% granu l ocytes , 35% monocytes ,  1 7% tumor 
cel l s  and 6% l ymphocytes . 
B .  Immuno l ogi c Status  of Mi ce Beari ng the 
Lewi s Lung Ca rc i noma 
The  i mmune competence of the tumor bear i n g  host i s  bel i eved to 
con st i tute a cr i t i ca l  l i mi ta t i on to the succe s s  of i mmunotherapy . 
Stud i e s  by Mora han et � ( 1 974 ) and  Scott ( 1 975a ) have s hown that the 
tumor growth retard i ng propert i es of pyran and  C .  parvum are l es s  ef­
fecti ve i n  i mmunosuppressed a n i ma l s .  Moreover , the work of  Prehn ( 1 97 1 ) 
and Sjogren ( 1 972 ) s uggests  that the admi n i stra t i on of i mmunomodu l ators 
to a n i ma l s  wi th  l ow l evel s of i mmune respon s i venes s  can enhance tumor 
growth . 
Thu s , stud i e s  were underta ken to c haracter i ze the immune status  
of mi ce bea r i ng the LLC in  hopes  of max i mi z i ng the c ure rate . Asses s -
ment o f  ant i body format i on i n  LLC beari ng  a n ima l s was accompl i s hed by 
determi n i ng the n umber of I gM ant i body formi ng  cel l s  i n  the sp l een . 
As an  i ndex of cel l med i ated i mmune respon s i veness  the DTH response 
to SRBC wa s emp l oyed . The  funct ion  of fi xed ma crophages i n  the RES wa s 
5 1  eva l ua ted  by mea sur i ng  vascu l ar c l earance a n d  R E S  organ upta ke of Cr-
l abel ed SRBC whi l e  host res i stance to L i s teri a monocytogenes wa s deter­
mi ned by measur i ng changes in the LD50 of the pathogen i n  tumor bea r i ng 
and control mi ce . 
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F i gure 8 
Cel l vo l ume h i s togram prepared from a 1 6  day Lewi s l ung impl ant  
BDF1 m i ce were i nocu l ated i n  the  g l uteus max imus wi th 1 x 1 0
6 
cel l s .  S i xteen days after impl ant the primary tumors were ex­
c i s ed ,  tryps i n i zed and sus pended in  cal c i um free PBS . The h i s togram 
was �enerated by el ectri cal  impu l ses  based on the cel l vol umes of 
1 0 , 000 cel l s .  Shaded areas refer to peaks wh i c h  were sorted , 
col l ected and anal yzed under l i ght mi croscopy . 
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Tabl e 6 
Di fferent i a l  ana l ys i s  of  cel l s  res i d i ng the Lewi s 
l un g  primary tumor bed 
Cel l s  res i d i ng i n  a 1 6  day LLC tumor were separated and col l ected i n  3 parts 
correspondi ng  to the 3 s haded peaks  depi cted in Fi g ure 6 .  Di fferent i a l s  were performed 
on 3 s l i des per pea k .  Res u l ts expressed a s  mean  oercent o f  tota l cel l s  + S . E .  
Pea k 1 Peak 2 Pea k  3 
cel l type % cel l type % ce 1 1  type 
erythrocytes 89 . 0+2 . 3  granu l ocytes 42 . 3+ 1 . 9  tumor cel l s  
epi thed l i a l  cel l s  1 1 . 0+2 . 3  monocytes 35 . 0+ 1 . 1  grandu l ocytes 
tumor cel l s  1 6 . 7+ 1 . 3  monocytes 
l ymphocytes 6 . 0+0 . 6  
% 
95 . 0+ 1 . 2  
4 . 3+0 . 9  




1 .  Al terat i o n s  i n  h umoral i mmu n i ty 
Pre l im i nary exper iments  were conducted to a s ses s  the ab i l i ty 
of C57BL/6 m i ce bear i n g  the pri mary LLC  to e l i c i t  a I gM response  to 
S RBC . As s hown i n  F i g ure 9B  the n umber of  PFC/ sp1 een progres s i ve l y  
decreased from n o n  tumor bear i n g  contro l va l ues  o f  58 . 3�7 . 1 o n  day 
9 to 3 . 5+2 . 1  30  days after i nocu l a t i on . The data pl otted as P FC/ 1 06 
s p l een ce l l s  ( F i gure 9A ) exh i b i ted a s l i ght ly  d i fferent pattern due 
to the sp l enomega l y  wh i c h  accompan i ed tumor growth ( F i gure 9 C ) . 
Tota l body we i ght  ( F i gure 90 )  rema i ned a t  control l evel s of 22 . 8�0 . 3g 
unt i l day 27  when a va l ue of 1 8 . 2�0 . 6g wa s recorded for the tumor 
bear i n g  mi ce .  
I t  s hou l d  be noted that the p l aque formi ng  ab i l i ty of C57BL/6 
mi ce to S RBC was q u i te vari ab l e in compari son to l i terature va l ue s . 
S tandard errors of  1 2% of control were recorded for the PFC/ 1 06 and 
PFC/ sp 1 een responses  w h i c h  had a n  n of  40 . Al though the cause  of the 
var i a b i l i ty i s  not c l ear  s imi l ar f i n d i ng s  wi th C57BL/6 mi ce and SRBC 
have been noted by other i nvesti ga tors ( Rec tor and Carter , 1 97 3 ) . 
I n  a n  effort to mi n imi ze vari ab i l i ty the p l aque formi ng a s say 
wa s conducted i n  BOF1 mi ce ( F i gure 1 0 ) .  As can be seen not on l y  was 
the p l aque form i n g  ab i l i ty of con tro l BDF1 mi ce stati st i ca l l y  greater 
wi th a contro l PFC/ 1 06 va l ue of 828�39 and PFC/ sp 1 een va l ue of 1 1 2�6 , 
but  the vari ab i l i ty was s i gn i fi cant ly  reduced . 
The response  of  the BOF1 mi ce beari ng  the LLC wa s s l i g ht ly  
d i fferent  however , wi th a reduct ion  i n  PFC/ s p1 een to  20�4 or  1 8% 
of contro l on the f i rst day of  measuremen t ,  day 7 ( F i gure l OB ) . 
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F i <'1 ure 9 
Abi l i ty of C57BL/6 mice  bear ing  the Lewi s 
l ung carc i noma to el i c i t  a orimary 1 qM 
response 
C57BL/6 m i ce were i nocul ated in the h i nd footpad wi th l X1 06 
cel l s .  F i ve days after tumor i nocul at i on and every thi rd day 
thereafter groups of tumor bear i ng  and control mi ce were immuni zed 
wi th 4X1 08 SRBC by the i ntraperi tonea 1 route . Four days after 
immuni zati on the mi ce were sacr if i ced and thei r sp l eens assayed 
for pl aque form i ng cel l s  ( P FC ) . Pa.nel s A ,  B ,  C and 0 s ummari ze 
changes in PFC/ 1 06 sp l een cel l s ,  PFC/sp l een , s p l een wei qht ex­
pres sed as percent body we i qht and tota l body we i ght  respecti vely . 
Resu l ts are p l otted as means  � S . E .  deri ved frow 5 mi ce per group 
except for non-tumor control s wh i ch conta i ned 40 mi ce . 
� l  
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Yet ,  i n  agreement  wi th the C57BL/6 s tud i es , further i mmuno l og i c  
impa i rment accompan i ed primary tumor growth . On day 1 8  the n umber 
of PFC/sp l een was reduced to 1 1 +7 and by day 24 no anti body response  
cou l d  be  detected i n  mi ce bear i ng t he  pri mary tumo r .  Surg i ca l  ex ­
c i s i on of  the  pri mary tumor on  d ay 1 3  h ad  no effect on surv i va l  t ime 
yet resu l ted i n  a marked i ncrease  i n  the number of sp l een cel l s  wi th 
pl aque formi ng a bi l i ty .  F i fteen days after tumor i nocul a t i on the 
n umber of  PFC/ sp l een was 36�3 and by day 21 the pl aque form i n g  abi l i ty 
of m i ce bear i n g  the meta s tat i c LLC returned to control l evel s .  
Sp l een we i g hts , c a l cu l a ted a s  percent  body we i gh t ,  i ncreased 4 
fo l d  over control  va l ues  of  0 . 58+0 . 01 i n  BDFl m i ce bear i n g  the primary 
tumor ( F i gure 1 0C ) . I n  contra s t ,  s pl een we i ghts  i n  the amputa ted 
group were e s sen ti a l l y  ha l f as l arge , reach i n g  a pea k va l ue of 1 . 26+0 . 2 1 
on day 1 5 . The d i fferences i n  the sp l een i ndexes exh i b i ted between 
the pr imary LLC group , meta s ta t i c  LLC group and  contro l group can ' t  
tota l l y  be a ttri buted to body we i ght  l o s s  ( Fi gure 1 0D ) . Body we i gh t  
wa s s i gn i f i cant l y decreased t o  83% of control on days 1 5 -27  for mi ce 
bear i ng the pri mary LLC tumor whereas a s i gn i fi cant  l o s s  of body we i gh t  
i n  t h e  amputated group o n ly  occurred on days 24-27 . 
S hown i n  F i gure 1 1  are the res u l ts obtai ned from repea ti ng  the 
above exper iment  i n  BDFl m i ce . As a s i mi l ar profi l e  was generated wi th 
the pri mary and meta sta t i c  LLC mi ce these data s uggest  that stra i n  d i f­
ferences may ex i st between the C57BL/6 and  BDFl tumor bear i ng  mi ce wi th 
regards to h umoral respon s i venes s .  
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F i gure 1 0  
Abi l i ty of BDFl mi ce bear i ng the primary and metastati c Lewi s l ung carc i noma to el i c i t  a 1 9M 
response 
BDFl mi ce were i nocul ated in the h i nd footpad wi th l X 1 0
6 
cel l s .  Thi rteen days after i nocu l at i on hal f of the tumor beari ng 
mi ce had the i r  primary tumor exc i sed by amputat i on . The abi l i ty 
of mi ce bear ing  the primary (4t ) and metastati c ( � )  LLC to el i c i t  
a primary 1 9/1 anti body response to SRBC was quanti tated by count­
i ng p l aque form i ng  cel l s  ( PFC ) every th i rd day beg i n n i ng 7 days 
after tumor i nocul at i on . Panel s A ,  B ,  C and 0 s ummari ze c hanges 
in PFC/ 1 06 sp l een ce l l s ,  PFC/sn l een , so l een we i ght expressed as 
percent body ei ght and tota l body wei aht res pecti vel y .  The a rrow 
refers to the day of amputat i on ,  day 1 3 .  Res u l ts are p l otted as 
means + S . E .  deri ved from 5 mi ce per tumor bear i n g  group . Control 
group cons i sted of 24 nai ve and 24 s ham operated mi ce . 
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F i gure 1 1  
Abi l i ty of  BOFl m i ce bear i ng the pri mary and metastati c Lewi s l ung carci noma to el i c i t  a 1 9M 
response 
BOFl mi ce were i nocul ated in  the h i nd footpad wi th l X 1 0
6 
cel l s .  Thi rteen days after i nocu l at ion  ha l f  of  the tumor beari ng 
mi ce had the i r  primary tumor exc i sed by amputat ion . The abi l i ty 
of mi ce bearing  the primary ( 4t ) and metasta t i c  ( � )  LLC to el i c i t  
a pri mary 1 9M anti body response to SRBC was quanti tated by count­
i ng pl aque forming  cel l s  (PFC ) every thi rd day beg i nn i ng 7 days 
after tumor i nocul a t i on . Panel s A ,  B ,  C and 0 s umma ri ze c hanges 
in PFCJID06 sp l een cel l s ,  PFC/ sr l een , spl een we i gbt expressed as 
percent body ei ght and tota l body we i ght respect i vel y .  Res u l ts 
are pl otted as means � S . E .  deri ved from 5 mi ce per tumor beari ng  
group . Control group con s i sted of 24 na i ve and 24 sham operated 
mi ce . 
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2 .  Al tera t i on s  i n  ce l l med i ated i mmun i ty 
The DTH respon s i veness  of BDFl mi ce bear i ng  the LLC was quanti tated 
by mod i fi ca t i on of a rad i o i sotope footpad a s say or i g i na l l y  devel oped 
by Paranjpe and Boone ( 1 974 ) . The rat i ona l e beh i nd th i s  techn i que i s  
that the i ncrease i n  vascu l ar permeab i l i ty wh i ch accompa n i es the DTH 
react i on ( Crowl e and H u , 1 96 7 )  a l l ows for the extravasation  of rad i o ­
l abel ed a l bumi n from the b l ood stream i n to the extracel l u l ar space of 
the footpad . 
Presen ted i n  F i gures 1 2 - 1 4  are the resu l ts obta i n ed from p i l ot 
stud i es d e s i gned to opt imi ze the DTH res pon se wi th regard s to the cha l ­
l enge dose , vol ume and t ime after sen s i t i zat ion  a s  we l l  a s  the dura t i on 
of exposure to the rad i o l abel ed a l bumi n .  Exper iments were i n i ti a l l y  
conducted to determ i n e  the optima l  t ime o f  1 2 5 1 - human serum a l bum i n  
( HSA)  i nj ec t i on and the optima l  durati on of  exposure to the i sotope 
( F i gure 1 2 ) . Exam i n a t i on of the data revea l s that tes t  a n ima l s wh i c h  
were pu l sed wi th  1 2 5 1 - HSA for 4 hours recorded a cons i stentl y h i gher 
s t i mu l a t i on i ndex ( S . l . )  than m i ce wh i c h  were sacri fi ced one hour after 
i nject i on . A max i mum S . l .  of 0 . 78+0 . 1 4  was recorded a t  the fi rst time 
po i n t ,  20 hours a fter cha l l enge , s ugge s t i ng that the optima l  response 
occurred a t  or before 20 hours . 
T hu s , another t ime course experiment was conducted to a scerta i n  
the otpima l  t ime o f  sacr i fi ce u s i ng a 4 hour 1 25 1 -HSA pu l se .  As 
s hown in F i gure 1 3  a max i mum respon se of 1 . 03+0 . 1 5  was recorded 1 8  
hours after c ha l l enge wi th  l xl 08 S RBC  i n  2 0  mi crol i ters . Al though 
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F i gure 1 2  
Characteri zat ion of the DTH assay : Determi nat i on 
of optimal i s tope exposure rer i od 
BDFl mi ce wre sen s i ti zed i n  the front  footpad wi th 1 0
7 SRBC . 
A chal l enge dose of 1 08 SRBC i n  20 mi crol i ters was admi n i s tered 
i nto the same footpad on day 4 .  At vari ous t imes after chal l enge 
the mi ce were i njected i . v .  wi th one Ci 1 25 1 - l abel ed h uman serum 
al bumi n .  One or four hours thereafter the test foot and contra -
l atera l foot were exc i sed and rad i oas sayed . DTH acti v i ty was 
ca l cu l a ted as a s t imul a t i on i ndex ( S . l . )  and pl otted at the t ime 
of footpad exc i s i on . Means � SE were deri ved from 1 0  mi ce per 
group except for the unsen s i t i zed control group wh i ch had 1 5  mi ce . 
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at  the h i g her cha l l enge dose of 2x1 08 S RBC a S . l .  of 1 . 04+0 . 1 9  was 
recorded , the s hape of the enti re c urve suggested tha t the DTH react ion  
was coup l ed wi th a de l ayed ant i body response ori g i na l l y  descri bed by 
Co l l i n s  and Mac kaness  ( 1 968 ) . T he i r f i n d i ngs  i nd i cated that i f  the 
c ha l l eng i ng  ant i gen i s  part i c u l ate and reta i ned l ong enough at the 
c ha l l enge s i te a mouse  can  make humora l ant i bod i e s  at th i s  s i te and 
deve l op a react i on wh i c h  i s  de l ayed because  of  the t ime requ i red for 
these ant i bod i es to be manufactured and react , rather than because  
the reac t i on i s  a true  DTH . Therefore , a dose of l x1 08 S RBC wa s 
se l ected a s  the c ha l l enge dose for further experi mentat i on . 
To determi ne  the pea k d ay of respon se a th i rd experiment was 
performed i n  wh i c h  the nl i ce where c ha l l en ged wi th 1 08 SRBC on days 
3 ,  4 or 5 after sen s i t i z a t i on . The data i n  F i gure 1 4  i nd i cate that 
the pea k DTH reac i t i v i ty occured on day 4 ,  wh i c h i s  in  agreement 
wi th the f i nd i ng s  of Paranj pe and Boone ( 1 974) . 
Col l ec t i vel y ,  t he res u l ts of the forego i ng  experiments i nd i cated 
that the optimum protoco l  for e l i c i t i n g  a DTH response was as fol l ows . 
M i ce were sen s i ti zed wi th 1 07 SRBC i n  the front footpad . A chal l enge 
dose of 1 08 S RBC was admi n i stered i n to the s ame footpad on day 4 .  
Fourteen hours after cha l l enge the m i ce were i njected i . v .  wi th one 
uCi  of 1 2 5 1 -HSA and four hours thereafter the test foot and contra ­
l atera l foot were exc i sed and rad i oas sayed . 
To a scerta i n  whether the a bove protocol resul ted i n  a true DTH 
reac t i on , footpad s from sen s i ti zed m i ce were exami ned under a l i ght  
1 01 
F i t:Jure 1 3  
Characteri zati on of the DTH assay : Determi nati on 
of optimal cha l l enqe dose and vol ume 
BDFl mi ce were sens i t i zed i n  the front footpad wi th 1 0
7 S RBC . 
Four days after sens i t i zat i on a cha l l enge dose of 1 08 SRBC i n  1 0  
mi cro l i ters ( » ) ,  1 08 SRRC i n  20 mi crol i ters ( .. ) or 2X 1 08 SRBC 
in 20 mi cro l i ters ( II )  was admi n i s tered i nto the s ame footpad . 
At var i ous times after cha l l enge the mi ce were i njected i . v .  wi th 
one C i  1 25 I _human serum a l bumi n and four  hours thereafter the 
tes t foot and contra l ateral foot were exc i sed and rad i o  as sayed . 
DTH reacti v i ty was ca l cu l ated as a st imul at ion  i ndex ( S . I . )  and 
pl otted at the time of footpad exci s i on .  Resu l ts reported a s  means 
deri ved from 10 mi ce per group . Standard errors were wi t h i n  1 5% 















0.25 0 I x I08 ( 10)-)  
e l  x 108 ( 20 )- )  
. 2  x 108 ( 20)-) 
( 4  1 6  1 8  2 0  2 2  24 
HOURS POST CHAL L E N G E  
1 03 
F i gure 1 4  
Characteri zati on o f  the DTH assay : T ime course 
for DTH react iv i ty 
BDFl mi ce were sens i t i zed i n  the front footpad wi th 1 0
7 S RBC . 
A cha l l enge dose of 1 08 SRBC i n  20 mi crol i ters was admi n i s tered 
i nto the same footpad on days 3 ( 0 ) ,  4 ( e ) or 5 ( . ) .  Fourteen 
hours after cha l l enge the mi ce were i njected i . v .  wi th one Ci 
1 25 1 -human serum a l bum i n  and four  hours thereafter the tes t foot 
and contra l atera l foot were exc i sed and rad i oas sayed . DTH reacti v-
i ty was ca l cu l ated as a st imu l at i on i ndex ( 5 . 1 . )  and p l otted at 
the time of footpad exci s i on . Resu l ts reported as means  deri ved 
from 1 0  mi ce per gro up .  Standard errors where wi thi n 1 5% of  the 
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mi c roscope for the presence of host  cel l s  i nfi l tra t i ng the react ion 
s i te .  S hown i n  F i gure 1 5  are hematoxyl i n  and eos i n  sta i ned footpad 
sect ions  from unsen s i t i zed ( Panel  A) and sen s i t i zed ( Panel  B) mi ce 
cha l l enged 24 hours prev i ou s l y  wi th  1 08 S RBC . Panel B revea l s a 
heavy i n f i l trati on of mononuc l ear cel l s  wi th an  absence of pol ymor­
phonuc l ear and pl a sma cel l s  s uggest i n g  that the DTH react i on was 
unaccompan i ed by an  Arthru s or  ant i body respons e .  
T o  further conf i rm the ab sence o f  a humoral component i n  our 
a s say sys tem the dra i n i n g  brach i a l and ax i l l ary i ymph nodes from 
a n i ma l s sen s i t i zed wi th  S RBC were a sept i cal l y  removed , poo l ed and 
a s sayed for pl aque form i n g  cel l s .  No PFC were detected a t  a sen s i ­
t i z i ng dose of 1 07 S RBC , a l though a t  a h i gher sen s i t i z i ng dose of 
1 08 S RBC , 290 PFC/ 1 06 l ymph node cel l s  were noted . 
The effect of  the LLC  on  the DTH respons i venes s  of BDFl mi ce i s  
summar i zed i n  F i gure 1 6 .  I n  contra st  to the ear l y  suppre s s i on i n  
humora l res pon s i venes s , DTH val ues i n  the tumor bear i n g  mi ce rema i ned 
at con trol l evel s of 0 . 78�0 . 05 through  day 1 3 .  Not un t i l  the mi ce 
had a pri mary tumor burden of 1 . 6 l �0 . 28g on day 1 7  was there a 
s i gn i fi cant  s uppres s i on of  DTH reacti v i ty .  Yet , i n  agreemen t  wi th 
the humoral  s tud i e s , exc i s i on of the pr imary tumor resu l ted in an 
i ncreased respons i veness  to S RBC . M i ce wh i ch had the i r  primary tumor 
exci sed on day 1 5  recorded a S . l .  of 0 . 5 1 and 0 . 24 on days 21 and 
25 respect i vel y .  
1 06 
Fi gure 1 5  
Mononuc l ear cel l i nfi l trat ion i n  DTH react i on 
Photo m icrographs (320 x magn i fi cat ion ) of footpad sect i ons  
from unsens i t i zed ( A )  and  sens i t i zed (B ) BDFl mi ce cha l l en�ed 
24 hours prev i ou s ly  wi th 1 08 SRBC . Note presence of monon ucl ear 
cel l s  and absence of PMN ' s  and pl as�a cel l s  i n  footpad undergo i ng 





Fi gure 1 6  
DTH respons i veness  of BDFl mi ce beari ng  the 
orimary and metastati c Lewi s l ung cari noma 
BDFl mi ce were i nocul ated i n  the h i nd footpad wi th l X 1 06 cel l s .  
Fi fteen days after i nocu l at i on ha l f  of the tumor beari ng  mi ce had 
the i r  pri mary tumor exc i sed by amputat i on . The DTH respons i venes s 
of mi ce beari ng the pri mary ( 4t )  and metastat i c  ( � )  LLC was quan-
ti tated by us i ng a rad i o i sotope footpad assay where a pos i ti ve 
response was accompan i ed by an extravasati on of 1 25 I - h uman serum 
a l bumi n from the bl ood stream i nto the extracel l u l ar space of the 
footpad .  DTH val ues were ca l c u l ated as a st imu l at i on i ndex ( S . I . )  
and pl otted on the day of SRBC cha l l enge . Means + S . E .  were deri ved 
from 5 m i ce per group except for the unsens i t i zed control group 
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The data i n  Tabl e 7 i nd i cate that the l ac k  of DTH respons i veness 
wa s not due  to a d ecreased product ion  of c hemotac ti c factors such  a s  
C5a ' a s  PMN i n fl ux  was not  depres sed i n  a carraggenan i nduced footpad 
swe l l i ng  response . Groups  of m i ce beari ng  28 day o l d  prima ry or  
meta s tat i c tumors were st i l l  capabl e of e l i c i t i ng an i n fl amma tory 
respon se to carrogeenan s i mi l ar to the control S . l .  of 7 . 79 .  
3 .  A l terat ion s  i n  RES func t i on 
The functi ona l  act i v i ty of  the RES i n  LLC a n ima l s was i n i ti a l l y  
eva l uated by measur i ng  the vascu l ar c l earance and organ d i stri but i on 
of forma l i n  k i l l ed 1 25 1 - L i ster i a  monocytogenes . Yet , the res u l ts 
generated from these exper iments were era t i c  wi th no b i o l og i ca l  
trends evi dent when o rgan uptake was  pl otted a s  % total c pms , c pms/mg 
t i s s ue or  norma l i zed to the n umber of bacter i a  per organ . I n  retro­
s pect a control t ime course  exper iment c ha racteri z i ng the organ 
d i s tr i but i on of 1 25 1 -L i steri a monocytogenes was performed . As shown 
i n  Fi gure 1 7  the percent uptake of L i steri a i n  the l i ver , l u ng and 
thymus  were not  con s tant  but decreased over t ime .  Therefore t i s sues  
exci sed and  rad i oas sayed a t  any one g i ven t ime po i nt wou l d  not 
neces sar i l y  corre l a te wi th RES func t i on , a s  a l tera t i on s  in  phagocyt i c  
acti v i ty cou l d  a l so b e  refl ected by c hanges i n  the rate o f  organ 
c l earance . Thus , a second t ime course experi ment wa s conducted u s i ng 
another RE parti c l e ,  5 1 Cr- l a be l ed S RBC ( Fi gure 1 8 ) . Exam i nat i on of 
the data revea l s that the organ uptake of  the 5 1 Cr-l abel ed SRBC 
rema i ned con stant from 30  to 90 mi nutes  after i . v .  i nj ecti on . 
1 1 1  
Tabl e 7 
Effect of  the Lewi s l ung carci noma on the 
carrageenan i nduced i n fl ammatory res ponse 
BDFl mi ce were i nocul ated in the h i nd footpad wi th l X 1 0
6 cel l s  
and fi fteen days l ater hal f of the tumor bea r i ng mi ce had thei r 
primary tumor exc i sed by amputa t i on . Twenty ei ght days after the 
tumor i nocu l a t i on the tumor beari ng and control mi ce rece i ved a 
0 . 02 ml i njecti on of a 1 %  carrageenan so l ut i on or p�ys i o l og i c  
sa l i ne i n  the front l eft footpad i n  concert wi th a i . v .  i nject ion  
of 1 25 I -human serum a l bumi n .  Three hours thereafter the  tes t 
foot and contra l ateral  foot were exci sed and rad i oas s ayed . Res u l ts 
reported a s  mean st imu l at i on i nd i ces + S . E .  deri ved from 3 m i ce 
per group . 
Group 
Na i ve 
LLCa 
LLCb 
St imu l at ion  I ndex 
7 . 79 + 0 . 64 
7 . 87 + 0 . 56c 
6 . 9d + 2 . 02c 
aMi ce bea r i n g  28 day ol d LLC wi th primary tumor i ntact . 
bM i ce bear i ng  28 day o l d LLC wi th primary tumor exc i sed on day 1 5 .  
CSt imu l a t i on i ndex not s tas t i st i ca l l y  di fferent from control va l ue .  
1 1 2  
F i gure 1 ]  
O d · · b t ·  f 
1 25
1 L ·  t . rgan l s trl u l on 0 - l S  erl a  
monocytogenes 
BDFl mi ce were i nj ected i . v .  wi th 
1 25 1 - L i ster i a  monocytogenes 
in a vol ume of 0 . 1  ml / 1 0g body wei ght . At sel ected t imes from 1 5  
mi nutes to 24 hours after i nject ion  groups of mi ce were sacri fi ced 
by decap i tat i on and al l owed to exsangu i nate .  The l i ver , s p l een , 
l ung , thymus and k i dneys were then exc i sed and rad i oassayed . 
Data was ca l cu l ated as percent organ uptake ( %  total cpms ) and 
reported as means deri ved from 8 mice per grouo . Standard errors 
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F i gure 1 8  
Organ d i stri but i on of 5 1 Cr-SRBC 
BDFl mi ce were i njected i . v .  wi th a 1 0% s o l ut ion  of 
5 1 Cr_ 
l a b l ed SRBC in a vo l ume of 0 . 1  ml / 1 0g body wei ght . At se l ected 
times from 3 mi nutes to 24 hours after i nj ecti on groups of mi ce 
were sacr i fi ced by decap i tat ion and al l owed to exsangu i nate . The 
l i ver , sp l een , l ung , thymus and k i dneys were then exc i sed and 
rad i oassayed . Data was ca l cu l ated as percent organ uptake ( %  
tota l cpms ) and reported as means deri ved from 7 mice per group . 
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1 1 6  
Therefore , t i s s ues  exci sed and rad i oas sayed 60 m i n u tes after 
i n j ec t i on prov i ded i nformat i on as to the phagocyt i c  acti v i ty of 
the vari ous  RES organ s .  
Var i a t i on s  i n  RES act i v i ty a s  a funct ion  of  tumor growth are 
s hown i n  Fi gure 1 9 . F i g ure 1 9  a s ummari zes the c hanges in the 
phagocyti c i ndex ( K ) and c l earl y s hows that the vascu l ar c l earance 
of 5 1 Cr- 1 abe1 ed SRBC wa s marked l y  reduced 1 and 2 days after tumor 
cel l i n oc u l a t i on . On day 1 a K val ue of 0 . 02 ,  wh i ch corresponds 
to a vascu l ar ha l f l i fe of 1 5  m i n .  wa s recorded a s  compared to the 
contro l va l ue of  0 . 04 .  S i mi l arl y ,  the phagocyti c  capac i ty o f  the 
l i ver was s uppres sed earl y on , wi th a 3 1 %  and 35% upta ke recorded 
on days 1 and 2 ,  as compared to 66% i n  the non tumor bear i n g  con ­
trol s ( Fi g ure 1 9b ) . V i a bl e tumor cel l s  a ppear to be neces sary for 
th i s  s uppress i on as an equ i va l ent  i nj ec t i on of 1 x 1 06 son i cated LLC 
cel l s  were wi thout effect RES funct i on ( Tab l e 8 ) . The i n i t i a l  
decrease i n  vascu l ar c l earnace a n d  l i ver uptake were fo l l owed by a 
phase  of  i ncreased act i v i ty ,  wh i c h  was max i ma l  at  6 to 9 days , and 
a s u bsequent decrease to con trol va l ues  by day 1 5 .  These a l tera t i on s  
cou l d not  b e  accounted for by uptake of the RE parti c l e i nto the 
primary tumor bed wh i c h was l es s  than 3% at a l l t imes , or by changes 
i n  c i rcu l a t i ng b l ood vol ume a s  determi ned by extrapol at i on of the 
s l ope of K bac k  to zero t ime . Fi gures 1 9c and 1 9d depi ct  the 
functi onal  act i v i ty of  s pl en i c  and a l veo l ar macrophages i n  the tumor 
bear i n g  m i ce .  The o n ly  s i gn i fi cant  changes  in phagocyt i c  uptake 
occurred on  days 1 and 2 wh i c h  cou l d s imp l y  refl ect an  i ncreased 
1 1 7  
F i gure 1 9  
Var i a t i ons i n  RES act i v i ty i n  mi ce bea r i nq the 
primary and metastati i Lewi s l ung carc � noma 
BDFl mi ce were i nocul ated i n  the h i nd footpad wi th l X 1 0
6 
ce 1 1  s . Fourteen days after i nocul at  i on ha I f  the tumor bea ri ng 
mi ce had thei r primary tumors exc i sed by amputat ion . The funct ion­
al  act i v i ty of the RES  i n  mi ce bea r i ng the primary ( .. ) and  meta ­
stati c ( � ) LLC was eva l uated by measur i ng the vascul ar  cl earance 
and organ d i stri buti on of a 1 0% sol u t i on of 5 1 Cr-l abe l ed S RBC 
i nj ected i . v .  in a vol uMe of  0 . 1  ml / 1 0g body we i ght . Panel A 
summar i zes changes i n  vascu l ar  c l earance cal cu l ated as  a phagocyti c 
i ndex ( K ) . Panel s B ,  C and 0 refl ect changes i n  l i ver , s p l een and 
l ung uptake ca l cu l ated as  a percentage of i nj ected rad i oact i v i ty .  
Res u l ts are pl otted a s  means + S . E .  deri ved from 5 m ice  per group 
except for the non-tumor bear i ng control group wh i c h  had 45 mi ce . 
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Tab l e 8 
Neces s i ty of v i a b l e tumor cel l s  for RES s uppres s i on 
BDFl mi ce were i nj ected i n  the h i n d  footpad wi th l X 1 0
6 v i abl e or son i cated 
LLC cel l s .  RES funct i on was asses sed twenty four  hours l ater by measur i ng  the 
vascu l ar  c l earance and organ d i s tr i buti on of a 1 0% so l ut i on  of 5 1 Cr- l abel ed S RBC 
i nj ected i . v .  i n  a vol ume of 0 . 1  ml / 1 0g body wei ght . Va s cu l ar  c l earance was 
ca l cu l a ted a s  a phagocyt i c  i ndex whereas organ upta ke was ca l cu l ated a s  a per­
centage of i nj ected rad i oact i v i ty .  Resu l ts expressed a s  means  + S . E .  deri ved 
from 5 mi ce per group . 
Group Phagocyti c  I ndex L i ver Spl een L i ver Thymus 
Nai ve 0 . 05+0 . 01 67+3 7 . 6+ 1 . 2  0 . 1 9+0 . 02 0 . 01 4+0 . 004 
V i abl e LLC cel l s  0 . 02+0 . 00a 31 +4a 2 3 . 4+1 . 2 1 . 39+0 . 22a 0 . 01 8+0 . 004 
Son i cated LLC cel l s  0 . 04+0 . 00 67+1 8 . 2+0 . 2  0 . 25+0 . 02 0 . 01 0+0 . 000 
ap < 0 . 05 as compared to na i ve contro l . 
U) 
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exposure to the RE parti c l e  due to decrease hepa t i c  u ptake . The 
erra t i c  uptake i n  the l un g s  on days 1 5  through  21 probabl y refl ects 
the growth of the metastat i c foc i  i n  the pu l monary bed . Thymus  uptake 
rema i ned a t  contro l l eve l s  throughout the s tudy ( data not s hown ) . 
I n  con tra s t  to the prev i ou s  stud i es , exc i s i on of  the pri mary tumor on 
day 1 4  resu l ted i n  no  s i gn i f i cant  c hanges in organ uptake , a l though 
vasc u l ar c l earance rema i ned e l evated on  days 1 7  through 2 1 . 
4 .  Host res i stance to L i s teri a monocytogenes 
The forego i n g  resu l ts  i nd i cated that the LLC marked l y  s u ppres sed 
RES funct ion  24  and 48 hours a fter i nocul a t i on . The present s tud i e s  
were d e s i gned t o  determ i ne  whether the ab i l i ty o f  the LLC to i n h i b i t  
RES functi on wou l d  man i fest  i tse l f by decrea s i ng host res i stance to 
L i steri a monocytogenes , an  i nfec t i on i n  wh i c h  macro phages and i mmune 
T cel l s  have been s hown to be i nvol ved in the e l im i nati on of the bac-
teri a ( Mac kene s s , 1 970 ; North , 1 97 3 ) . 
Presented i n  Tab l e 9 are the resu l ts obta i ned from expos i n g  tumor 
bear i n g  and control BDFl m i ce to var ious  d i l u t i on s  of L i s teri a mono­
cytogenes rang i ng  from 1 03 to 1 08 bacteri a .  As can be seen the LD50 ' s  
for the var i o u s  LLC groups  were not stati s t i cal l y  d i fferent  from the 
val ue of 1 09 1 0  1 0
7 . 1 8  CFU LD50 obta i ned for the non tumor beari ng 
contro l group .  
C ,  Respons i veness  of  Lewi s Lung Carc i n oma to MVE 
1 . LD50 determi nati ons  for the MVE pol ymers 
Stud i es were i n i ti a l l y  conducted to obta i n  acute tox i c i ty 
1 2 1 
Tabl e 9 
Effect of the Lewi s l ung  carc i noma on res i s tance 
to L i s teri a monocytogenes 
Na i ve and tumor bear i ng  BDF1 mi ce were cha l l enged i . v .  wi th 
1 03 to 1 08 L i s teri a monocytogenes two days pri or to a footpad 
i nocu l at i on of 1 X 1 06 LLC cel l s ,  one day after LLC i nocu l at i on or 
1 2  days after LLC i nocu l at i on . Morta l i ty was recorded dai l y  for 
1 4  days . LD50 ' s  were ca l c u l ated by the method of L i tchfi e l d and 
Wi l coxon and reported as the 1 09 1 0 col ony form i n g  u n i ts (CFU ) that 
resu l ted in 50% morta l i ty .  Res u l ts were deri ved from 8 mi ce per 
group . 
L D SO 
Group 1 09 1 0CFU 95% confi dence l imi ts 
Nai ve 7 . 1 8  6 . 64 - 7 . 7 1 
LLCa 6 . 54� 6 . 03 - 7 . 05 
LLCb 6 . 1 9  d 5 . 4 1 - 6 . 97 LLCc 7 . 1 8  6 . 64 - 7 . 7 1 
aMi ce were cha 1 1 enqed wi th L i s teri a monocytogenes two days pri or 
to LLC i nocu l at i on .  
bM i ce were cha l l enged wi th L i steri a monoc�togenes one day after 
LLC i nocu l ati on . 
cMi ce were cha l l enged wi th L i s teri a monocytogenes twe l ve days 
after LLC i nocu l at i on . 
dLD50 not stast i s t i ca 1 1 y  d i fferent from na i ve contro l . 
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data on the fi ve MVE frac t i on s .  As s hown i n  Tab l e 1 0  the LD5 I o s 
of the MVE pol ymers i ncreased wi th  i ncrea s i n g  mo l ecul ar we i g h t ;  MVE - l  
was s i g n i fi cantl y l e s s  tox i c  than MVE 2 ,  3 ,  4 a n d  5 ,  a n d  MVE 2 ,  3 and 
4 were s i gn i f i cant ly  l es s  tox i c  than MVE-5 . Lethal i ty occurred wi thi n 
3 m i n u tes of  i n j ec t i on and the cause of death i s  at  present un known . 
Necropsy a t  the t ime of  death s howed no macroscop i c  patho l ogy . 
MVE-3 was se l ected for the Lewi s l ung stud i es a s  recent f i nd i ng s  
by Mora han e t  � ( 1 978 )  have i nd i cated that MVE-3 ma i nta i n s  the 
ab i l i ty to act i vate macrophages and prov i des protect i on aga i n s t  i n ­
fect ion  wi th  a n  i mproved therapeut i c  i ndex . 
2 .  Effi cacy o f  MVE-3 a l one  or MVE-3  coupl ed wi th 
cytoreduct i ve therapy 
The resu l ts of  the preced i ng sect i on i nd i cated that the immuno-
l og i c  capab i l i t i es of  m i ce beari ng  the Lewi s l ung  carc i noma are 
impa i red . Yet , the patterm of i mmunodef i c i ency s uggested that RES 
and T ce l l funct i ons  were i ntac t  from day 3 through  the second week 
of tumor growt h .  Moreover , s urg i ca l  exc i s i on o f  the primary tumor 
burden part i a l l y  restored the s uppres sed immune functi on s .  Accord i ng l y ,  
the i mmunotherapeut i c  reg i mens  were des i gned t o  treat early i n  the 
d i sease state or  a fter cytoreduct i ve t herapy i n  an  effort to have 
immunocompetent a n i ma l s wi th a "mi n i ma l " tumor burden . 
Pre l im i nary exper iments were des i gned to a scerta i n  whether 
MVE-3  was effect i ve by i tse l f aga i n st  the LLC when admi n i stered ear ly  
Tab l e 1 0  
L050 determi nat i ons  for the MVE fract i ons  
COFl mi ce were admi n i s tered the  MVE  po l ymers i ntravenous l y  in  vari ou s  doses 
in 0 . 1  ml / 1 0g body we i ght . Mi ce were observed for morta l i ty for 1 4  days . L050 
and s l ope determi n at i on s  were ca l cu l ated by the method of L i tchfi e l d  and Wi l coxon . 
Res u l ts  deri ved from 8 m i ce  per g roup . 
M . H . a Po lymer LOro (mg/ kg ) s l ope ( 95% con l dence l i mi ts ) ( 95% confi dence l i mi ts ) 
pyran 30 , 000 78 1 . 1 1 2  
( NSC  4601 5 )  ( 73-83 ) ( 1  . 1 06 - 1 . 1 1 8 ) 
1 1 2  1 . 1 03 
MVE - l  1 2 , 500 ( 1 03- 1 22 )  ( 1  . 1 00- 1 . 1 06 )  
98 1 . 047  
MVE-2  1 5 , 500 ( 94- 1 0 2 )  ( 1 . 046- 1 . 04 7 )  
94 1 . 06 1  
MVE -3 2 1  , 300 ( 89-99 ) ( 1 . 060-1 . 06 1  ) 
95 1 . 040 
MVE-4 32 ,000 ( 91 -98 ) ( 1 . 040-1 . 041 ) 
86 1 . 1 20 
MVE-5  52 ,600 ( 81 -91  ) ( 1 . 1 1 7 - 1 . 1 23 )  




i n  the d i sease s ta te . Tabl e 1 1  represents  l out  of 3 experiments 
where wee k l y  i . v .  treatment wi th MVE-3 i n i t i ated on day 7 was not 
effec t i ve i n  i nc reas i n g  l i fe span or i n h i b i t i ng primary tumor growth . 
Presented i n  Tab l e 1 2  are the resu l ts obta i n ed from comb i n i ng 
MVE-3  wi th  s urg i ca l  exc i s i on of  the primary tumor . Al though s urgery 
parti a l l y  restores  the i mmune competence of  the test  a n ima l s week l y  
MVE-3  treatment s ti l l  proved t o  b e  i n effect i ve i n  en hanc i n g  l i fe s pan  
over  the control MST  of 2 9 . 7�1 . 2  days . 
The a b i l i ty of MVE-3 to synerg i ze wi th conventi onal  modes  of 
therapy was fi rst a s ses sed by emp l oy i ng  MVE-3  in comb i nat i on wi th  s urgery 
and cyl c l ophosphami de ( CTX ) ( Fi gure 20 ) . Acute i . v .  i nj ect ion s  of 
CTX s i gn i fi cantl y pro l onged the MST in a dose response fas h i on . Doses  
of 50 , 7 5 , 1 00 and  1 50 mg/ kg produced mean  s urvi val  t imes  of  33 . 2�1 . 0 ,  
37 . 8�1 . 8 ,  4 1 . 6�2 . 2  and  42 . 6�1 . 4  days res pect i ve l y a s  compared to 
27 . 9+ 1 . 5  days for the s urgery control group . However , week l y  adm i n i ­
s trat i on o f  MVE-3  coup l ed wi th CTX fa i l ed to enhance the l i fe span of 
the tumor bea r i ng m i ce over that observed wi th CTX a l one . Mu l ti pl e  
i n j ec t i on s  of CTX ( 1 00 mg/ kg ) further reduced the metasta t i c  tumor burden 
of  the m i ce as evi denced by the 8 1 %  i ncrease in l i fe span ( Tab l e 1 3 ) . 
Yet , s i mi l ar to the a bove exper iment s urv i va l  t ime for the MVE treated 
m i ce  wa s not stati s t i ca l l y  d i fferent from the s urgery-CTX contro l . 
As MVE-3  was unabl e to synerg i ze wi th  s u rgery and  chemotherapy 
experiments were conducted emp l oy i n g  MVE -3  i n  comb i nat ion  wi th  rad i o ­
therapy ( Tab l e 1 4 ) . Local i rrad i a t i on of the primary tumors on day 
Tabl e  1 1  
Ant i tumor acti v i ty of  MVE -3 aga i ns t  the Lewi s l ung 
carc i noma 
BDF1 mi ce were i nocul ated wi th  1 X 1 0P LLC cel l s  i n  the h i nd  footpad .  On days 7 , 
1 4  and 2 1  the mi ce were i nj ected i . v .  wi th p hys i o l og i c  s a l i ne or MVE -3 . Mean s  + S . E .  
deri ved from 8 mi ce per group . 
Treatment 
none 
sa l i ne 
MVE -3 ( 5mg/ kg ) 
MVE-3 ( 25mg/ kg ) 
tWE - 3  ( 5Omg/ kg ) 
aMean s urvi val t ime .  
MSTa 
( days ) 
3 1 . 3+ 1 . 0  
30 . 4+2 . 0  
2 7 . 3+2 . 0  
29 . 8+1 . 7  
33 . 2+2 . 2  
7 




1 02+1 5 
Tumor vol ume (mm3 ) 
Da�s Post LLC i nocu l a t i on 
1 0  1 4  1 8  
298+2 1  697+44 1 42 1 + 1 2 1  
280+29 71 4+68 1 55 3+1 72 
237+32 725+78 1 632+1 85 
354+45 822+90 1 744+201  
269+31 652+53 1 459+1 57 
22 N Ul 
2204+227 
23 1 8+287 
2283+309 
2474+4 1 3 
201 1 +266 
1 26 
Tab l e  1 2  
Effect of MVE -3  coupl ed wi th surgery on the 
surv i va l  t ime of Lewi s l ung  beari ng mi ce 
BDFl mi ce were i nocu l ated wi th l X 1 0
6 LLC cel l s  in  the h i nd 
footpad on day 0 fo l l owed by s urg i ca l  exc i s i on ( S x )  of the primary 
tumors on day 1 4 .  MVE -3 was admi n i stered i ntravenous ly  on days 1 6  





Sx  + MVE 
Sx + MVE 
Sx + MVE 
( 5mg/ kg ) 
( 25mg/ kg ) 
( 5Omg/ kg ) 
MST 
( days ) 
29 . 7+ 1 . 2  
32 . 4+1 . 4  
30 . 7+1 . 2  
31 . 9+1 . 0 
3 1 . 8+0 . 9  
1 2 7 
f i gure 20 
Effect of MVE-3 coupl ed wi th s urgery and 
cyc l ophosphami de on the surv i va l  time of  
Lewi s l ung beari ng mi ce 
BDfl mi ce were i nocul ated w ith  l X 1 0
6 LLC cel l s  i n  the h i nd 
footpad on day 0 fo l l owed by surg i ca l  exc i s i on ( Sx )  of  the primary 
tumor on day 1 4 .  S ixteen days after i nocu l at ion  cycl ophosphami de 
( CTX ) was admi n i stered i . v .  i n  doses of  50 mg/ kg ( () ) ,  75 mg/ kg 
( e ) '  1 00 mg/ kg ( 0  ) or 1 50 mg/ kg ( . ) .  MVE -3 ( 25 mg/ k g )  was 
admi n i s tered i . v .  on days 1 8 ,  25 , and 32 . Surv i va l  curves were 
generated from 1 0  mi ce per group except for the Sx control group 
wh i c h  had 34 mi ce . 
1 28 
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Tab l e 1 3  
Effect of HVE-3  coupl ed wi th s urgery and mul t i p l e 
cyc l ophos pham i de i nject i ons  on the s urv i va l  t ime 
of Lewi s l ung  bear i ng mi ce 
BDFl m i ce were i nocu l ated w i th l X 1 0
6 LLC cel l s  i n  the h i nd 
footpad on day 0 fo l l owed by s urg i ca l  exc i s i on ( S x )  of the pri ma ry 
tumor on  day 1 4 .  Cyc l ophosphami de ( CTX ) was admi n i s tered i . v .  i n  
doses o f  1 00 mg/ kg on days 1 6  and 23 . MVE - 3  ( 25 mg/ kg ) was admi n ­
i stered i . v .  o n  days 1 7  and 24 . Mean surv i val  t imes (MST ) + S . E .  
deri ved from 8 mi ce per group . 
Treatment 
none 





( days ) 
2 7 . 1 + 1 . 2  
29 . 4+1 . 1  
29 . 9�O . 9b 53 . 1  + 1 .  B
b 49 . 4+2 . 5  , c 
I LSa 
( % )  
1 .  7b 80 . 6b c 68 . 0  ' 
a l n creaded l i fe span cal c u l a ted by compari son of MST between 
drug treated and Sx  control group . 
bp <0 . 05 a s  compared to Sx contro l . 
cSurv i val  t ime not stast i s t i ca l l y  d i fferent from Sx-CTX 
contro l . 
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7 wi th  2500 , 3500 or  4 500 rads i ncreased l i fe s pan  by 5 1 % ,  66% and 80% 
respect i ve ly  a nd i n h i b i ted primary tumor g rowth i n  dose response fas h i on 
up  to 85% . Yet , four week ly  i nj ec t i on s  of MVE-3 ( 25 mg/ kg ) i n i t i ated 
2 days after radi otherapy s ti l l  fa i l ed to enhance l i fe s pan or i n h i b i t  
tumor growt h  over  that observed w i t h  rad i at i on a l one . 
I t  s hou l d  be noted that the mean s urvi val  t imes for the pri mary 
tumor control  groups i n  t h i s experiment and  the fo l l ow ing  experiment 
were s i g n i f i cantl y decreased i n  compar i son to previ ous LLC stud i e s . 
The tumor pas sages were mon i tored for bacter i a l  contami nat ion  and 
found to be nega t i ve . 
As MVE-3 was unab l e to synerg i ze w i t h  rel at i ve ly  h i g h  doses  of 
rad i at i on an  a ttempt was made to m i n i mi ze the immunosuppress i ve 
effects of  rad i a ti on by l oweri ng  the doses of rad i at i on and admi n i ­
s ter i ng MVE-3  i . t .  p r i or to rad i otherapy .  I t  was hoped that 
i ntra l e s i ona l  MVE-3 treatment before rad i otherapy wou l d  not on ly  
d i s p l ay ant i tumor acti v i ty but  st imu l ate ho st  cel l s  re s i d i ng i n  the 
primary tumor bed to pro l i ferate and become more rad i ore s i s ta nt .  
T h e  res u l ts obta i ned from admi n i s teri ng MVE-3  before a n d  after 
rad i otherapy are s ummar i zed i n  Tabl e  1 5 .  As observed in earl i er 
exper iments  l oca l  radi otherapy a l one was effect i ve and week l y i . v .  
MVE-3 t herapy a l one  i neffect i ve i n  prol ong i ng l i fe s pan . I n  contra st  
to  systemi c MVE-3 treatment , an acute i ntra l e s i ona l  i nj ect i on of 
MVE-3  proved to be effi cac i ou s  by i ncrea s i ng l i fe s pan 35 . 9% over 
sa l i ne control s .  Moreover , t he comb i nati on of i ntral e s i ona l  MVE -3 
wi t h  3000 rads s i gn i fi cantl y prol onged s urvi val t ime a s  d i d  MVE-3  
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Tab l e  1 4  
Effect of  MVE-3  coup l ed wi th  rad i otherapy on 
the surv i va l  t ime of Lewi s l ung beari n9  mi ce 
C57BL/6 mi ce were i nocu l ated wi th l X 1 06 LLC cel l s  i n  the h i nd 
footpad on day O .  Seven days after i nocu l a t i on the pri mary tumors 
were l oca l l y  i rradi ated wi th  2500 , 3500 or 4500 rads ( r ) . Four 
wee k l y  i . v .  i nject ions  of MVE -3 ( 25  mg/ kq ) were i n i t i a ted on day 
9 .  Mean surv i val  t imes (MST ) + S . E .  were deri ved from 1 0  mi ce 
per group . 
Treatment 
none 
MVE ( 5mg/ kg ) 
MVE ( 2 5mg/ kg ) 




2500r + MVE ( 25mg/kg ) 
3500r + HVE ( 25mg/ kg ) 
4500r + MVE ( 2 5m�/ kg ) 
a l ncreased l i fe s pan . 
MST 
( days ) 
1 7 . 9+0 . 9  
1 8 . 2+2 . 1  
1 9 . 6+2 . 4  
20 . 0+3 . 3  
27 . 0�3 . 0� 
29 . 7�2 . 6b 32 . 3+2 . 6  
26 . 0+3 . 0b , c 
2 7 . 6+3 . 7b , c 
3 1 . 6+2 . 3b , c 
bp < 0 . 05 a s  compared to pr i mary tumor contro l . 
I LSa 
( % }  
1 . 7 
9 . 5  
1 1  . 7  
b 50 . 8b 65 . 9b 80 . 4  
45 . 3b , c 
54 . 2b , c  
76 . 5b , c  
cSurvi val  t ime not stast i s t i ca l l y  di fferent from appropri ate 
rad i at i on contro l . 
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Tabl e  1 5  
Effi cacy of MVE -3  adm i n i s tered before and after 
rad i otherapy of the Lew i s  l ung carci noma 
BDFl m i ce were i nocul ated wi th  l X1 0
6 LLC cel l s  i n  the h i nd 
footpad on day O .  I nt ratumor ( i  . t . ) i nj ecti ons of phys i o l og i c  
sa l i ne o r  MVE-3  ( 50 mg/ kg ) were admi n i s tered 5 days a fter tumor 
i nocu l a t i on fol l owed by l ocal  i rrad i at i on of the pri mary tumors 
on day 9 .  Week l y  i . v .  i nj ec t i ons  of MVE ( 25 mg/ kg )  were i n i t i ated 
on day 1 1 . Mean s urv i va l  t i mes (MST ) + S . E .  were deri ved from 1 0  
mi ce per g roup . 
Drug rou te MST at rad i a t i on doses of 
none 1 000r 2000r 
sa l i ne i .  t .  2 1 . 7+ 1 . 5  32 . 5+2 . 9a 37 . 5+2 . 4a 
29 . 5+ 3 . 8a 35 . 8+2 . l a 38 . 3+3 . 1  a MVE 
MVE 
MVE 
i . t .  
i . v .  
i . t .  + i  . v . 
2 1 . 5+2 . 5  
NOC 
33 . 9+2 . 7a - a 40 . 5+3 . 2  
40 . 1 +2 . 4a 
53 . 2+1 . 4a , b 
ap (  0 . 05 a s  compared to non i rrad i ated sa l  i ne control . 
bp (  0 . 05 as compared to appropr i a te i rrad i ated control . 
cNot done . 
3000r 
37 . 4+2 . 4a 
47 . 0+ 1 . 8a , b 
43 . 7+2 . 7a - a 46 . 4+2 . 2  
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therapy before and after 2000 rads of  rad i a t i on . The rel a t i ve success  
of these comb i ned treatment moda l i t i es has  to be q ua l i fi ed however a s  
t he  a ppropr i ate MVE-3 i . t . +i . v .  con trol was omi tted . 
W i th the l a s t  ava i l ab l e group of BDFl m i ce , the temporal rel at ion ­
s h i p  between i ntra l es i ona l  MVE-3  treatment  and rad i otherapy was 
i nvesti gated ( Tabl e 1 6 ) . I n  accordance wi th the prev i ou s  s tudy MVE-3  
admi n i stered i ntra l e s i on a l l y  s i gn i f i cant l y enhanced l i fe s pan  by 
28 . 1 %  and i n h i bi ted pr imary tumor g rowth up to 37% . Systemi c MVE-3  
therapy coupl ed wi th  i ntral es i ona l  MVE-3  ( control group omi tted i n  
the prev i ou s  s tudy ) d i d  not  i ncrease  the ant i tumor effect over that 
observed with i ntra l e s i ona l  MVE-3 a l one . Loca l  i rrad i at i on of  the 
pr ima ry tumor  wi th  2000 rads i n h i b i ted pr ima ry tumor growth and pro­
l onged l i fe span , wh i l e  the comb i nat ion  of MVE-3  wi th day 8 rad i at i on 
marg i na l l y  enhanced l i fe s pan by 1 8 . 8% over rad i at i on control s .  
3 .  Effi cacy of  MVE-2 admi n i stered by i n ha l at i on 
Based on  the rel at i ve s uccess  of MVE-2 admi n i stered by i n ha l at i on 
to m i ce beari ng the Mad i son 1 09 carci noma ( see M1 09 res u l t secti on ) an 
attempt was made to i ncrease the effi cacy of MVE aga i n st  the LLC by 
l oca l i z i ng the compound i n  the meta stati c tumor bed . Yet , a s  s hown 
i n  Tabl e 1 7 , concentrat i on s  of MVE -2 rang i n g  from 0 . 1  mg/ml to 5 mg/ml 
were i neffect ive  i n  prol ong i n g  the l i fe s pan of mi ce beari ng  the 
metastat i c  L L C .  I t  s hou l d  b e  noted t h at  C57BL/6 mi ce a n d  a l ower 
mol ecu l ar  we i g ht  MVE frac t i on , MVE -2 , were empl oyed i n  th i s  s tudy due 
to the unava i l ab i l i ty of  BDFl mi ce and MVE-3 . 
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Tabl e 1 6  
Determi nati on  of the temporal rel ati on s h i p 
between i ntra l es i ona l  MVE -3 treatment and rad i otherapy 
BDFl mi ce were i nocul ated wi th l X 1 0
6 LLC  cel l s  i n  the h i nd 
footpad on day O .  I ntratumor ( i  . t . ) i nj ecti ons  of phys i o l og i c  s a ­
l i ne or MVE - 3  ( 50 mg/ kq ) were admi n i stered 5 days after tumor 
i nocul at i on fo l l owed by l oca l  i rradi a t i on ( 2000 rads ) of the pri ma ry 
tumors on days 7 ,  8 , 9 , 1 0  or 1 1 .  Week ly  i . v .  i nj ecti ons of MVE -3  
( 2 5  mg/kg ) were i n i t i ated 2 days after rad i otherapy . Mean s urvi va l  
t imes (MST ) + S . E .  deri ved from 1 0  mi ce per group . 
Treatment 
Drugs 
s a l i ne i . t . + i . v .  
MVE i . t .  
MVE i .  t + i .  v .  
s a l i ne i .  t .  
MVE i . t .  
MVE i .  v .  
MVE i . t .  + i  . v . 
MVE i . t . +i . v .  
MVE i . t . + i . v .  
MVE i .  t . + i . v .  
MVE i . t . + i . v .  







1 0  
1 1  
MST 
( days )  
2R . 8+2 . l  
36 . 9+1 . 5  
36 . 6+1 . 9 
39 . 4+ 1 . 4  
39 . 7+2 . 3  
37 . 3+2 . 4  
42 . 7+3 . 1  
46 . 8+3 . 0  
42 . 6+3 . 3  
44 . 7+2 . 2  
44 . 2+2 . 6  
I LSa 
( % )  
- b 28 . \ 
27 . 1  
0 . 8  
-5 . 3  
8 . 4  
l 8 . Bc 
8 . 1  
1 3 . 5  
1 2 . 2  
a l ncreased l i fe span as compared to appropri ate control group . 
bp < 0 . 05 a s  compared to non i rrad i ated sa l i ne contro l . 
cp < 0 . 05 a s  compared to appropri ate drug treated or i rradi  ated 
contro l . 
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Tabl e 1 7  
Effi cacy of MV E -2 admi n i stered by i n hal at ion  
to  mi ce beari ng  t he  Lewi s l ung  carc i noma 
C57BL/6 mi ce were i nocul a ted wi th  1 X 1 06 LLC cel l s  i n  the 
h i nd footpad on day 0 fo l l owed by surg i ca l  exc i s i on ( S x )  of the 
pr ima ry tumors on day 1 4 .  Seventeen days after i nocu l at ion  and 
twi ce a week thereafter the noses and mouths of the tes t a n ima l s  
were exposed to a nebul i zed mi s t  o f  phys i ol og i c  sa l i ne or MVE -2 . 




Sx- sa 1 i ne 
Sx-MV E -2 ( 0 . 1  mg/m1 ) 
Sx-MV E -2 ( 0 . 5  mg/m1 ) 
Sx-MVE -2  ( 1 . 0  mg/m1 ) 
Sx-MVE-2  ( 5 . 0  mg/m1 ) 
MST 
(days ) 
2 7 . 4+ 1 . 5  
30 . 4+1 . 5 
29 . 6+1 . 5 
33 . 9+1 . 2  
32 . 9+1 . 3 
32 . 9+2 . 3  
29 . 0+1 . 5 
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D .  Respo n s i venes s  of  the Lewi s Lung Carc i noma to 
Corynebacter i um Parvum 
1 .  L D50 determ i n a t i on for C .parvum 
A pre l im i nary LD50 s tudy was conducted to determ i ne  the i . v .  
dosages o f  C .parvum for s u bsequent experiments . As s hown i n  Tab l e 
1 8  the LD50 for C .parvum i nj ected i . v .  i n to BDFl m i ce was 53 mg/kg 
wi th 95% confi dence l imi ts  of  37 to 7 1  mg/ kg . Lethal i ty occurred 
a pprox imate l y  1 5  mi nutes  a fter i nj ec t i on and the cause  of death 
i s  at  present un known . Necropsy at  the t ime of death s howed no  
macroscop i c  patho l ogy . 
2 .  Effi cacy o f  C .parvum a l one or  C .parvum coupl ed wi th  
cytoreduc t i ve therapy 
Tab l e 1 9  s ummar i zes  the res u l ts  obta i ned from 2 separate 
exper iments  de s i gned to a scerta i n  the effi cacy of C .parvum aga i n st 
the LLC . Week ly  i . v .  admi n i s trat ion of  C .parvum at  doses of 1 4  mg/kg 
and 21  mg/ kg marg i na l l y  enhanced l i fe s pan by 24 . 5% and 24 . 1 %  respect-
i ve l y .  S i mi l ar l y ,  i ntra l es i ona l  C .parvum treatment produced a 
s l i ght  but s i g n i f i cant  pro l ongat i on i n  MST at  doses of 7 , 2 1  and 70 
mg/kg . Tumor g rowth was u naffected by i ntravenous C .parvum whereas 
i n tral e s i ona l  C .parvum ( 70 mg/ kg ) treatment cau sed a 1 3 . 1 %  and 20 . 2% 
i n h i b i t i on of  pr ima ry tumor growth on days 9 and 1 2  respecti vel y ,  
retu rn i ng to con trol va l ues  by day 1 5  ( data not s hown ) . 
Presented i n  Tab l e 20  a re the resu l ts  obtai ned from comb i n i ng 
i n travenou s C .pa rvum wi th s u rg i ca l  exc i s i on of the primary tumor . 
Surgery on day 1 4 ,  a t i me when the t umor had a l ready metastas i zed 
Tabl e 1 8  
LD50 determi nat i on  o f  C .pa rvum 
BDFl mi ce were admi n i s tered C .parvum i ntravenous l y  i n  va ri ous doses i n  
0 . 1  ml / 1 0g body we i gh t .  Mi ce were observed for morta l i ty for 1 4  days . L D50 
and s l ope determi nat i on s  were ca l cu l ated by the method of L i tchfi e l d and Wi l coxon . 
Res u l ts deri ved from 6 or  7 mi ce per group . 
Dose  #dea� 
(mg/ kg ) #mi ce 
1 0  0/7  
25 0/ 7 
50 3/6 
75  5/ 7 
1 00 7/ 7  
LD' s l ope 
( 95% conf�gence l i mi ts ) ( 95% confi dence l i mi ts ) 
5 2  
( 37 - 7 1  ) 
1 . 520 




Tabl e 1 9  
Ant i tumor act i v i ty of C .parvum aga i n st  the 
Lewi s l ung  carci noma 
BDFl mi ce were i nocul ated wi th l X 1 0
6 
LLC cel l s  i n  the h i nd 
footpad on day O .  On days 7 , 1 4  and 2 1  the mi ce were i nj ected 
wi th phys i o l og i c  sa l i ne or  C .parvum by the i nd i cated route . Mean 
s urv i va l  t imes ( MST ) � S . E .  deri ved from 1 0  mi ce per group except 
for the sa l i ne control groups wh i c h had 20 mi ce per group . 
Treatment MST I LSa 
Drug route ( da.Ys ) ( % )  
s a l i ne i . v .  26 . 1  + 1 . 5  
C . parvum (7 mg/ kg ) i . v .  29 . 8�2 . 3b 1 4 . 2 b C . pa rvum ( 1 4  mg/ kg ) i .  v .  32 . 5�2 . 1 b 25 . 5b C . parvum ( 2 1  mg/ kg ) i .  v .  32 . 4+1 . 8  24 . 1  
sa l i ne i .  t .  28 . 7+ 1 . 5  
C . parvum ( 2  mg . kg ) i . t .  26 . 3�2 . 4b 
-8 . \ 
C . parvum ( 7  mg/ kg ) i . t .  34 . 0�2 . 1 b 1 8 . 5b C . parvum ( 2 1  mg/ kg ) i . t .  34 . 3�2 . 2b 1 9 . 5b C . parv um ( 70 mg . kg ) i .  t .  35 . 9+2 . 2  2 5 . 1  
a l ncreased l i fe span a s  compared to appropri ate sa l i ne control . 
bp < 0 . 05 as compared to appropri ate sal i n e  contro l . 
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to the l un g , had no  effect on s u rv i val  t ime . However , when C .parvum 
trea tment  was coupl ed wi th  s urgery a s l i g ht  pro l ongati on in MST 
occurred at the 1 0 , 1 5  and 20 mg/kg doses . 
The resu l ts obta i ned from comb i n i ng systemi c C .parvum treatment 
wi th rad i otherapy a re s ummari zed i n  Tab l e 2 1 . As observed in  earl i er 
exper i ments  i rrad i a t i on of  the tumors wi th 2 500 , 3500 or 4500 rads 
s i gn i f i can t l y  pro l onged the MST i n  a dose response fa s h i on . I n tra ­
venou s admi n i stra t i on of  C .parvum a l one a l so enhanced l i fe span by 
20 . 3% .  Moreover ,  the comb i n a t i on o f  C .parvum wi th 2 500 rads or  3500 
rads s i g n i f i cant l y  i ncreased l i fe s pan by 23 . 2% and 33 . 1 %  res pect i ve l y  
i n  compar i son t o  t h e  appropr i ate i rradi ated contro l s .  
E .  Characteri zat ion  of the Mad i son 1 09 Lung Carci noma 
1 .  P r imary tumor growth 
Presented i n  F i gure 21 are g rowth curves for the M1 09 i nocul ated 
i n  the h i nd footpad of Bal b/c and CDFl mi ce . The resu l ts  i nd i cate 
that no  detectab l e d i fferences exi st  i n  the growth rates of the 
pr imary M1 09 tumor i n  the two stra i n s  of m i ce  and that both tumor 
mode l s fol l ow Gompertz i an growth wi th a decrease i n  growth rate a s  
t he  tumo r burden i ncreases . Gro s s  exami nat ion of the  tumors revea l ed 
that the maj ori ty of tumors u l cerated by day 20 and by day 2 5 essen­
t i a l l y  a l l o f  the tumors  had necro t i c  cores s urrounded by a pro l i fe­
rati n g  s he l l .  
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Tabl e 20 
Effect  of C .parvum coup l ed wi th surgery 
on the s urv i va l  t ime of Lewi s l ung beari ng mi ce 
BDr l m i ce were i nocul ated wi th l X 1 0
6 LLC cel l s  i n  the h i nd 
foot on day 0 fo l l owed by surg i ca l  exc i s i on ( S x )  of the pri mary 
tumors on day 1 3 .  C .parvum was admi n i stered i ntravenous ly  on 
days 1 5  and  2 3 .  Mean s urv iva l  t imes ( MST ) +S . E .  deri ved from 9 




Sx + C . parvum ( 5mg/ kg ) 
Sx  + C . parvum ( 1 0  mg/ kg ) 
Sx  + C . parvum ( 1 5  mg/ kg ) 
Sx + C . parvum ( 20  mq/ kg ) 
MST 
( days )  
30 . 7+ 1 . 1  
2 1 . 0+0 . B  
32 . 0:E:0 . Bb 35 . ()�1 . O
b 34 . 8+0 . 7  - b 35 . 0+ 1 . 2  
a l ncreased l i fe s pan  as compared to Sx control group . 
bp < 0 . 05 as compared to Sx control grouD . 
1 4 1 
Tabl e 2 1  
Effect of C . parvum coupl ed wi th radi otheraoy on 
the s urv i va l  t ime of Lewi s l ung beari ng  mi ce 
BDF 1 mi ce were i nocul ated wi th 1 X 1 0
6 LLC cel l s  in the h i nd 
footpad on day O .  Seven s ays after i nocu l at ion  the primary tumors 
were l oca l l y  i rrad i a ted wi th  2500 , 3500 , or 4500 rads ( r ) . Four 
week ly  i . v .  i nj ecti ons  of C .parvum ( 1 4  mg/kg ) were i n i t i ated on 
day 9 .  Mean s urv i va l  t imes ( MST ) �S . E .  were deri ved from 1 0  mi ce 
per group except for the pr ima ry tumor control group wh i c h had 
20 mi ce . 
Treatment 
none 




2500r + C . parvum 
3500r + C . parvum 
4500r + C . parvum 
a l nc reased l i fe span . 
MST 
(days ) 
26 . l �1 . \ 
31 . 4+1 . 6  
b 3 l . 1 �1 . 5b 35 . 4�1 . 8b 36 . 1 +2 . 8  
38 . 3+ l . 6 b , c 
47 . 1 :£2 . 3� ' c 
37 . 2+ 1 . 9  
bp( 0 . 05 as compared to pr imary tumor control . 
Cp ( 0 . 05 as compa red to appropri ate i rrad i ated con trol . 
I LSa 
( % )  
20 . 3b 
b 1 9 . 2b 35 . 6b 38 . 3  
46 . 7 b , c 
80 . 5b , c  
42 . 5b 
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F i  gure 2 1  
Growth characteri st i cs of  t he  M1 09 footpad tumor 
Bal b/c  ( 0 ) or CDFl Ce ) mi ce were i nocul ated i n  the h i nd 
footpad wi th 5X1 05 M1 09 cel l s .  The primary footpad tumor vol umes 
were meas ured wi th d i a l  cal i pers and expressed as mean tumor vo l ­
umes Cmm3 ) deri ved from 7 to 1 0  m i ce per group . Standard errors 
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2 .  Metastat i c  s pread 
Recent stud i es by Mark s  et  � ( 1 978 )  have i nd i cated that the 
M 1 09 tumor meta stas i zes  pr imar i l y  to the l ung  wi th i n  3 weeks  and 
resu l ts i n  the death of  the host a bout  35  days after tumor i mp l a n t .  
T he  fol l owi ng  experiment was des i gned t o  suppl ement  these observati ons  
by determ i n i ng the metastat i c  rate of  the M 1 09 tumor . As s hown i n  
Tab l e 2 2  metas tas i s  occu rred very ear l y  i n  Ba l b/c mi ce wi th  1 00% deaths 
recorded when the pr ima ry tumors  were removed 7 days after tumor 
i nocu l a t i on . Surg i ca l  exci s i on of  the primary tumor on day 1 8  or 
thereafter had no  effect on the s u rv i va l  t ime of the Bal b/c mi ce . I n  
the CDFl host the MST was l es s  than i n  the syngene i c  Ba l b/c mouse , yet 
the tumor a ppeared to metasta s i ze s l ower a s  evi denced by the greater 
i ncreases  i n  l i fe s pan  afforded by s u rg i ca l  remova l  of the pr imary 
footpad tumor . 
Necropsy a t  the t ime of  death reveal ed that the M1 09 metasta s i zes  
primar i l y  to the l un g s . Yet , sma l l metastat i c  foci were a l so observed 
i n  the l i ver , spl een and reg i ona l  l ymph nodes when v i ewed under a 
d i sect i n g  m i c roscope . 
3 .  Immunogen i c i ty 
Presented i n  F i gure 22  are growth c urves for a secondary M1 09 
tumor cha l l enge i n  normal Bal b/c rec i p i ents  ( Pane l  A )  or  i n  Ba l b/c 
mi ce bea r i ng an  estab l i s hed M1 09 tumor i n  the contra l ateral foot 
( Pane l  B ) . M i ce  bear i ng a pr ima ry M 1 09 tumor c l earl y d i spl ayed con ­
comi tant tumor i mmu n i ty ,  exh i b i t i ng the capac i ty to suppres s  the 
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Tabl e 22 
Effect of primary tumor exc l s l on on s urvi va l 
of �1 09 beari ng mi ce 
Ba 1 b/ c  or  COF 1 mi ce were i nocu l ated wi th 5X1 0
5 M1 09 cel l s  i n  
the h i n d  footpad and the primary footpad tumors removed on days 7 , 
1 0 , 1 4  or  1 8 .  Mean s urv iva l  ti mes ( MST ) � S . E .  deri ved from 8 
mi ce per g roup except for the pri�ary tumor contro l s wh i ch had 
25 mi ce per group . 
Mous e  stra i n  
Ba 1 b/c 
Ba 1 b/c 
Ba 1 b/c 
Ba 1 b/c 
Ba1 b/c  
COF1 COF1 COF 1 COF1 
Day of s u rgery 
7 
1 0  
1 8  
22 
1 0  
1 8  
22 
MST 
( days ) 
38 . 5+1 . 4  - b 63 . 1 �3 . 2b 45 . 9+2 . 6  
40 . 2+2 . 2  
35 . 1 +1 . 9 
3 1 . 9�1 . 9
b 57 . 0�7 . 5b 37 . 0+ 1 . 5  
34 . 4+1 . 9 
I LSa 
( % )  
- b 6 3 . \ 1 9 . 2  
4 . 4  
-8 . 8  
b 78 . 7b 1 6 . 0  
7 . 8  
a l n creased l i fe s pan  ca l c u l ated by compari s i on of MST between 
s u rgery groups  and appropri ate prima ry tumor contro l . 
bp (  0 . 05 as compared to appropri ate primary tumor control . 
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growth of a secondary M 1 09 c ha l l enge . I nocu l a t i on of the secondary 
cha l l enge however , had no  effect on the growth of the primary tumor 
( data not  s hown ) . 
The concom i tant i mmune response was tumor spec i fi c  ( F i gure 2 3 ) . 
Mi ce bea r i ng a pr ima ry M1 09 tumor i n  the l eft h i nd footpad s uppres sed 
the g rowth of a s econdary M 1 09 c ha l l enge , but  were wi thout effect on 
the growth of the P81 5 mastocytoma . 
F .  Respons i veness  of the  Mad i son 1 09 Lung Carc i noma to MVE-2  
1 .  E ffi cacy of  MVE - 2  a l on e  aga i n s t  the M1 09 
S ummar i zed i n  Tab l e 23  are the res u l ts obtai ned from admi n i s ter i n g  
a s i ng l e  dose of MVE-2 t o  M1 09 beari ng  a n i ma l s .  Wh i l e  a marg i na l  
i nc rease i n  l i fe s pan was observed wi th a s i ng l e i . v .  i nj ec t i on of 
MVE-2 ( 50 mg/kg ) on d ay 7 ,  the data suggests that acute admi n i stra­
t i on of MVE -2 , g i ven i . v .  or  i ntral es i ona l l y ,  does  not marked l y  affect 
MST . However , mul t i p l e  i nj ec t i on s  of MVE-2 ( 25 mg/ kg ) s i gn i f i cant l y  
en hanced l i fe s pan  by a l l three routes of  admi n i s trat ion  tested ; 
i . v . , i . t .  and i . p .  ( Tabl e 2 4 ) . The i . v .  and  i . t .  routes of adm i n i s ­
tra t i on were more effect i ve than MVE-2  del i vered by the i . p .  route . 
I n  accordance wi th  the l i fe s pan data i . v .  and  i . t .  adm i n i s trati on 
of MVE-2  a l so i n h i bi ted primary tumor growth up  to 65% , whereas i . p .  
admi n i stra t i on was wi thout a s i gn i fi cant  effect o n  tumor vol ume . 
Stud i es were next u ndertaken to compare the anti tumor act i v i ty 
of MVE -2 , t he more tox i c  pol yan i on pyran -copo l ymer , and the b i o l og i ­
cal  vacc i ne C .  parvum . As s hown i n  Tabl e 25 the act i v i ty of a l l the 
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F i gure 22 
Effect of an establ i s hed M1 09 tumor on the 
growth of a second M1 09 tumor chal l enge 
Ba1 b/c  mi ce were i nj ected in the l eft h i nd footpad wi th 
5X1 05 M1 09 ce l l s .  E l even days l ater ( day 0 on the fi gure ) these 
tumor bear i ng mi ce and norma l mi ce were chal l enged in the r ight  
hi nd footpad wi th vary i ng numbers of M 1 09 tumor cel l s  rang i ng  
from 1 X1 04 to l X1 06 M1 09 cel l s .  Depi cted are growth curves for 
the secondary tumor chal l enge i n  norma l Ba 1 b/c reci pi ents ( Panel  
a )  or in  Ba1 b/c mi ce beari ng an establ i s hed tumor in  the contra ­
l a tera l foot ( Panel b ) . Resu l ts are deri ved from 8 mi ce per grour . 
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Fi gure 23 
Effect of an establ i s hed M1 09 tumor on the 
growth of a second M1 09 or P81 5 tumor 
cha l l enge 
5 
COFl mi ce were i nj ected i n  the l eft h i nd footpad wi th 5X1 0 
M1 09 cel l s .  E l even days l ater ( day 0 on the fi gure ) these tumor 
beari ng mi ce and norma l mi ce were cha l l enged i n  the ri ght hi nd 
footpad with  5X1 05 M1 09 or l X1 0  P81 5 tumor cel l s .  Dep i cted are 
growth curves for the secondary M1 09 tumor cha l l enge i n  norma l 
COFl rec i p i ents ( .. ) or i n  COFl mi ce beari ng  an establ i s hed 
M1 09 tumor in the contra l ateral foot ( () ) ;  and growth curves for 
the P81 5 footoad tumor i n  norma l COF 1 rec i p i  ents ( &  1 or i n  
COFl mi ce bear i ng an establ i s hed M1 09 tumor i n  the contra l a tera l  
foot ( 6.  ) .  Resu l ts are deri ved from 8 mi ce per group . Stan -
dard errors are wi t h i n  1 3% of the means i n  a l l cases . 
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Tab l e  23 
I neffecti venes s  of acute admi n i s trat i on of MVE -2 aga i ns t  the M1 09 
Bal b/c mi ce were i nocul ated wi th 5X1 05 M1 09 cel l s  i n  the l eft 
h i nd footpad on day O .  A s i ng l e  i nj ect i on of phys i o l og i c  sa l i ne or 
MVE -2 ( 50 mg/ kg ) was admi n i s tered on days 7 ,  8 or 1 2  by the i nd i cated 
route . Mean s u rv i va l  t ime (MST ) + S . E .  der i ved from 8 mi ce per 
group . 
Treatment  MST 
( days ) 
Day 7 sa l i ne ( i . t . )  45 . 8+ 1 . 5  
Day 7 MVE - 2  ( i . t . )  40 . 2+3 . 0  
Day 7 s a l i ne ( i . v . ) 36 . 2:.1 . 7a 
Day 7 MVE-2  ( i . v . ) 42 . 2+ 1 . 3  
Day 8 s a l i ne ( i . t . ) 36 . 2+ 1 . 4  
Day 8 rWE -2  ( i . t . ) 39 . 2+1 . 4 
Day 1 2  s a l i ne ( i . t . ) 38 . 5+ 1 . 4  
Day 1 2  MVE-2  ( i . t . )  36 . 3+1 . 2 
Day 1 2  s a l i ne ( i . v . )  37 . 3+ 1 . 6  
Day 1 2  MVE - 2  ( i . v . )  40 . 7+1 . 5 
ap < 0 . 05 as compared to approori ate s a l i ne control group . 
Tab l e 24 
Effi cacy of mul t i p l e  MVE -2 i nj ec t i on s  agai n s t  the M1 09 
CDF l mi ce were i nocul ated wi th 5X 1 0
5 M1 09 cel l s  i n  the l eft h i nd footpad on  day 
O .  Beg i nn i ng o n  day 7 and  then week l y ,  the mi ce were admi n i s tered phys i o l 0 9 i C  s a l i ne 
or �VE -2 ( 2 5  mg/ kg ) by the i nd i cated route . Means  + S . E . deri ved from 1 6  mi ce per 
group and 9 mi ce per MVE-2  treated grouD . 
Tumor vol ume ( mm3 ) 
Treatment '�STa Da�s pos t M1 09 i nocul a t i on 
( days ) 20 23 2 7  30 34 
sa l i ne 39 . 4�2 . 0b 1 63�3� 23 1�32b 395+64 6 1 6+50 842+81 MVE -2 ( i . v . )  58 . 7+5 . 1  26+9 52+ 1 2 1 1 6+3 1  b 1 52+31 b 3 5 1+73b 
s a l i ne 37 . 0+2 . 2  1 76�2\ 3 1 6�3b 499+70 665�55b 888+91  MVE-2 ( i  . v . ) 68 . 6+3 . 5b 26+1 0 44+8 46+9b 56+ 1 4  1 1 9+2 1  b 
sa l i ne 42 . 9�3 . \ 46+1 0 88+ 1 5 1 6 5+1 9 234+37 6 1 9+ 1 1 6  
MVE-2  ( i  . p . ) 54 . 0+3 . 3  59+1 3 66+1 8 1 36+29 2 1 8+73 660+2 1 3 
aMean s urv i va l  t ime 
bp ( 0 . 05 
(J1 
N 
1 5 3 
i mmunomodu l ators was comparab l e a t  doses of  1 0  mg/kg and 25 mg/ kg . 
MVE-2 l o st act i v i ty a t  5 mg/kg . 
As tumor vol ume has  been s hown to const i tute a cr i t i ca l  l imi ta ­
t i on to the s ucce s s  of  i mmunotherapy , exper iments were a l so conducted 
i n  wh i c h  MVE-2 therapy was i n i t i ated at  d i fferent i n terval s after 
M1 09 i nocu l a t i on . Summari zed i n  Tab l e 26  are the resu l ts obta i ned 
from 4 separate s tu d i e s  empl oyi ng  mu l t i pl e  i . v .  i nj ect i on s  of 
MVE-2 ( 50 mg/kg ) . The i n i t i a t i on date of systemi c therapy marked l y  
affected the effi cacy o f  MVE - 2 . Week l y  i . v .  admi n i strat ion  i n i ti ated 
on day 7 produced a 49% pro l ongat i on i n  s u rv i val t ime whereas treat­
ment w i t h he l d  unt i l day 20  was wi thout a s i gn i f i cant  effect on l i fe 
s pan . 
2 .  Effi cacy of MVE - 2  coup l ed wi th s urgery or rad i otherapy 
The a b i l i ty of MVE -2  to synerg i ze wi th conventi onal  modes of 
therapy was a s sessed by empl oyi n g  MVE-2 i n  comb i n at i on wi th s urgery 
or  rad i a t i on . Surg i ca l  exc i s i on of  the pri mary footpad tumor on days 
1 0  or 1 4  s i gn i fi can t l y  prol onged the MST ( Tab l e 2 7 ) . L i kewi se , when 
the tumor beari n g  hosts  were treated i . v .  wi th MVE ( 50 mg/ kg ) an 
i ncreased l i fe s pan  was observed . However ,  s urgery comb i ned w i th MVE -2 
fa i l ed to prol ong the MST over that observed wi th MVE -2 a l one . S im i l ar 
resu l ts were obta i ned when MVE-2  ( 50 mg/ kg )  was admi n i stered i . v .  or 
i . t .  6 d ays pri or to s urgery , week ly  ( i . v . ) start i ng 2 days after 
s urgery ,  or both pri or to and after s u rgery . 
Presented i n  Tabl e 28 are the resu l ts obtai ned from comb i n i ng 
MVE-2  wi th  l oca l  rad i at i on of the pri mary footpad tumor . Loca l  
rad i otherapy wi th  1 000 , 2000 , or 3000 rads fa i l ed to  pro l ong s ur-
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Tabl e 25 
Compar i s i on of  ant i tumor acti v i ty of MVE-2 , Pyran 
and C .pa rvum aga i n st  the M1 09 
Ra l b/c  mi ce were i nocul ated w i t h  5X 1 05 M 109  cel l s  i n  the h i nd 
footpad on day O .  ({eek l y  i . v .  admi n i strat i on of MVE-2 , pyran and 
C . parvum wre i n i t i ated on day 7 .  Mean surv i val t imes (MST ) + S . E .  
were deri ved from 1 0  mi ce per group . 
Treatment  
Drug Dose  (mg/ kg) 
s a l i ne 
MVE -2 5 
MVE-2  1 0  
MVE -2 25 
MVE - 2  5 0  
Pyran 5 
Pyran 1 0  
Pyran 25  
C .  oarvum 5 
C .  parvum 1 0  
C .  parvum 25 
r-.1ST 
( days ) 
31 . 8+ 1 . 5  
32 . 9+ 1 . 9  - a 43 . 5�2 . 5a 
45 . 1 +2 . 4  
43 . 6+2 . 0a 
41 . 0+2 . 4a 
43 . 9+2 . 9a - a 49 . 0+3 . 8  
40 . 1  + 1 . 7a - a 41 . 4�2 . 0a 41 . 9+ 1 . 7  
a p < 0 . 05 a s  compared to primary tumor control grou[l . 
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Tabl e 26 
E ffi cacy of  mul t i p l e MVE-2  i nj ect ions  i n i t i ated at 
d i fferent i nterva l s after M1 09 i nocu l at i on 
Ba l b/c m i ce were i nocu l ated wi th 5X1 05 �1 09 cel l s  i n  the l eft 
h i nd footpad .  Wee k l y  i . v .  admi n i strat i on of MVE-2  ( 50 mg/ kg )  or  
phys i o l og i c  s a l i ne was i n i t i ated on days 7 ,  1 3 ,  1 5  of 20  after tumor 
i nocu l a t i on . Tumor vol umes and means  s urv i va l  t imes (MST ) + S . E .  
were deri ved from 8 mi ce per group . 
Treatment Tumor vol umea '�ST 1 LS
b 
(rrrrn3 ) ( days ) ( % )  
Day 7 - s a l i ne 46+1 5 39 . 4+2 . 0  -
Day 7 - MVE - 2  5 1 +.1. 58 . 7+5 . 1  49 . 0c 
Day 1 3  - sa l i ne  1 82+1 5 34 . 7+3 . 0  
Day 1 3  - MVE -2 1 97+1 9  47 . 8+1 . 8c 37 . 8c 
30H2Ll 36 . 2+1 . 4  
284+21 45 . 0+2 . 3c 24 . 3c 
Day 1 5  - s a l i ne 
DilY 1 5  - MVE-2  
Day 20 s a l i ne 476+33 38 . 5+1 . 1  
Day 20 - MVE - 2  6 7 1 +1 04 42 . 0+2 . 1  9 . 1  
aTumor vol ume on i n i t i a l  day of drug therapy . 
b l n creased l i fe span cal cu l ated by compari son of MST between 
drug treated and ap�ropri ate s a l i ne control group . 
Cp < 0 . 05 
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Tabl e 2 7  
Effect of MVE -2 coup l ed wi th surgery o n  the 
s urv i va l  time of M1 09 beari ng  mi ce 
Ba l b/c mi ce were i nocu l ated wi th 5 X 1 0
5 
M1 09 cel l s  i n  the l eft 
h i nd footpad on day 0 fo l l owed by s u rg i ca l  exc i s i on of the pr ima ry 
tumors on days 1 0 ,  1 4  or  1 9 .  NVE -2 ( 50 mg/ kg )  was admi n i s tered 
i ntravenous l y  on days 7 ,  14 and 21 . Mean s urvi val  t imes ( MST ) � 
S . E .  deri ved from 8 mi ce per group excert for the pri marY tumor 
control g roup  wh i c h had 25 mi ce . 
Treatment r�ST 
Drug S urgery on day ( days ) 
s a l i ne 38 . 5+ 1 . 4  
MVE-2  50 . 5+2 . 6a 
s a l i ne 1 0  45 . 9+2 . 6
a 
MVE - 2  1 0  55 . 0+2 . 7a , b 
s a l i ne 1 4  45 . 6+2 . 8a 
MVE -2 1 4  50 . 6+2 . 8a , b 
s a l i ne 1 9  39 . 1 +2 . 1  
MVE - 2  1 9  46 . 5+2 . 2a , b 
ap ( 0 . 05 as compared to the pr imary tumor control . 
bMST for s u rg ery-MVE grouD was not s tast i cal l y  d i fferent from 
the group treated wi th MVE-2 a l one . 
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v i val  t ime a l though  pr imary tumor growth wa s i n h i b i ted up  to 50% . 
Week l y  i . v .  admi n i stra t i on of  MVE-2 ( 50 mg/ k g )  to non - i rrad i a ted 
tumor bea r i ng hosts , or  a s i ng l e  i . t .  i nj ect ion  coupl ed wi th the 
week ly  i . v .  i nj ecti on s  were equa l l y  effect i ve i n  pro l ong ing  surv i va l  
t i me .  Yet , s imi l ar to t h e  s u rgery experi ments , treatment  wi th MVE-2  
before or  after rad i otherapy d i d  not  i ncrease  the ant i tumor effect of 
MVE - 2  over that o bserved with MVE-2 a l one . 
3 .  Effi cacy of MVE-2  admi n i stered i ntrap l eura l l y  or by 
i n ha l at i on 
As  death of  the a n i ma l s beari ng the M1 09 res u l ts from l ung 
metasta s i s  ( Marks  et  �, 1 978 ) an  attempt was made to i ncrease  the 
effi cacy of  MVE - 2  by admi n i steri ng  the compound i ntrapl eura l l y  i n  
c l ose  prox im i ty t o  estab l i s hed metastati c tumor foc i ( Tab l e 2 9 ) . 
I ntrap l eura l  a dmi n i stra t i on of  MVE-2 not o n ly  a l l owed for greater 
contact between MVE-2 , a l veo l ar  macrophages and tumor cel l s ,  but  5 
fo l d  h i gher concentra t i on s  of  MVE-2 cou l d be empl oyed . The res u l ts  
i nd i cate that i ntrap l eural  i nj ect ion s  of MVE-2  ( 2 50 mg/ kg )  s i gn i fi -
cant l y prol onged l i fe s pan  by 30% over s u rgery control s ,  whereas 
i . v .  admi n i strat ion  o f  MVE-2 ( 25 mg/ k g )  at  th i s  l ate date was wi thout 
effect on  s urv i va l  t ime . 
To fol l ow up  on t h i s o bservat ion  experiments were des i gned to 
de l i ver MVE-2  to the tumor bear i ng  m i ce by the i n ha l at i on rou te 
( Tab l e 30 ) . B i weekly expos ure of the noses and mouths  of the tes t 
a n i ma l s to MVE -2 ( l mg/ml ) res u l ted i n  greater than a 50% i ncrease 
in l i fe span  as compared to the s urgery control group . H i gher doses 
Tabl e 28 
Effect of radi otherapy or  radi otherapy coupl ed wi th MVE - 2  on s u rv i va l  
t ime of M1 09 bear i ng  mi ce 
Bal b/c mi ce were i nocul ated wi th 5X 1 05 M 1 09 cel l s  i n  the h i nd footpad on day 
o fol l owed by l oca l  i rrad i at i on of the T)rimar'y tumors on day 1 3 .  I n tratumor ( i . t . ) 
i nj ecti ons  of  phys i ol oq i c  s a l i ne of r-tVE-2  ( 50 mg/ kq ) were adITJi n i s tered 8 days a fter 
tumor i nocul at i on . Week ly  i . v .  i nj ecti ons  of phys i o l oq i c  sa l i ne or  MVE - 2  ( 50 mg/ kg ) 
were i n i t i ated on d�y 1 5 .  Mean s u rv i a l  t imes (MST ) + S . E .  were deri ved from 1 0  mi ce 
per group .  
Treatment MST at rad i at ion  doses of 
Drug Route none 1 000r 2000r 
sa l i ne i . t .  and i . v .  36 . 2+1 . 4  37 . 5+0 . 8b 41 . 7+ 1 1 . 3b 
MVE -2 i . v . 4S . 0+2 . 3a 44 . 7+2 . 4a , b 47 . 4+3 . Sa , b 
MVE-2  i . t .  and  i . v .  49 . 3+2 . Sa 56 . 4+4 . 0a , b 48 . 8+2 . 8a , b 
ap ( O . OS as compared to appropri � te s a l i n e  or sa l i ne - i rrad i ati on control . 
bMST not s i an i fi cant l y  d i fferent from appropri ate druq treated control . 
3000r 
39 . S+ 1 . 1  b 
48 . 6+3 . 5a , b 




Tabl e 29 
Ant i tumor act i v i ty of  MVE - 2  admi n i s tered i ntrapl eura l ly  
to mi ce bea r i ng the  meta stati c M1 09 
Ba l b/c  mi ce were i nocul ated wi th 5 X 1 05 M 1 09 cel l s  in the h i nd 
footpad on day 0 fo l l owed by s urg i ca l  exc i s i on of the pri ma ry tumors 
on day 1 5 .  I n trapl eural  i nj ect i ons  of phys i o l og i c  sa l i ne or  MVE-2  
( 250 mg . kg ) were admi n i stered on days 1 7 ,  20 and 24  i n  a vol ume of  
0 . 02 ml uti l i z i ng 30  gauge needl es . No deaths were recorded over 
the 75 day observa t i on peri od in non -tumor bear i ng control mi ce 
rece i v i ng i ntrap l eural  �VE -2 treatment . Mean s urvi val  t imes ( MST ) 
+ S . E .  were deri ved from 8 mi ce ner group . 
Treatment MST 
Drug Route ( days ) 
s a l i ne i . v . 43 . 0+1 . 8  
MVE - 2  i . v . 41 . 7+1 . 3 
s a l i ne i ntrap l eural 40 . 1  +4 . 8  
MVE-2  i ntrapl eural  55 . 9+4 . 7a 
a p < 0 . 05 a s  compared to the group recei v i na i ntrapl eura l  sa l i ne 
treatment .  
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of MVE-2 were i neffec t i ve i n  pro l ong i n g  the MST . Necropsy at the 
t ime of  death i nd i cated that the l ungs  of the tes t an ima l s were on l y  
moderate l y  l aden wi th  tumor . Moreover , metastati c foc i  were read i l y  
observab l e i n  t he l i vers  of  s everal test mi ce . 
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Tabl e 30 
Anti tumor acti v i ty of MVE-2  admi n i s tered by i n ha l at i on to mi ce 
bea r i n g  the metastat i c M 1 09 
Ba l b/ c mi ce were i nocul ated wi th 5X1 05 M 1 09 cel l s  i n  the h i nd 
footpad on day 0 fol l owed by s u r9 i ca l  exc i s i on (Sx ) of the pr ima ry 
tumors  on day 1 5 .  Seventeen days after i nocu l at i on a twi ce a week 
thereafter the noses and mouths  of the tes t  a n ima l s were exposed to 
a nebu l i zed mi s t  of phys i o l og i c  s a l i ne or MVE-2 . No deaths were re-
corded for non-tumor bea r i n 9  control mice rece i v i n g  MVE-2  by i n -
ha l at i on . Mean s u rv i va l  t imes ( MST ) + S . E .  deri ved from 1 0  mi ce 
per group . 
Treatment 
none 
Sx-sa l i ne 
Sx-MVE -2  
Sx-Mve-2  
Sx-MVE-2  
Sx-MV E -2 
( 1  mg/ml ) 
(20 mg/ml ) 
( 50 mq/ml ) 
( 1 00 mg/ml ) 
MST 
( days ) 
38 . 0+0 . 7  
47 . 0+2 . 9  
> 70a 
47 . 8+3 . 7  
47 . 6+3 . 5  
46 . 0+3 . 4  
ap < O . 05 a s  compa red to Sx-s a l i ne control grou o .  
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I V .  D I SCUSS I ON 
A s uccessfu l  outcome from any form of cancer treatment  must 
depend on those features of  a tumor wh i c h  make it  d i s t i nct in  some 
way from s urround i n g  norma l t i s s u e .  When v i ewed i n  thi s way suc­
cessfu l  cancer  s urgery or  rad i otherapy can be seen  to  depend not  
on l y  on the l oc at i on of the  tumor but a l so on the  h i s topathol ogy 
of the tumor wh i c h  d i s t i ng u i shes  the neopl a s t i c  growth from norma l 
t i s s u e .  Treatment w ith  i rradi a t i on or  c hemotherapy wi l l  a l so tend 
to re l y  on the a bnorma l growth rate and metabol i sm of the ma l i gnant 
ce l l s  to d i s t i n gu i s h  t hem from normal ce l l s .  Thus , in  part , the 
c urrent i nadequa c i es of  cancer treatments refl ects the i r  l ack  of 
se l ect i v i ty ;  the absence of  s pec i f i c  target s i tes on the mal i gnant 
cel l and the con sequent i nab i l i ty to d i s t i ngu i s h  between norma l and 
neopl a st i c t i s sue . I t  i s  i n  th i s context that i mmunotherapy prov i des 
such a n  a ttrac t i ve concept , a s  theoreti cal l y  the immune response  
s hou l d  be abl e to sel ect i ve ly  destroy tumor cel l s  not amenabl e to 
k i l l i n g  by convent i ona l  treatment modes . Yet , i n  practi ce , an opt ima l  
l ethal  i n terac t i on between the effector l i mbs of  the  immune response 
and tumor cel l s  has  been s hown to be dependent on a mi n ima l  tumor 
burden and an  i ntact l ympho i d  system . 
Ba sed on  these f i n d i ngs  the overa l l object i ves of thi s thes i s  
proj ect were to ( 1 ) character i ze the i mmune s tatus of tumor bear i ng 
mi ce and ( 2 )  deve l op a rat i ona l  protocol con s i s t i ng of s urgery or 
rad i otherapy comb i ned w ith  i mmunotherapy to max i m i ze the i r  cure rate . 
1 63 
To carry out these  object i ves  the Lewi s l u ng carc i noma was 
i n i t i a l l y  sel ected . Data was presented wh i ch i nd i cated that the LLC 
footpad tumor meta sta s i zes  primar i l y  to the l ungs . These res u l ts 
conf i rmed the fi nd i ngs  of  Mayo ( 1 972a ) wi th the i . m .  LLC and extended 
h i s  work  by n ot i ng that metastat i c  foci cou l d  a l so be detected i n  the 
l i ver , sp l een and k i dneys . Moreover ,  i n  contra st  to the publ i s hed 
observa t i on s  by Geran et  � ( 1 972 ) no  d i fferences cou l d be detected i n  
the g rowth rates o f  the i . m .  and footpad LLC tumors wh i c h  suggests  that 
our data generated wi th  the footpad LLC wou l d  be comparabl e wi th the 
res u l ts  obta i n ed by others u s i ng the i . m .  LLC . 
As BDFl mi ce became unava i l ab l e dur i ng the course of these i nves­
t i gat ion s , exper iments were a l so  conducted wi th the M1 09 carc i noma i n  
Ba l b/c  and CDFl m i ce . Data was presented wh i ch i nd i cated tha t the 
M1 09 , l i ke the LLC , i s  a so l i d  mur ine  tumor wh i c h  metastas i zes pri ­
mar i l y  to the l un g s . Yet ,  i n  marked contrast  to the f i nd i ng s  of 
others wi th  the LLC , ( Otu et  �. , 1 977 ; Morahan and Kapl an , 1 97 7 )  
the M1 09 c l ear ly  d i sp l ayed concomi tant tumor immun i ty ,  exh i b i t i n g  the 
capac i ty to s u ppre s s  the growth of a secondary M1 09 chal l enge . 
S tud i es undertaken to c haracter i ze the immune competence of mi ce 
bea r i n g  the LLC i n d i cated that the immunol og i c  capabi l i ti es of  the 
tumor bea r i ng hosts were i mpa i red . The LLC mi ce devel oped an anem i a  
a n d  l eu kocytos i s  a n d  were defi c i ent  i n  the i r ab i l i ty to el i c i t  an 
ant i body response , deve l op a DTH react i on , or  phagocytize  SRBC . I t  
has  been s uggested that a poor respon se to SRBC may not b e  i nd i ca ­
t i ve of an  i mmune def i c i ency , b u t  rather may demonstrate the 
pos s i bi l i ty that m i ce are undergo i n g  an a ct i ve i mmune response  to 
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the i r  tumors  ( Ad l er et �. , 1 9 7 1 ; Kerbel , 1 974 ) . However , i nvest i ga­
t i on s  by  Otu  et  a l  ( 1 97 7 )  and Morahan and Kapl an ( 1 97 7 )  have  been 
unabl e to detect any concomi tan t immun i ty or  transpl antat i on res i stance 
to the LLC . I t  cou l d  a l so be argued that the above resu l ts are re l a ted 
to the carri age of v i ru s .  Chron i c  i nfect i on wi th l act i c  dehydrogenase 
v i ru s  has been s hown to compromi se the i mmune s tatus  of  tumor beari ng 
an ima l s ( I o r i o  et �, 1 974 ; Ri l ey ,  1 974 ) . Yet , the  tumors uti l i zed for 
these stud i e s  were peri od i ca l l y  s hown to be free from l act i c  dehyd ro­
genase v i ru s .  Thu s , we feel that the decreased i mmune respons i veness 
to SRBC in  the tumor bear i ng m i ce i s  i nd i cat i ve of a defect in  non­
s pec i fi c  i mmun i ty i nduced by the tumo r .  
T h e  pattern of  i mmunodefi c i ency i n  t h e  L L C  an ima l s appeared to 
be i n  contra st  to most stud i es .  Genera l l y  i t  has been found tha t ,  i n  
man and  a n ima l s bea r i ng sol i d  tumors , cel l medi ated immun i ty i s  mode­
rate l y  to  severe l y  depres sed wh i l e  anti body respons i veness rema i n s 
i ntact  ( Ad l er et  �,  1 97 1 ; B i ozz i  et �. , 1 953 ; Fahey and Humphrey , 
1 962 ; Gatt i et �. , 1 962 ; Sol owey and Rapapert , 1 96 5 ) . However , i n  
the present stud i es reduct i on i n  RES act i v i ty and the n umber of PFC 
were noted on the fi rst  days of  measurement ,  days and 7 res pec t i vel y ,  
wh i l e  DTH react i v i ty rema i ned i ntact unt i l  day 1 7 .  The impai rment of 
h umora l res pon s i veness  and RES funct i on cannot be attri buted to the 
general debi l atat i ng effect of  tumors , s i nce the depres s i on in  pl aque 
form i ng  ab i l i ty and  phagocyto s i s  were noted before the tumors became 
pa l pab l e and the mi ce s howed any overt s i g n s  of i l l nes s .  The poss i ­
b i l i ty that the growi ng  tumor rel eases  an i n h i b i tor of immune funct ion , 
e i ther d i rectl y or  i n d i rectl y ,  s eems therefore to be the most l i ke ly  
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expl anat i on for these  f i n d i ng s . Th i s  concept i s  s upported by data 
wh i c h  i nd i c ated that s u rg i ca l  removal  of the primary tumor res u l ts 
i n  a rebound i ncrease in ant i body form i ng cel l s  to control l evel s .  
Moreover , i ntact tumor cel l s  appeared to be necessary for the impa i red 
i mmune competence as son i cated tumor cel l s  were wi thout effect on RES 
funct i on . An exten s i ve revi ew on the pos s i bl e  mech�n i sms for the 
decreased immuno l og i c  capab i l i t i es of tumor bear i ng an ima l s has been 
presented i n  the I ntroduct i on . 
Enhancement of  vascu l ar c l earance and l i ver upta ke were recorded 
i n  the second week  of tumor growth . I n  contra st  to the f i nd i ngs  of 
Saba et � ( 1 97 5 )  th i s  a ct i va t i on cannot be attri buted to l i ver hyper­
trophy , s i nce l i ver we i g ht  and l i ver we i g ht  expres sed as percent body 
we i ght  i n  the tumor bea r i n g  a n ima l s d i d  not s i gn i fi cantly d i ffer from 
control val ues . The enhanced RES funct ion d i d  co i n c i de wi th rap i d  
expan s i on o f  the tumor mass  from 2 7  mg o f  tumor on day 5 to 3 1 6 mg 9 
days after tumor i nocul a t i on , and i t  i s  tempting  to specu l ate that 
the tumor products  of  rap i d l y  d i v i d i ng cel l s  may be act ing  as a Kupffer 
cel l st imu l u s .  
I n  the term i n a l  s tages o f  d i sease , the system i c  spread o f  the 
tumor coupl ed w ith  the b i ol og i cal  events secondary to the presence 
of the neopl a s i a  a ppeared to c reate a genera l i zed anergy in the LLC 
bea r i n g  m i c e .  The thym i c  i nvo l ut i on observed l ate in the d i sease 
s tate has been attri buted by Begg ( 1 953 )  and Ertl ( 1 972 ) to e l evated 
s tero i d  l evel s .  I t  fol l ows that i f  sero i d  l evel s i n  tumor bear i ng 
hosts  a re s u ffi c i ent ly  h i g h  to cause  a marked and progre s s i ve thymus 
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atrophy , then such  l evel s may a l so be h i g h enough to contri bute to 
the s u ppressed PFC and DTH res pon s i veness  of the LLC m i ce . 
The b i o l o g i ca l  con sequences of tumor i nduced immunosuppres s i on 
have not yet been fu l l y  e l uc i da ted . Data was presented wh i c h  i nd i ­
cated that the LLC does not suppres s  host res i stance to L i steri a 
monocytogenes , an i nfec t i on i n  wh i c h  macrophages and immune T cel l s  
are i nvol ved i n  the e l i mi na t i on of the mi croorgan i sm .  Yet , these 
f i n d i ng s  may be rel ated to the l ow sens i t i v i ty of  the b i ol og i ca l  
a s say . From the data presented in  Tabl e 9 it  wou l d  appear that 
greater than a l og d i fference i n  the n umber of L i steri a monocytogenes 
col ony form i n g  un i ts i s  needed to demonstrate a s i gn i fi cant reduct i on 
i n  host res i stance , wh i c h  wou l d  trans l ate i nto greater than a 90% 
reduct ion  i n  macrophage and/or T cel l acti v i ty .  The ques t i on a l so 
rema i n s  a s  to whether the depressed immune status of the tumor bea r i ng 
host  i s  d i rected at  the tumor per se , permi tt i ng conti nued growth and 
expan s i on of  t he tumor , or  o n l y  a nonspec i fi c  impa i rment  d i rected at  
non tumor ant i gen s .  Based  on the  observat i on s  of Otu  et � ( 1 97 7 )  and 
the res u l ts  presented here i n , it  i s  pos s i b l e that the ab i l i ty of the 
LLC to s u ppres s  i mmune funct i on soon a fter i nocu l at i on is  respon s i bl e  
for the l ac k  o f  i mmunogen i c i ty exh i b i ted by th i s  tumor . Another con ­
sequence of the suppres sed i mmune s tatus  i s  that l es i on s  may m i n imi ze 
the effec t i veness  of  cancer therapy .  Surgery , rad i at i on , and chemo­
therapy have a l l been s hown to be i mmunosuppres s i ve ( Harr i s  and Bagai , 
1 972 ) . The aggre s i veness  of  therapy may therefore have to be m i n imi zed 
i n  i mmunosuppres sed hosts . Moreover , the effi cacy of immunotherapy 
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h a s  been s hown to be dependent on the i mmune status of the tumor 
bear i n g  host ( Hanna et  �. , 1 973 ; Scott , 1 975a ) . 
Stud i es conducted wi th systemi c MVE-3 aga i n st  the LLC c l earl y 
i nd i ca ted that i . v .  treatment wi th MVE-3  a l one wa s i n effect i ve i n  
pro l on g i n g  l i fe s pan o r  i n h i b i t i ng primary tumor growth . Yet 
Snodgra s s  et al ( 1 97 5 ) have reported that system i c  treatment wi th 
pyran on  days 1 -8 a fter LLC i nocu l at i on i n h i b i ted the growth of the 
pr ima ry tumor up to 87% and i ncreased the MST from 3 1 . 9  days to 50 . 4  
days . The d i spar i ty between the i r  resu l ts and ours may be rel ated 
to d i fferences i n  the mo l ecu l ar  we i ght  of the po l ymers and the dos i ng 
reg i mens  emp l oyed . 
The ant i tumor act i v i ty of polyan i on i c  po l ymers has been s hown to 
be c l o s e ly  re l ated to mo l ecu l ar we i ght  ( Regel son et �, 1 975 ) . The 
exper iments  performed by Snodgra s s  et � were wi th a po l yd i s perse 
broad mo l ec u l ar  we i g ht  range pyran co-po lymer , Hercu l es XA 1 24- 1 7 7 , 
wh i c h ha s  an  average mo l ecu l ar we i g ht  of  30 , 000 dal tons ( Regel son 
et �, 1 97 5 ) . Yet , pyran has  been s hown to be h i g h ly  tox i c  in the 
c l i n i c ,  produc i ng thrombocytopen i a ,  fever , hypotens i on ,  sei zures  
and l o s s  of v i s i on i n  some pat i ents  ( Regel son et �,  1 977 ) . I n  a n  
effort to  i mprove t he therapeut i c  i ndex of th i s  c l a s s  of compounds , 
our  stud i e s  empl oyed a l ower mo l ecul ar  we i ght  fract i on of the parent 
copo l ymer , MVE -3 , wh i c h  has  recent ly  been s hown by our l aboratory to 
pos ses s  l es s  ant i tumor act i v i ty aga i n s t  the LLC ( Morahan et �. , 1 979 ) . 
Moreover ,  the treatment reg imen empl oyed by Snodg ras s  and co­
workers d i ffered from our protocol s not on ly  in  the frequency of drug 
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admi n i strat i on ,  but  i n  the i n i t i at ion  date of  therapy . As s tud i es by 
Fl orenti n et a l  ( 1 97 6 )  wi th  BCG and Morahan ( personal commun i cat i on ) 
wi th  pyran have i nd i cated that da i l y  treatment appears to be no better 
than a l ternate day or wee k l y  treatment ,  the re l at i ve success  of the i r  
stud i es may l arge ly  b e  attri buted to the early i n i t i at i on date of 
therapy , i . e .  day 1 .  
I n  contra st  to systemi c MVE-3 ( 2 5 mg/ kg ) treatment ,  an acute 
i ntra l es i ona l  i nj ec t i on a t  50 mg/ kg proved to be effi cac ious  by i n ­
creas i ng l i fe s pan 35 . 9% and 28 . 1 %  i n  two separate experiments . 
( Tab l es 1 5  and 1 6 ) .  I t  i s  un l i ke l y  that the effi cacy of i n tra l e s i onal  
MVE-3  can  be attri buted to the 2 - fo l d  i ncrease in  dose a s  earl i er 
exper iments  w ith  i . v .  MVE-3 treatment a t  50 mg/kg was i neffect i ve i n  
pro l ong i ng MST . I t  i s  therefore our bel i ef that the d i fferences seen 
wi th  the d i fferent routes of MVE-3 admi n i s trat i on can be expl a i ned on 
the bas i s  of drug d i stri b ut i on . A l though synthet i c  po l ya n i on s  are not 
d i rectl y cytotox i c  for tumor cel l s  ( Morahan et a l , 1 974)  l ocal i zed 
concentrat i o n s  of MVE-3 wi th i n  the primary tumor bed may a l l ow for 
act i vat ion  of effector cel l s  i n  c l ose prox imi ty to the tumor bed 
and thus  i n h i bi t  the metastat i c  proces s . Thi s concept i s  s upported 
by the f l ow m i crofl ourimetri c stud i es wh i c h  i nd i cated that host 
cel l s  res i ded in  the primary tumor bed . Moreover , Snodgras s  et � 
( 1 97 5 )  have noted an i ncreased i n f i l tra t i on of h i st i ocytes i nto the 
primary tumor bed i n  pyran treated m i ce and recent s tu d i es by Kapl an  
and coworkers ( unpubl i s hed observa t i on s )  have  s hown that  host cel l s  
deri ved from the pri mary tumor bed of pyran treated mi ce i n h i b i ted 
the growth  o f  LLC ce l l s  both � v i tro ( 1 2 5 IUDR i ncorporat i on )  and � 
v i vo ( tumor growth ) .  
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The a b i l i ty ot MVE-3 to synerg i ze wi th convent i ona l  modes of 
treatment was a s ses sed by emp l oy i ng  MVE-3  i n  comb i nat i on wi th surgery , 
c hemotherapy , or  rad i otherapy .  Al though s u rgery and l ocal rad i other­
apy marked l y  reduced the prima ry tumor burden and CTX adm i n i strat ion 
s ubstanti a l l y  i n h i b i ted the meta stat i c  growth of the LLC , system i c  MVE - 3  
treatment  s t i l l  proved t o  b e  i neffect i ve i n  fu rther prol ong i ng l i fe 
s pan . One pos s i bl e  factor wh i c h may have contri buted to the i neffec­
ti veness  of  MVE-3 i n  these protocol s i s  the i mmunosuppress i on i nduced 
by cytoreduct i ve therapy . Surgery , rad i at i on and c hemotherapy have 
a l l been s hown to be i mmunosuppres s i ve ( Harri s and Baga i , 1 972 ) and 
stud i es by Hanna et � ( 1 973 ) , Scott ( 1 975a ) and Morahan et � ( 1 974 ) 
have s hown that i mmunosuppres s i on can abrogate the anti tumor acti v i ty 
of  BCG , C .  parvum and pyran res pect i vel y .  A second component wh i c h 
may have contri buted to the i n act i v i ty of  MVE-3 rel ates to the rel ati ve 
d i s t r i b u t i on of the pol yani on . I n  the LLC tumor system the m i ce d i e  
o f  pu l monary i n s uffi c i ency resu l t i ng from metastas i s  to the l ung . Yet , 
the system i c  adm i n i stra t i on of  pyran to n a i ve a n ima l s i s  known to d i s ­
tri bute i tse l f primar i l y  to the l i ver and sp l een , wi th l e s s  than 4% 
l oca l i z i n g  i n  the l ung ( Rege l son et �. , 1 970 ) . Accord i ng l y ,  system i c  
admi n i stra t i on o f  MVE-3 probab l y  res u l ts  i n  " l ow" concentra t i on s  o f  
the compound i n  the metas ta t i c  tumor bed wh i c h  wou l d  n o t  favor succes s ­
f u l  immunotherapy .  Th i s i s  s upported by stud i es wi th BCG ( Zbar e t  �, 
1 972 ) , C .  parvum ( Scott , 1 975b ) and Bordetel l a  pertus s i s  ( Bast  e t  �, 
1 977 ) wh i c h  have i nd i cated that d i rect contact between tumor cel l s  
and the i mmunomodu l ator marked l y  enhances the ant i tumor act i v i ty of 
the i mmunomodu l ator . 
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The concepts of  immunosuppres s i on and  drug d i stri but ion under­
mi n i ng the ant i tumor act i v i ty of MVE -3 a re a l so s upported by the 
resu l ts obta i ned from comb i n i ng i ntra l e s i ona l  MVE-3 treatment wi th 
l oca l  rad i otherapy .  I ntra l e s i onal  therapy not on l y  resu l ted in " h i g h "  
concentrat i on s  o f  MVE-3  i n  the prima ry tumor bed ear ly  i n  the d i sease 
s tate , but  may have m i n i r l i zed the i mmunosuppress i ve e fffects of 
i on i z i ng rad i at i on ( L i ndah l  and Ede l man , 1 968 ; Prempree and Merz , 
1 969 ; Schm i d ke and Di xon , 1 97 3 ;  Ge i ger et � ,  1 97 3 ) . Al ternat i vel y ,  
i rrad i a t i on has  a l so  been s hown to produce changes i n  the ant igen i c  
s tructure o f  t i s s ues ( Al ekeoff , 1 970 )  wh i ch may have enhanced the 
tumor cel l a nt i gen i c i ty of the LLC . 
Data wa s presented wh i c h  i nd i cated that the LLC q u i c k l y  metasta ­
s i zes  to  the  l un g  where i t  i s  not  amenab l e to  s urgery or l ocal  rad i o ­
therapy .  Moreover , res u l ts obta i ned f rom i ntra l e s i onal  MVE treatment 
i nd i cated that l oca l i zed concentrat i on s  of MVE-3  i n  the primary tumor 
bed were effect i ve i n  prol ong i n g  l i fe s pan , presumab ly  by i n h i b i t i ng 
the metasta t i c  proces s . Thu s , an  attempt was made to l oca l i ze MVE-2 
in the l u ng by expo s i n g  the noses and mouths of the LLC bear i n g  m i ce 
to an aerosol i zed mi st  of MVE-2 . Prel im i nary s tu d i es wi th na i ve mi ce 
of d i fferent stra i n s  s uggested that MVE -2 admi n i stered by i n ha l at ion  
becomes l oca l i zed i n  the  l ungs  a s  l u ng we i g hts were s i gn i f i cant ly  
i ncrea sed , but  the hepatospl enomega l y  wh i c h  accompan i e s system i c  MVE-2  
treatment was not evi dent after 10  da i l y  exposures to  an aeroso l i zed 
mi st  of MVE-2 . Neverthel e s s , i n  the one p i l ot study conducted wi th 
LLC bear i n g  mi ce , MVE - 2  fa i l ed to pro l ong s u rv i va l  t ime . Necropsy 
at  the t ime of death revea l ed l ungs  heav i l y  l aden wi th tumor sugge s t i ng 
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that death was not  due to the metas ta t i c  s pread of the LLC to other 
v i ta l  organ s .  
One pos s i bl e reason why MVE-2  was i neffect i ve i n  pro l ong ing  MST 
rel ates to the therapy reg i men wh i ch was empi r i ca l  i n  regard s  to 
dos i metry and  s chedu l e .  As synthet i c  pol yan i on s  have been s hown to 
i n h i b i t  a s  wel l a s  enhance tumor growth ( Kri pke and Borsas , 1 974 ; 
S chu l l er et  �, 1 97 5 )  the effi cacy of MVE-2  admi n i s tered by i n ha l a ­
t i on  t o  L L C  m i ce s hou l d  n o t  b e  d i scounted unt i l systema t i c  stud i es have 
del i n i ated the optimum dose and schedu l e  dependency of MVE-2  admi n i s ­
tered by th i s  route o f  admi n i strat i on . 
Another factor wh i c h  most a s s ured l y  contri buted to the i neffec­
t i venes s  of  MVE - 2  i s  t he l ac k  of tumor ce l l anti gen i c i ty exh i b i ted 
by the LLC  ( Otu et �, 1 97 7 ; Morahan and Kapl an , 1 97 7 ) . As an under­
l y i n g  concept of tumor i mmunol ogy i s  that there are characteri s t i c  
ant i gens i n  or o n  tumor ce l l s  that d i sti ngu i s h them from normal host 
ce l l s  i t  i s  not  s urpri s i ng that weak l y  ant igen i c  tumor systems have 
not been very respon s i ve to treatment wi th  immunotherapy ( Parr , 1 97 2 ; 
Ba l dwi n and  P i nn , 1 973 ; Bast  et �, 1 97 6 ) . I n d i rect evi dence i n  sup­
port of th i s  concept was  deri ved from experiments performed i n  our  
l aboratory wi th  contam i nated L LC cel l s .  I n  two separate stud i es , 
systemi c MVE -3  treatment res u l ted i n  a s i gn i f i cant pro l onga t i on i n  
s urv i va l  t i me and i nh i b i ti on of tumor growth when h i gh l y  anti gen i c  
bacter i a  res i ded i n  the primary tumor bed . 
The  res u l ts obta i ned wi th  systemi c and i ntral e s i ona l  C .  parvum 
aga i n st  t he LLC were s i gn i fi cant ly  better i n  compari son wi th  MVE-3 . 
Yet , the reasons  or the i ncreased effi cacy of C .  parvum are un known . 
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Acti vated macrophages have been i mpl i cated a s  maj or effectors of tumor 
res i stance i nduced by both of these drugs ( Kapl an and Morahan , 1 976 ) , 
and  comparab l e ant i tumor act i v i ty i s  u s ua l l y  d i spl ayed by these agents 
( Tab l e 2 5 ) .  Moreover ,  the d i stri buti on and pers i stence of C .  parvum 
as determ i ned by 
1 25 I - l abel i n g  ( S cott and Mi l a s ,  1 97 7 )  or 
99m
techneti um­
l a be l i n g  ( Barth and S i ng l a ,  1 978 )  paral l el s  the res u l ts obta i n  wi th 
pyran ( Regel son et �, 1 970 ) . However , the l ack of a pronounced effect 
wi th  C .  parvum can probab ly  be attri buted to the same factors as pre­
v i o u s l y  men t i oned ; l ac k  of LLC tumor cel l ant igen i c i ty ,  l ow l evel s of 
C .  parvum l oca l i zed i n  the l u ng , and immunosuppre s s i on i nduced by the 
tumor and cytoreduct ive  therapy . 
I n  contrast to the LLC stud i e s  wi th MVE-3 , the M 1 09 was respon -
s i ve to a l e s s  act ive  l ower mol ecul ar we i g ht fract i on of mal e i c  v i nyl  
ether , MVE-2 . Al though acute admi n i strat i on of MVE-2 d i d  not marked l y  
effect MST , mul t i p l e  i nj ect ion s  of MVE - 2  s i gn i fi cantly pro l onged the 
l i fe s pan  of  the host and i n h i b i ted the growth of the primary M1 09 
tumo r .  MVE-2  proved to be effect i ve when the hosts had a mean primary 
tumor burden of  284 mm3 and establ i s hed metas tati c foc i ( Tab l e 2 6 ) . 
These data a l so confi rmed the fi ndi ngs  of the LLC stud i es i n  that the 
effi cacy of MVE-2  appeared to be part i a l l y  dependent on drug d i stri -
but i on . Earl y i n  the d i sease state i n tra l es i ona l  i nj ect ions  proved 
to be most effecti ve i n  i n h i b i t i n g  tumor growth and prol ong i ng the 
MST . Yet , a s  the tumor metasta s i zed to the l ung , system i c  admi n i s -
tra t i on of MVE-2 a l one , or MVE-2  coupl ed wi th surg i ca l  exc i s i on or 
rad i otherapy of the primary tumor became i ncreas i ng l y  l es s  effect ive . 
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Late i n  the d i sease state on l y  MVE-2  i n troduced d i rectly i nto the 
meta stat i c  tumor bed by i ntrapl eural  i nj ect i on s  or i n ha l at i on proved 
to be effi cac i ou s  i n  prol ong i n g  l i fe s pan . 
I n  s ummary , data was presented wh i c h  i nd i cated that the abi l i ty 
to control growth of the LLC  wi th  non spec i f i c  immunotherapy was modes t .  
Earl y i ntra l e s i ona l  admi n i stra t i on o f  MVE-3  marg i nQ l l y  enhanced l i fe 
s pan , presumab ly  by i n h i b i t i n g  the metastati c proces s .  Yet , a s  the 
tumor metas tas i zed to the l ung , systemi c admi n i strat ion  of MVE-3  
a l one , or MVE-3  coupl ed wi th  surgery , c hemotherapy , or l oca l  rad i o ­
therapy was i n effect i ve . Converse l y ,  the M1 09 tumor was s hown t o  be 
re l at i ve l y  respons i ve to MVE treatment . Mu l ti pl e  i nj ect i ons  of MVE -2 
i n  doses  rang i ng from 1 0  to 50 mg/kg s i gn i fi cantl y prol onged the l i fe 
s pan  of t he host and  i n h i b i ted the growth of the pr imary tumor .  The 
effi cacy of  MVE therapy appeared to be dependent on drug d i s tri but i on 
s i nce routes of admi n i s trat i on wh i c h  l oca l i zed MVE i n  the primary tumor 
bed ear ly  i n  the d i sease s tate or i n  the metasta t i c  tumor bed l ate i n  
the d i sease s tate were the most effect ive  i n  prol ong i n g  l i fe span . 
The d i vergent res u l ts  obtai ned wi th the two tumor l i nes may be attri ­
buted to the i mmunosuppres s i ve effects of the LLC and the tumor cel l 
a nt i gen i c i ty exh i bi ted by the M1 09 . 
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V . PROPOSED  FUTURE RESEARCH 
Future research efforts wi th MVE s hou l d  be d i rected towa rds 
opt imi z i ng the parameters for i n hal a t i on treatment and understand i ng 
the mechan i sm ( s )  of ant i tumor act i on .  I n i t i a l experiments s hou l d  be 
a i med at  del i n i at i ng procedures that  wi l l  max im i ze the effecti venes s 
of  MVE - 2  aga i n s t  the meta stat i c  M1 09 .  These s tud i e s wou l d  i nvol ve 
determi n i ng the s chedu l e and dose dependency of MVE del i vered by the 
i n ha l a t i on route . Moreover ,  a s  pre l im i nary i n hal a t i on exper i ments 
have suggested that  death of the M1 09 bear i n g  m i ce mi ght  be due to 
neopl a st i c  g rowth i n  the l i ver , exper iments s hou l d  a l so be performed 
empl oyi ng  i n ha l a t i on treatment i n  conjunc t i on wi th system i c  therapy 
( MVE and/or chemotherapy ) . S imul taneou s ly  wi th the forego i ng stud i es 
exper iments s hou l d  be d i rected towards cal i brat i ng the i n ha l a t ion  pro­
cedure pos s i bl y  by u s i ng qu i n i ne s u l fate in a fl ourescence a s say or by 
empl oy i n g  radi ol abel ed MVE under control l ed cond i t i ons . 
To adequate l y  a s se s s  the effi cacy of MVE del i vered by the i n hal a ­
t i on route i t  wou l d  be des i rab l e to conduct pa ra l l e l i n vest i gat ions  i n  
other metasta s i z i n g mu ri ne  tumor model s wh i c h  d i s p l ay a d i fferent spec­
trum of act i v i ty towards i mmunotherapy , such a s  the LLC or  B1 6 mel anoma . 
Furthermore , a s  MVE has been s hown to possess  ant i v i ral acti v i ty ( H i rsch  
et �, 1 972 ; Morahan et �, 1 975 ) , an  i n teres t i n g  and c l i n i ca l l y  u seful 
fal l out  from these stud i es mi ght  materi a l i ze by admi n i s tering  MVE by 
i n hal at i on to m i ce  i nfected wi th i nfl uenza v i ru s . 
1 7 5 
Once the parameters requ i red for maxi mum cures have been del i ne­
a ted the maj or  effort s hou l d  be d i rected towards determ i n i ng the 
mechan i sm ( s )  of a ct i on . Transp l antat i on res i stance stud i e s shoul d be 
i n i t i a l l y  conducted as i t  wou l d  be of pri mary importance to determ i ne  
whether t he  " c ured " mi ce are  i mmune to  recha l l enge , or whether tumor 
growth was i n h i b i ted by non - i mmunol og i c  mechan i sms . Bri efl y ,  m ice  
that are cured wou l d be recha l l enged wi th graded doses  of homol ogou s 
and hetero l ogous tumor cel l s ,  and the i n c i dence , l atency and growth 
of the tumors measured . I f  immun i ty i s  observed , the parti cu l ar effector 
cel l s  cou l d be i dent i f i ed by means  of a Wi nn neutra l i zat ion a s say or pa s ­
s i ve tran sfer  of vari ous  cel l types ( a l veo l ar macrophages , bl ood mono ­
cytes ,  etc . ) i n to tumor beari ng rec i p i ents . I f  i t  became apparent that 
the cured a n i ma l s are not spec i f i ca l l y  immune , th i s  wou l d  suggest a 
rol e for non spec i fi cal l y  acti vated macrophages i n  e l i c i t i ng the cures . 
Once the cel l type ( s )  re spon s i b l e  for the tumor i n h i b i ti on have been 
i dent i f i ed � vi tro a s says s hou l d  be des i gned to c haracter ize  the 
host cel l -tumor i nteract i on . 
The proposed i nvesti gat ions  s hou l d a l l ow i mmunotherapeut i c  proto­
col s to be deve l oped on more rati onal  bases than empi ri cal grounds . 
Understand i ng the optimum parameters of  appl i cat i on and mechan i sm of 
act ion  of MVE i s  requ i red before con s i stent benefi c i a l  effects can be 
produced . 
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